

2017 Aetna Pharmacy Drug List - Individual  
**Acamprosate Calcium**

---

**Products Affected**

- *acamprosate calcium*

<b>QL Criteria</b>	6 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Accu-Chek Aviva Plus

## Products Affected

- ACCU-CHEK AVIVA PLUS IN VITRO

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Accu-Chek Compact Plus

## Products Affected

- ACCU-CHEK COMPACT PLUS

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Accu-Chek SmartView

## Products Affected

- ACCU-CHEK SMARTVIEW

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Accu-Chek Softclix Lancet Dev

---

## Products Affected

- ACCU-CHEK SOFTCLIX LANCET DEV  
KIT

<b>QL Criteria</b>	1 device Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Accutrend Glucose

## Products Affected

- ACCUTREND GLUCOSE

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Acetaminophen-Codeine

## Products Affected

- *acetaminophen-codeine oral solution*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Acetaminophen-Codeine

## Products Affected

- *acetaminophen-codeine oral tablet*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Acetaminophen-Codeine #2

### Products Affected

- *acetaminophen-codeine #2*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017



## Acetaminophen-Codeine #3

### Products Affected

- *acetaminophen-codeine #3*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Acetaminophen-Codeine #4

### Products Affected

- *acetaminophen-codeine #4*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Acitretin

---

## Products Affected

- *acitretin*

<b>QL Criteria</b>	2 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Acitretin

---

## Products Affected

- *acitretin*

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Actemra

## Products Affected

- ACTEMRA INTRAVENOUS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Actemra.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Actemra.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Actemra.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Actemra.html</a>
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Actemra

## Products Affected

- ACTEMRA SUBCUTANEOUS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Actemra.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Actemra.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Actemra.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Actemra.html</a>
QL Criteria	1 syringe Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Actimmune

## Products Affected

- ACTIMMUNE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/actimmune.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/actimmune.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Actoplus met XR

---

## Products Affected

- ACTOPLUS MET XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 15-1000  
MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of metformin 1500mg/day
<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Actoplus met XR

---

## Products Affected

- ACTOPLUS MET XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 30-1000  
MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of metformin 1500mg/day
<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Adapalene

---

## Products Affected

- *adapalene external lotion*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of tretinoin
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Adcirca

## Products Affected

- ADCIRCA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
QL Criteria	2 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Addyi

## Products Affected

- ADDYI

PA Criteria	Criteria Details
<b>Covered Uses</b>	Treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	The patient is a premenopausal female 18 years of age or older with a documented diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD) that is appropriately documented (i.e., evaluated by a complete clinical assessment, using DSM-4, interviews/questionnaires), and hypoactive sexual desire disorder (HSDD) is not caused by a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance, and the patient does not have any of the following: alcohol use, concomitant use of Addyi with moderate or strong CYP3A4 inhibitors, or hepatic impairment. For renewals only: The patient is a premenopausal female 18 years of age or older with a documented diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD) that is appropriately documented (i.e., evaluated by a complete clinical assessment, using DSM-4, interviews/questionnaires), and the patient has been receiving the requested drug for at least 8 weeks and has reported symptom improvement.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Initial: 12 weeks - Renewal: 1 year
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	Annual Review: 10/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Adefovir Dipivoxil

---

## Products Affected

- *adefovir dipivoxil*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Adempas

## Products Affected

- ADEMPAS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
QL Criteria	3 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advair Diskus

---

## Products Affected

- ADVAIR DISKUS INHALATION  
AEROSOL POWDER BREATH  
ACTIVATED 100-50 MCG/DOSE, 250-50  
MCG/DOSE

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Dulera
<b>QL Criteria</b>	1 diskus Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advair Diskus

---

## Products Affected

- ADVAIR DISKUS INHALATION  
AEROSOL POWDER BREATH  
ACTIVATED 500-50 MCG/DOSE

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Dulera
<b>QL Criteria</b>	2 inhalers Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advair HFA

---

## Products Affected

- ADVAIR HFA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Dulera
<b>QL Criteria</b>	1 inhaler Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advance Intuition Test

## Products Affected

- ADVANCE INTUITION TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advate

## Products Affected

- ADVATE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Advocate Duo

### Products Affected

- ADVOCATE DUO DEVICE

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	1 meter Per 1 year
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Advocate Redi-Code

### Products Affected

- ADVOCATE REDI-CODE IN VITRO

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



## Advocate Redi-Code+ Test

### Products Affected

- ADVOCATE REDI-CODE+ TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advocate Test

## Products Affected

- ADVOCATE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Afeditab CR

---

## Products Affected

- *afeditab cr oral tablet extended release 24 hour 30 mg*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Afeditab CR

---

## Products Affected

- *afeditab cr oral tablet extended release 24 hour 60 mg*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Afinitor

## Products Affected

- AFINITOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tab Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# AgaMatrix AMP Test

## Products Affected

- AGAMATRIX AMP TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# AgaMatrix Jazz Test

## Products Affected

- AGAMATRIX JAZZ TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# AgaMatrix KeyNote Test

## Products Affected

- AGAMATRIX KEYNOTE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017



# AgaMatrix Presto Test

## Products Affected

- AGAMATRIX PRESTO TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Akynzeo

## Products Affected

- AKYNZEO

PA Criteria	Criteria Details
Covered Uses	Prophylaxis of nausea and vomiting associated with cancer chemotherapy
Exclusion Criteria	
Required Medical Information	A documented diagnosis of nausea and vomiting associated with cancer chemotherapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of aprepitant and either ondansetron or granisetron
QL Criteria	2 capsules Per 1 month
Notes/References	Annual Review: 03/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aldurazyme

## Products Affected

- ALDURAZYME

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alendronate Sodium

---

## Products Affected

- *alendronate sodium oral tablet 10 mg*

<b>QL Criteria</b>	1 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alendronate Sodium

---

## Products Affected

- *alendronate sodium oral tablet 35 mg, 70 mg*

<b>QL Criteria</b>	4 tabs Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alendronate Sodium

---

## Products Affected

- *alendronate sodium oral tablet 40 mg, 5 mg*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alfuzosin HCl ER

---

## Products Affected

- *alfuzosin hcl er*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alimta

## Products Affected

- ALIMTA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Alimta.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Alimta.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Almotriptan Malate

---

## Products Affected

- *almotriptan malate*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: sumatriptan, naratriptan, rizatriptan
<b>QL Criteria</b>	6 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alogliptin Benzoate

---

## Products Affected

- *alogliptin benzoate*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alogliptin-Metformin HCl

---

## Products Affected

- *alogliptin-metformin hcl*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alogliptin-Pioglitazone

---

## Products Affected

- *alogliptin-pioglitazone*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alosetron HCl

---

## Products Affected

- *alose tron hcl*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 1 month each of diphenoxylate/atropine and loperamide
<b>Notes/ References</b>	Annual Review: 10/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aloxi

## Products Affected

- ALOXI INTRAVENOUS SOLUTION 0.25 MG/5ML

PA Criteria	Criteria Details
Covered Uses	PENDING
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	PENDING
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ALPRAZolam ER

---

## Products Affected

- *alprazolam er*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ALPRAZolam XR

---

## Products Affected

- *alprazolam xr*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Altoprev

---

## Products Affected

- ALTOPREV

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: atorvastatin, lovastatin, pravastatin, simvastain
<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alvesco

---

## Products Affected

- ALVESCO

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of QVAR
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Amitiza

---

## Products Affected

- AMITIZA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of lactulose or polyethylene glycol
<b>QL Criteria</b>	2 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Amlodipine Besylate-Valsartan

---

## Products Affected

- *amlodipine besylate-valsartan*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Amlodipine-Olmesartan

---

## Products Affected

- *amlodipine-olmesartan*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Amlodipine-Valsartan-HCTZ

---

## Products Affected

- *amlodipine-valsartan-hctz*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Amnesteem

---

## Products Affected

- *amnesteem*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of minocycline or doxycycline
<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Amphetamine-Dextroamphet ER

## Products Affected

- *amphetamine-dextroamphet er*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of an immediate release stimulant
QL Criteria	2 capsules Per 1 Day
Notes/References	Annual Review: 09/2017
Revision Date	Prior Authorization: September 26, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Amphetamine-Dextroamphetamine

---

## Products Affected

- *amphetamine-dextroamphetamine*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ampyra

## Products Affected

- AMPYRA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Anoro Ellipta

---

## Products Affected

- ANORO ELLIPTA

<b>QL Criteria</b>	1 kit Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Anzemet

---

## Products Affected

- ANZEMET ORAL

<b>QL Criteria</b>	10 tabs Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# APAP-Caff-Dihydrocodeine

## Products Affected

- *apap-caff-dihydrocodeine oral capsule*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 capsules Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Apidra

---

## Products Affected

- APIDRA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of a Humulin or Humalog product
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Apidra SoloStar

---

## Products Affected

- APIDRA SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of a Humulin or Humalog product
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Aprepitant

---

## Products Affected

- *aprepitant oral capsule 40 mg, 80 mg*

<b>QL Criteria</b>	3 capsules Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aprepitant

---

## Products Affected

- *aprepitant oral capsule 80 & 125 mg*

<b>QL Criteria</b>	9 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Apriso

---

## Products Affected

- APRISO

<b>QL Criteria</b>	4 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aptiom

---

## Products Affected

- APTIOM ORAL TABLET 200 MG

<b>QL Criteria</b>	6 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aralast NP

## Products Affected

- ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG, 500 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Alpha-1%20Antitrypsin%20Inhibitor%20Therapy.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Alpha-1 Antitrypsin Inhibitor Therapy.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Aranesp (Albumin Free)

### Products Affected

- ARANESP (ALBUMIN FREE) INJECTION SOLUTION 100 MCG/ML, 200 MCG/ML, 25 MCG/ML, 300 MCG/ML, 40 MCG/ML, 60 MCG/ML SOLUTION PREFILLED SYRINGE 100 MCG/0.5ML, 150 MCG/0.3ML, 200 MCG/0.4ML, 25 MCG/0.42ML, 300 MCG/0.6ML, 40 MCG/0.4ML, 500 MCG/ML, 60 MCG/0.3ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Erythropoiesis_Stimulating_Agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Erythropoiesis_Stimulating_Agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Arcalyst

## Products Affected

- ARCALYST

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/immunomodulators_CAP.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/immunomodulators_CAP.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Arcapta Neohaler

---

## Products Affected

- ARCAPTA NEOHALER

<b>QL Criteria</b>	1 cap Per 1 Day
<b>Notes/ References</b>	Annual Review: 07/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# ARIPiprazole

---

## Products Affected

- *aripiprazole oral solution*

<b>QL Criteria</b>	30 ml Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ARIPiprazole

---

## Products Affected

- *aripiprazole oral tablet*
- *aripiprazole oral tablet dispersible*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Armodafinil

## Products Affected

- *armodafinil oral tablet 150 mg*
- *armodafinil oral tablet 200 mg, 250 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patient's ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	

<b>ST Criteria</b>	FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY: A documented contraindication, intolerance, allergy, or failure of an adequate trial of at least two immediate release stimulants and modafinil (modafinil requires prior authorization). FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME: A documented contraindication, intolerance, allergy, or failure of an adequate trial of modafinil (modafinil requires prior authorization).
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: June 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Armodafinil

## Products Affected

- *armodafinil oral tablet 50 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patient's ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	

<b>ST Criteria</b>	FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY: A documented contraindication, intolerance, allergy, or failure of an adequate trial of at least two immediate release stimulants and modafinil (modafinil requires prior authorization). FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME: A documented contraindication, intolerance, allergy, or failure of an adequate trial of modafinil (modafinil requires prior authorization).
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: June 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Arzerra

## Products Affected

- ARZERRA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Arzerra.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Arzerra.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ascomp-Codeine

## Products Affected

- *ascomp-codeine*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017



<b>QL Criteria</b>	120 capsules Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Asmanex 120 Metered Doses

---

## Products Affected

- ASMANEX 120 METERED DOSES

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of QVAR
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Asmanex 14 Metered Doses

---

## Products Affected

- ASMANEX 14 METERED DOSES

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of QVAR
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Asmanex 30 Metered Doses

---

### Products Affected

- ASMANEX 30 METERED DOSES

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of QVAR
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Asmanex 60 Metered Doses

---

## Products Affected

- ASMANEX 60 METERED DOSES

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of QVAR
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Asmanex HFA

---

## Products Affected

- ASMANEX HFA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of QVAR
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Assure 3 Test

### Products Affected

- ASSURE 3 TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Assure 4 Test

### Products Affected

- ASSURE 4 TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Assure Platinum

## Products Affected

- ASSURE PLATINUM

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Assure Pro Test

## Products Affected

- ASSURE PRO TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Atomoxetine HCl

---

## Products Affected

- *atomoxetine hcl oral capsule 10 mg, 18 mg, 25 mg, 40 mg, 60 mg*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of a stimulant
<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Atomoxetine HCl

---

## Products Affected

- *atomoxetine hcl oral capsule 100 mg, 80 mg*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of a stimulant
<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Atorvastatin Calcium

---

## Products Affected

- *atorvastatin calcium oral*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Atripla

---

## Products Affected

- ATRIPLA

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aubagio

## Products Affected

- AUBAGIO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	1 tab Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Avandia

---

## Products Affected

- AVANDIA ORAL TABLET 2 MG, 4 MG

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Avonex

## Products Affected

- AVONEX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	1 kit Per 30 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Avonex Pen

## Products Affected

- AVONEX PEN INTRAMUSCULAR  
AUTO-INJECTOR KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	4 pens Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Avonex Prefilled

## Products Affected

- AVONEX PREFILLED  
INTRAMUSCULAR PREFILLED  
SYRINGE KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	4 syringes Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Balsalazide Disodium

---

## Products Affected

- *balsalazide disodium*

<b>QL Criteria</b>	9 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Banzel

---

## Products Affected

- BANZEL ORAL TABLET

<b>QL Criteria</b>	8 tabs Per 1 Day
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Bayer Breeze 2 Test

### Products Affected

- BAYER BREEZE 2 TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bayer Contour Next Test

## Products Affected

- BAYER CONTOUR NEXT TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bayer Contour Test

## Products Affected

- BAYER CONTOUR TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Beconase AQ

---

## Products Affected

- BECONASE AQ

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of fluticasone propionate and flunisolide
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Belsomra

## Products Affected

- BELSOMRA

PA Criteria	Criteria Details
Covered Uses	Insomnia
Exclusion Criteria	
Required Medical Information	A diagnosis of insomnia
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of zolpidem
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: October 07, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Belviq

## Products Affected

- BELVIQ

PA Criteria	Criteria Details
Covered Uses	Body Mass Index (BMI) greater than 30kg/m <sup>2</sup> or BMI greater than 27kg/m <sup>2</sup> with one or more of the items in the required medical information section
Exclusion Criteria	Concomitant use of two or more anti-obesity agents, pregnancy
Required Medical Information	Hypertension (systolic blood pressure greater than 140mm Hg or diastolic blood pressure greater than 90mm Hg on more than one occasion), Dyslipidemia (LDL cholesterol greater than/= 160mg/dL: HDL cholesterol less than 35mg/dL: triglycerides greater than/= 400mg/dL), Type 2 Diabetes Mellitus, Coronary Heart Disease, or Obstructive Sleep Apnea
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of phentermine cap or phendimetrazine tab
QL Criteria	2 tablets Per 1 Day
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Benlysta

## Products Affected

- BENLYSTA INTRAVENOUS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/benlysta.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/benlysta.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/benlysta.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/benlysta.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Benlysta

## Products Affected

- BENLYSTA SUBCUTANEOUS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/benlysta.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/benlysta.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/benlysta.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/benlysta.html</a>
QL Criteria	4 injections Per 1 month
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Berinert

## Products Affected

- BERINERT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/hereditary_angioedema.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/hereditary_angioedema.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/hereditary_angioedema.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/hereditary_angioedema.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Betaseron

## Products Affected

- BETASERON SUBCUTANEOUS KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	15 vials Per 1 fill
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bexarotene

## Products Affected

- *bexarotene*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Targretin.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Targretin.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Bicalutamide

---

## Products Affected

- *bicalutamide*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bimatoprost

## Products Affected

- *bimatoprost ophthalmic*

PA Criteria	Criteria Details
Covered Uses	open-angle glaucoma, ocular hypertension
Exclusion Criteria	
Required Medical Information	A documented diagnosis of glaucoma or ocular hypertension
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of latanoprost
Notes/References	Annual Review: 03/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bosulif

## Products Affected

- BOSULIF ORAL TABLET 100 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	4 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bosulif

## Products Affected

- BOSULIF ORAL TABLET 500 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	1 tab Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Botox

## Products Affected

- BOTOX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/botulinum_toxin.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/botulinum_toxin.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/botulinum_toxin.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/botulinum_toxin.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bravelle

## Products Affected

- BRAVELLE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Breo Ellipta

---

## Products Affected

- BREO ELLIPTA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Dulera
<b>QL Criteria</b>	2 blisters Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Brilinta

---

## Products Affected

- BRILINTA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of clopidogrel
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Brilinta

---

## Products Affected

- BRILINTA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of clopidogrel
<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Brovana

---

## Products Affected

- BROVANA

<b>QL Criteria</b>	60 vials Per 1 fill
<b>Notes/ References</b>	Annual Review: 07/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Budesonide

## Products Affected

- *budesonide inhalation*

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	For ages 5-8 documented inability to use metered dose inhalers
Age Restrictions	Less than 8 years of age
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	No prior authorization required for children 1-4 years of age. Medical Exception allowed for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory and for Nasal Polyps when all criteria met: A diagnosis of chronic sinusitis with nasal polyposis, endoscopic sinus surgery has been performed, and standard nasal steroid sprays have been used as part of post-operative management and have failed.
Notes/References	Annual Review: 07/2017
Revision Date	Prior Authorization: July 25, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bunavail

---

## Products Affected

- BUNAVAIL BUCCAL FILM 2.1-0.3 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of buprenorphine-naloxone sublingual tablet and Suboxone SL film
<b>QL Criteria</b>	6 films Per 1 Day
<b>Notes/ References</b>	Annual Review: 04/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bunavail

---

## Products Affected

- BUNAVAIL BUCCAL FILM 4.2-0.7 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of buprenorphine-naloxone sublingual tablet and Suboxone SL film
<b>QL Criteria</b>	3 films Per 1 Day
<b>Notes/ References</b>	Annual Review: 04/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bunavail

---

## Products Affected

- BUNAVAIL BUCCAL FILM 6.3-1 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of buprenorphine-naloxone sublingual tablet and Suboxone SL film
<b>QL Criteria</b>	2 films Per 1 Day
<b>Notes/ References</b>	Annual Review: 04/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Buphenyl

## Products Affected

- BUPHENYL ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Buprenorphine

## Products Affected

- *buprenorphine*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017



<b>QL Criteria</b>	4 patches Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Buprenorphine HCl

---

## Products Affected

- *buprenorphine hcl sublingual*

<b>QL Criteria</b>	3 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Buprenorphine HCl-Naloxone HCl

---

## Products Affected

- *buprenorphine hcl-naloxone hcl*

<b>QL Criteria</b>	3 tabs Per 1 Day
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# BuPROPion HCl

---

## Products Affected

- *bupropion hcl oral*

<b>QL Criteria</b>	6 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## BuPROPion HCl ER (Smoking Det)

---

### Products Affected

- *bupropion hcl er (smoking det)*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## BuPROPion HCl ER (SR)

---

### Products Affected

- *bupropion hcl er (sr)*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## BuPROPion HCl ER (XL)

---

### Products Affected

- *bupropion hcl er (xl)*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Butalbital-APAP-Caff-Cod

## Products Affected

- *butalbital-apap-caff-cod oral capsule 50-325-40-30 mg*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 capsules Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Butalbital-ASA-Caff-Codeine

## Products Affected

- *butalbital-asa-caff-codeine*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 capsules Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Butorphanol Tartrate

## Products Affected

- *butorphanol tartrate nasal*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	2 bottles Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bydureon

## Products Affected

- BYDUREON SUBCUTANEOUS PEN-INJECTOR

PA Criteria	Criteria Details
Covered Uses	Type 2 Diabetes Mellitus (NIDDM)
Exclusion Criteria	Diagnosis of metabolic syndrome or any other pre-diabetic diagnosis, diagnosis of Type 1 Diabetes, treatment of diabetic ketoacidosis, pediatric patients, patients with multiple endocrine neoplasia syndrome type 2 (MEN2), family history of medullary thyroid carcinoma (MTC), patients with a history of pancreatitis
Required Medical Information	Patient must have an A1C level is greater than 6.5%,
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of two of the following: Invokana/Invokamet, Jentaduetto/Tradjenta, or Januvia/Janumet/Janumet XR
QL Criteria	4 pens Per 1 month
Notes/References	Annual Review: 02/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

## Byetta 10 MCG Pen

### Products Affected

- BYETTA 10 MCG PEN SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
Covered Uses	Type 2 Diabetes Mellitus (NIDDM)
Exclusion Criteria	Diagnosis of metabolic syndrome or any other pre-diabetic diagnosis, diagnosis of Type 1 Diabetes, treatment of diabetic ketoacidosis, pediatric patients, patients with multiple endocrine neoplasia syndrome type 2 (MEN2), family history of medullary thyroid carcinoma (MTC), patients with a history of pancreatitis
Required Medical Information	Patient must have an A1C level is greater than 6.5%,
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of two of the following: Invokana/Invokamet, Jentaduetto/Tradjenta, or Januvia/Janumet/Janumet XR
QL Criteria	1 pen Per 1 fill
Notes/References	Annual Review: 02/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Byetta 5 MCG Pen

### Products Affected

- BYETTA 5 MCG PEN SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
Covered Uses	Type 2 Diabetes Mellitus (NIDDM)
Exclusion Criteria	Diagnosis of metabolic syndrome or any other pre-diabetic diagnosis, diagnosis of Type 1 Diabetes, treatment of diabetic ketoacidosis, pediatric patients, patients with multiple endocrine neoplasia syndrome type 2 (MEN2), family history of medullary thyroid carcinoma (MTC), patients with a history of pancreatitis
Required Medical Information	Patient must have an A1C level is greater than 6.5%,
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of two of the following: Invokana/Invokamet, Jentaduetto/Tradjenta, or Januvia/Janumet/Janumet XR
QL Criteria	1 pen Per 1 fill
Notes/References	Annual Review: 02/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017



# Bystolic

---

## Products Affected

- BYSTOLIC ORAL TABLET 10 MG, 5 MG • BYSTOLIC ORAL TABLET 2.5 MG

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	Annual Review: 07/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bystolic

---

## Products Affected

- BYSTOLIC ORAL TABLET 20 MG

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	Annual Review: 07/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Calcipotriene

---

## Products Affected

- *calcipotriene external*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of a medium to high potency topical steroid
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Calcipotriene-Betameth Diprop

---

## Products Affected

- *calcipotriene-betameth diprop*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of calcipotriene and a medium to high potency topical steroid
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Calcitonin (Salmon)

---

### Products Affected

- *calcitonin (salmon)*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of alendronate weekly 70mg
<b>QL Criteria</b>	1 bottle Per 1 fill
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Calcitrene

---

## Products Affected

- *calcitrene*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of a medium to high potency topical steroid
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Canasa

---

## Products Affected

- CANASA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Apriso
<b>QL Criteria</b>	1 unit Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Candesartan Cilexetil

---

## Products Affected

- *candesartan cilexetil oral tablet 16 mg, 4 mg, 8 mg*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Candesartan Cilexetil-HCTZ

---

## Products Affected

- *candesartan cilexetil-hctz*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Capecitabine

## Products Affected

- *capecitabine*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Caprelsa

## Products Affected

- CAPRELSA ORAL TABLET 100 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Caprelsa

## Products Affected

- CAPRELSA ORAL TABLET 300 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tab Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Carbaglu

## Products Affected

- CARBAGLU

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cardura XL

---

## Products Affected

- CARDURA XL

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CareSens N Glucose Test

## Products Affected

- CARESENS N GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cartia XT

---

## Products Affected

- *cartia xt oral capsule extended release 24 hour 120 mg, 300 mg*
- *cartia xt oral capsule extended release 24 hour 180 mg*

<b>QL Criteria</b>	1 cap Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Cartia XT

---

## Products Affected

- *cartia xt oral capsule extended release 24 hour 240 mg*

<b>QL Criteria</b>	2 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cayston

---

## Products Affected

- CAYSTON

<b>QL Criteria</b>	3 vials Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Celecoxib

---

## Products Affected

- *celecoxib oral*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two non steroidal anti-inflammatory drugs (NSAID)
<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cerdelga

## Products Affected

- CERDELGA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gaucher_disease.html">?http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gaucher_disease.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 caps Per 1 Day
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cerezyme

## Products Affected

- CEREZYME INTRAVENOUS SOLUTION  
RECONSTITUTED 400 UNIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gaucher_disease.html">?http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gaucher_disease.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cesamet

---

## Products Affected

- CESAMET

<b>QL Criteria</b>	2 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cetrotide

## Products Affected

- CETROTIDE SUBCUTANEOUS KIT 0.25 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infer-tility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infer-tility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cevimeline HCl

---

## Products Affected

- *cevimeline hcl*

<b>QL Criteria</b>	3 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Chantix

---

## Products Affected

- CHANTIX

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Chantix Continuing Month Pak

---

## Products Affected

- CHANTIX CONTINUING MONTH PAK

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Chenodal

## Products Affected

- CHENODAL

PA Criteria	Criteria Details
<b>Covered Uses</b>	For treatment of cholesterol-type gallstones in patients over 18 years of age and have tried and failed 2 years of generic Actigall (ursodiol) therapy and are not able to undergo surgery due to systemic disease or age, and for treatment of diagnosed Cerebrotendinous Xanthomatosis (CTX) in patients over 18 years of age
<b>Exclusion Criteria</b>	Intrahepatic duct calculus, Chronic constipation in patients with cholesterol gallstones, Prophylaxis of recurrent gallstones, Hyperlipidemia, Rheumatoid Arthritis
<b>Required Medical Information</b>	Prior to initial coverage for gallstone disease, a cholecystogram or other appropriate imaging studies is required to determine presence of radiolucent gallstones, stones that are transparent to x-rays. Due to high risk of hepatotoxicity and adverse effects, for the first 3 months, authorization is required each month pending hepatic function tests (for both gallstones and CTX). After initial 3 months, authorization required every 3 months for length of treatment, pending hepatic function tests. At 6 months prior to authorization, the following results are required, serum cholesterol levels, hepatic function test, and cholecystogram (monitor dissolution of stones). Safety of use beyond a total of 24 months has not been established
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 month (initial authorization), 3 month (reauthorization)
<b>Other Criteria</b>	Max authorization up to 2 years
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Chorionic Gonadotropin

---

## Products Affected

- *chorionic gonadotropin intramuscular*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cialis

## Products Affected

- CIALIS ORAL TABLET 5 MG

PA Criteria	Criteria Details
Covered Uses	Benign Prostatic hyperplasia (BPH)
Exclusion Criteria	Use solely for erectile dysfunction.
Required Medical Information	Diagnosis of benign prostatic hyperplasia
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of two alpha blockers and one 5-alpha reductase inhibitor
QL Criteria	1 tablets Per 1 Day
Notes/References	Annual Review: 07/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ciclodan

## Products Affected

- *ciclodan external solution*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Onychomycosis due to dermatophyte
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of onychomycosis confirmed by either a positive KOH stain (potassium hydroxide), positive PAS stain (para-aminosalicylic acid), a positive DTM (dermatophyte test medium) or positive fungal culture (NOTE: This positive test should be within the last 3 - 6 months and associated with the current infection)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Failure of an adequate trial of one systemic (oral) alternative is terbinafine (6 weeks for fingernail infections, 12 weeks for toenail infections), griseofulvin (6 months), itraconazole (60 days (PulsePak) for fingernail infections, 90 days for toenail), or if a member has hepatic dysfunction or increased risk for liver disease (for example, has a history of alcohol abuse or a history of hepatitis), or is female and is pregnant and/or breastfeeding. (No trial needed)
<b>Notes/References</b>	Annual Review: 07/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ciclopirox

## Products Affected

- *ciclopirox external solution*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Onychomycosis due to dermatophyte
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of onychomycosis confirmed by either a positive KOH stain (potassium hydroxide), positive PAS stain (para-aminosalicylic acid), a positive DTM (dermatophyte test medium) or positive fungal culture (NOTE: This positive test should be within the last 3 - 6 months and associated with the current infection)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Failure of an adequate trial of one systemic (oral) alternative is terbinafine (6 weeks for fingernail infections, 12 weeks for toenail infections), griseofulvin (6 months), itraconazole (60 days (PulsePak) for fingernail infections, 90 days for toenail), or if a member has hepatic dysfunction or increased risk for liver disease (for example, has a history of alcohol abuse or a history of hepatitis), or is female and is pregnant and/or breastfeeding. (No trial needed)
<b>Notes/References</b>	Annual Review: 07/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cimzia

## Products Affected

- CIMZIA SUBCUTANEOUS KIT 2 X 200 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html</a>
QL Criteria	1 kit Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Cimzia Prefilled

## Products Affected

- CIMZIA PREFILLED

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html</a>
QL Criteria	1 kit Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cimzia Starter Kit

## Products Affected

- CIMZIA STARTER KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Cimzia.html</a>
QL Criteria	1 kit Per 1 year
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Citalopram Hydrobromide

---

## Products Affected

- *citalopram hydrobromide oral tablet*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Citalopram Hydrobromide

---

## Products Affected

- *citalopram hydrobromide oral tablet*

<b>QL Criteria</b>	1 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Claravis

---

## Products Affected

- *claravis*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of minocycline or doxycycline
<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Clever Chek Auto-Code

### Products Affected

- CLEVER CHEK AUTO-CODE

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	1 meter Per 1 year
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Clever Chek Auto-Code Test

### Products Affected

- CLEVER CHEK AUTO-CODE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Clever Chek Auto-Code Voice

### Products Affected

- CLEVER CHEK AUTO-CODE VOICE IN VITRO

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017



## Clever Chek Test

### Products Affected

- CLEVER CHEK TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Clever Choice Auto-Code Test

### Products Affected

- CLEVER CHOICE AUTO-CODE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Clever Choice Micro Test

### Products Affected

- CLEVER CHOICE MICRO TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Climara Pro

---

## Products Affected

- CLIMARA PRO

<b>QL Criteria</b>	1 box Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CloNIDine HCl ER

---

## Products Affected

- *clonidine hcl er*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of a stimulant
<b>QL Criteria</b>	4 tabs Per 1 Day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clopidogrel Bisulfate

---

## Products Affected

- *clopidogrel bisulfate oral*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clopidogrel Bisulfate

---

## Products Affected

- *clopidogrel bisulfate oral*

<b>QL Criteria</b>	1 tab Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CloZAPine

---

## Products Affected

- *clozapine oral tablet 100 mg*
- *clozapine oral tablet dispersible 100 mg*

<b>QL Criteria</b>	9 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# CloZAPine

---

## Products Affected

- *clozapine oral tablet 200 mg*

<b>QL Criteria</b>	4 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CloZAPine

---

## Products Affected

- *clozapine oral tablet 25 mg, 50 mg*
- *clozapine oral tablet dispersible 25 mg*

<b>QL Criteria</b>	3 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CloZAPine

---

## Products Affected

- *clozapine oral tablet dispersible 12.5 mg*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CloZAPine

---

## Products Affected

- *clozapine oral tablet dispersible 150 mg*

<b>QL Criteria</b>	6 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CloZAPine

---

## Products Affected

- *clozapine oral tablet dispersible 200 mg*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Codeine Sulfate

## Products Affected

- *codeine sulfate oral tablet*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Colchicine

---

## Products Affected

- *colchicine oral tablet*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# CombiPatch

---

## Products Affected

- COMBIPATCH

<b>QL Criteria</b>	8 patch Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Cometriq (100 mg Daily Dose)

### Products Affected

- COMETRIQ (100 MG DAILY DOSE)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Cometriq (140 mg Daily Dose)

### Products Affected

- COMETRIQ (140 MG DAILY DOSE)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Cometriq (60 mg Daily Dose)

### Products Affected

- COMETRIQ (60 MG DAILY DOSE)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Complera

---

## Products Affected

- COMPLERA

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Contrave

## Products Affected

- CONTRAVE

PA Criteria	Criteria Details
Covered Uses	Body Mass Index (BMI) greater than 30kg/m <sup>2</sup> or BMI greater than 27kg/m <sup>2</sup> with one or more of the items in the required medical information section
Exclusion Criteria	Concomitant use of two or more anti-obesity agents, pregnancy
Required Medical Information	Hypertension (systolic blood pressure greater than 140mm Hg or diastolic blood pressure greater than 90mm Hg on more than one occasion), Dyslipidemia (LDL cholesterol greater than/= 160mg/dL: HDL cholesterol less than 35mg/dL: triglycerides greater than/= 400mg/dL), Type 2 Diabetes Mellitus, Coronary Heart Disease, or Obstructive Sleep Apnea
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of phentermine cap or phendimetrazine tab
QL Criteria	4 tablets Per 1 Day
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Copaxone

## Products Affected

- COPAXONE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cordran

---

## Products Affected

- CORDRAN EXTERNAL TAPE

<b>QL Criteria</b>	1 roll Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Coreg CR

---

## Products Affected

- COREG CR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of carvedilol
<b>QL Criteria</b>	1 cap Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Corlanor

## Products Affected

- CORLANOR

PA Criteria	Criteria Details
<b>Covered Uses</b>	FDA labeled use for heart failure
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of stable, symptomatic chronic heart failure with left ventricular ejection fraction less than or equal to 35%, who are in sinus rhythm with resting heart rate greater than or equal to 70 beats per minute, and who are on maximally tolerated doses of beta-blockers (bisoprolol/bisoprolol-HCTZ, carvedilol, carvedilol CR, metoprolol succinate/metoprolol succinate-HCTZ, nebivolol) or have a documented contraindication to beta-blocker use.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of one month of a formulary ACE Inhibitor, ACE Inhibitor/HCTZ combination product, Angiotensin-Receptor Blocker, or Angiotensin-Receptor Blocker/HCTZ combination product
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Cosopt PF

---

## Products Affected

- COSOPT PF

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of dorzolamide/timolol
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Creon

## Products Affected

- CREON

PA Criteria	Criteria Details
<b>Covered Uses</b>	Exocrine pancreatic Insufficiency
<b>Exclusion Criteria</b>	Uses not approved by the FDA, uses unapproved and not supported by the literature or evidence as an accepted off-label use. (see Off-Label Use Policy for determining accepted use).
<b>Required Medical Information</b>	Diagnosis of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 2 weeks of Zenpep
<b>Notes/References</b>	Annual Review: 07/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Crinone

## Products Affected

- CRINONE VAGINAL GEL 4 %

PA Criteria	Criteria Details
<b>Covered Uses</b>	ART (Assisted Reproductive Technology), secondary amenorrhea, prevention of early pregnancy failure
<b>Exclusion Criteria</b>	Not covered for uses not approved by the FDA or if the use is unapproved and not supported by the literature or evidence as an accepted off-label use (see Off-Label Use Policy for determining accepted use).
<b>Required Medical Information</b>	Covered for prevention of early pregnancy failure, for ART (Assisted Reproductive Technology) when there is a documented diagnosis of progesterone deficiency in an infertile woman who has infertility coverage, and for secondary amenorrhea when there is a documented diagnosis of progesterone deficiency in an infertile woman who has infertility coverage
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	Annual Review: 10/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Crinone

## Products Affected

- CRINONE VAGINAL GEL 8 %

PA Criteria	Criteria Details
Covered Uses	ART (Assisted Reproductive Technology), secondary amenorrhea, prevention of early pregnancy failure
Exclusion Criteria	Not covered for uses not approved by the FDA or if the use is unapproved and not supported by the literature or evidence as an accepted off-label use (see Off-Label Use Policy for determining accepted use).
Required Medical Information	Covered for prevention of early pregnancy failure, for ART (Assisted Reproductive Technology) when there is a documented diagnosis of progesterone deficiency in an infertile woman who has infertility coverage, and for secondary amenorrhea when there is a documented diagnosis of progesterone deficiency in an infertile woman who has infertility coverage
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of Crinone 4%
Notes/References	Annual Review: 10/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Cuvposa

## Products Affected

- CUVPOSA

PA Criteria	Criteria Details
<b>Covered Uses</b>	neurologic conditions associated with drooling (e.g. cerebral palsy)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentaion of neurologic conditions associated with drooling (e.g. cerebral palsy) to reduce severe chronic drooling
<b>Age Restrictions</b>	3 years to 16 years
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cycloset

---

## Products Affected

- CYCLOSET

<b>QL Criteria</b>	6 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Cystagon

## Products Affected

- CYSTAGON

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cystaran

## Products Affected

- CYSTARAN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/EYE/opthalmic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/EYE/opthalmic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 bottles Per 1 month
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dacogen

## Products Affected

- DACOGEN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Daklinza

## Products Affected

- DAKLINZA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Daliresp

## Products Affected

- DALIRESP

PA Criteria	Criteria Details
Covered Uses	Severe COPD
Exclusion Criteria	Use for relief of acute bronchospasm
Required Medical Information	A diagnosis of severe COPD (FEV1 less than 50% predicted) associated with chronic bronchitis and at least one documented COPD exacerbation in the previous year
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of Incruse and either Advair, Symbicort, or Serevent
QL Criteria	1 tab Per 1 Day
Notes/References	Annual Review: 06/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Darifenacin Hydrobromide ER

---

## Products Affected

- *darifenacin hydrobromide er*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of oxybutynin or trospium IR and through either Vesicare or Myrbetriq
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Daytrana

## Products Affected

- DAYTRANA

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of an immediate release stimulant
QL Criteria	1 patch Per 1 Day
Notes/References	Annual Review: 09/2017
Revision Date	Prior Authorization: September 26, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Decitabine

## Products Affected

- *decitabine*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Delzicol

---

## Products Affected

- DELZICOL

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Apriso
<b>QL Criteria</b>	12 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Denavir

---

## Products Affected

- DENAVIR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of oral acyclovir
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Descovy

## Products Affected

- DESCOVY

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviral_hiv.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviral_hiv.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Desloratadine

---

## Products Affected

- *desloratadine oral tablet*
- *desloratadine oral tablet dispersible 2.5 mg*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: Claritin OTC, Zyrtec OTC, Allegra OTC
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Desloratadine

---

## Products Affected

- *desloratadine oral tablet dispersible 5 mg*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: Claritin OTC, Zyrtec OTC, Allegra OTC
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Desvenlafaxine Succinate ER

## Products Affected

- *desvenlafaxine succinate er*

PA Criteria	Criteria Details
Covered Uses	Major Depressive Disorder (MDD)
Exclusion Criteria	
Required Medical Information	A diagnosis of Major Depressive Disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of three different antidepressants from at least two different therapeutic subclasses (includes SSRIs, SNRIs, NDRIs, TCAs, tetracyclic antidepressants, and MAOIs) (step therapy not required if patient is a new member and has been receiving medication therapy for more than 4 weeks.)
QL Criteria	1 tablet Per 1 Day
Notes/References	Annual Review: 05/2017
Revision Date	Prior Authorization: April 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Dexilant

## Products Affected

- DEXILANT

PA Criteria	Criteria Details
<b>Covered Uses</b>	Diagnosis of Zollinger-Ellison syndrome, Uncomplicated gastroesophageal reflux disease (Gerd) with breakthrough symptoms, Complicated GERD and other higher risk conditions such as feflux-associated laryngitis, recent gastrointestinal bleed, grade 3 or 4 erosive esophagitis, or GERD exacerbated asthma.
<b>Exclusion Criteria</b>	Non-Covered uses include uses not approved by the FDA, or if use is unapproved and not supported by the literature or evidence as an accepted off-label use (see Off-Label Use Policy for determining accepted use). Quantity levels exceeding the quantity limitations on PPIs, Dexilant dosing exceeding 60mg/day
<b>Required Medical Information</b>	A diagnosis of Zollinger-Ellison syndrome, uncomplicated gastroesophageal reflux disease (GERD) with breakthrough symptoms, Complicated GERD and other higher risk conditions such as feflux-associated laryngitis, recent gastrointestinal bleed, grade 3 or 4 erosive esophagitis, or GERD exacerbated asthma.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year, short term court of high dose= 3 months
<b>Other Criteria</b>	
<b>ST Criteria</b>	ONCE DAILY DOSING OF RABEPRAZOLE (20mg), DEXILANT (60mg), AND NEXIUM (40mg): A documented contraindication, intolerance, allergy, or failure of Prilosec OTC/omeprazole, Prevacid 24H OTC, and pantoprazole. HIGH DOSE NEXIUM (80mg) OR HIGH DOSE RABEPRAZOLE (40mg): A documented contraindication, intolerance, allergy, or failure of 80mg/day of Prilosec OTC/omeprazole or pantoprazole or though 60mg/day of Prevacid 24H OTC.
<b>QL Criteria</b>	1 capsule Per 1 Day

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017



# Dexmethylphenidate HCl

---

## Products Affected

- *dexmethylphenidate hcl*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dexmethylphenidate HCl ER

## Products Affected

- *dexmethylphenidate hcl er*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of an immediate release stimulant
QL Criteria	2 capsules Per 1 Day
Notes/References	Annual Review: 09/2017
Revision Date	Prior Authorization: September 26, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dextroamphetamine Sulfate

## Products Affected

- *dextroamphetamine sulfate oral solution*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	40 ML Per 1 Day
Notes/References	Annual Review: 10/2017
Revision Date	Prior Authorization: September 26, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dextroamphetamine Sulfate

---

## Products Affected

- *dextroamphetamine sulfate oral tablet*

<b>QL Criteria</b>	4 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dextroamphetamine Sulfate ER

## Products Affected

- *dextroamphetamine sulfate er*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	3 caps Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 26, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# DiazePAM

---

## Products Affected

- *diazepam rectal*

<b>QL Criteria</b>	1 pack Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diclofenac Sodium

---

## Products Affected

- *diclofenac sodium transdermal gel 1 %*

<b>QL Criteria</b>	200 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dificid

## Products Affected

- DIFICID

PA Criteria	Criteria Details
Covered Uses	clostridium difficile associated diarrhea
Exclusion Criteria	Initial episodes of mild, moderate, or severe CDI. Severe complicated CDI (i.e. hypotension, ileus, megacolon, or shock).
Required Medical Information	A diagnosis of clostridium difficile associated diarrhea in adults
Age Restrictions	18 years old or greater
Prescriber Restrictions	
Coverage Duration	10 Days of therapy
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of two courses of antibiotics, metronidazole and/or oral vancomycin
QL Criteria	20 tabs Per 1 fill
Notes/References	Annual Review: 09/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Diltiazem CD

---

## Products Affected

- *diltiazem cd oral capsule extended release*  
*24 hour 120 mg, 180 mg*

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diltiazem CD

---

## Products Affected

- *diltiazem cd oral capsule extended release*  
*24 hour 240 mg*

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diltiazem HCl ER

---

## Products Affected

- *diltiazem hcl er oral capsule extended release 24 hour 240 mg*

<b>QL Criteria</b>	2 cap Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diltiazem HCl ER Beads

---

## Products Affected

- *diltiazem hcl er beads oral capsule extended release 24 hour 120 mg, 180 mg, 300 mg, 360 mg*

<b>QL Criteria</b>	1 cap Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diltiazem HCl ER Beads

---

## Products Affected

- *diltiazem hcl er beads oral capsule extended release 24 hour 240 mg*

<b>QL Criteria</b>	2 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diltiazem HCl ER Beads

---

## Products Affected

- *diltiazem hcl er beads oral capsule extended release 24 hour 420 mg*

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diltiazem HCl ER Coated Beads

---

## Products Affected

- *diltiazem hcl er coated beads oral capsule extended release 24 hour 120 mg, 180 mg*
- *diltiazem hcl er coated beads oral capsule extended release 24 hour 360 mg*

<b>QL Criteria</b>	1 cap Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# DiTIAZem HCl ER Coated Beads

---

## Products Affected

- *diltiazem hcl er coated beads oral capsule  
extended release 24 hour 240 mg*

<b>QL Criteria</b>	2 cap Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# DiTIAZem HCl ER Coated Beads

---

## Products Affected

- *diltiazem hcl er coated beads oral capsule  
extended release 24 hour 300 mg*

<b>QL Criteria</b>	1 cap Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dilt-XR

---

## Products Affected

- *dilt-xr oral capsule extended release 24 hour*  
240 mg

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dipentum

---

## Products Affected

- DIPENTUM

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Apriso and balsalazide
<b>QL Criteria</b>	4 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Divigel

---

## Products Affected

- DIVIGEL

<b>QL Criteria</b>	1 packet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Donepezil HCl

---

## Products Affected

- *donepezil hcl oral tablet 23 mg*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of donepezil 10mg
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Doxycycline

---

## Products Affected

- *doxycycline*

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dronabinol

## Products Affected

- dronabinol*

PA Criteria	Criteria Details
Covered Uses	Anorexia associated with weight loss in patients with AIDS, Chemotherapy-induced nausea and vomiting
Exclusion Criteria	Multiple sclerosis (spasticity), Fibromyalgia (Neuropathic Pain)
Required Medical Information	A diagnosis of anorexia associated with weight loss in patients with AIDS or for the treatment of chemotherapy induced nausea and vomiting
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Initial: 6 months. Continuation: 12 months if demonstrated adequate response to therapy.
Other Criteria	
ST Criteria	FOR CHEMOTHERAPY INDUCED NAUSEA AND VOMITING ONLY: A documented contraindication, intolerance, allergy, or failure of prochlorperazine, chlorpromazine, haloperidol or metoclopramide
QL Criteria	2 caps Per 1 Day
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Duavee

## Products Affected

- DUAVEE

PA Criteria	Criteria Details
Covered Uses	Treatment of moderate to severe vasomotor symptoms associated with menopause, Prevention of postmenopausal osteoporosis
Exclusion Criteria	
Required Medical Information	A documented diagnosis of moderate to severe vasomotor symptoms associated with menopause or prevention of postmenopausal osteoporosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of estrogen products and raloxifene
QL Criteria	1 tab Per 1 Day
Notes/References	
Revision Date	Prior Authorization: October 12, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Dulera

---

## Products Affected

- DULERA

<b>QL Criteria</b>	1 inhaler Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# DULoxetine HCl

---

## Products Affected

- *duloxetine hcl oral capsule delayed release particles 20 mg*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# DULoxetine HCl

---

## Products Affected

- *duloxetine hcl oral capsule delayed release particles 30 mg*
- *duloxetine hcl oral capsule delayed release particles 40 mg*

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# DULoxetine HCl

---

## Products Affected

- *duloxetine hcl oral capsule delayed release particles 60 mg*

<b>QL Criteria</b>	1 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dutasteride

---

## Products Affected

- *dutasteride*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of finasteride
<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Easy Plus II Glucose Test

### Products Affected

- EASY PLUS II GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 1 month
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Easy Step Test

## Products Affected

- EASY STEP TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Easy Talk Blood Glucose Test

### Products Affected

- EASY TALK BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Easy Touch Test

## Products Affected

- EASY TOUCH TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Easy Trak Blood Glucose Test

## Products Affected

- EASY TRAK BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EasyGluco

## Products Affected

- EASYGLUCO IN VITRO

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EasyMax 15 Test

## Products Affected

- EASYMAX 15 TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EASYMax Test

## Products Affected

- EASYMAX TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EasyPlus Blood Glucose Test

## Products Affected

- EASYPLUS BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EasyPRO Plus

## Products Affected

- EASYPRO PLUS IN VITRO

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Edarbi

---

## Products Affected

- EDARBI

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Edarbyclor

---

## Products Affected

- EDARBYCLOR

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Edurant

---

## Products Affected

- EDURANT

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Elaprase

## Products Affected

- ELAPRASE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Elelyso

## Products Affected

- ELELYSO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gaucher_disease.html">?http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gaucher_disease.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gaucher_disease.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gaucher_disease.html</a>
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Element Test

## Products Affected

- ELEMENT TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Elestrin

---

## Products Affected

- ELESTRIN

<b>QL Criteria</b>	52 gm Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Eletriptan Hydrobromide

---

## Products Affected

- *eletriptan hydrobromide*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: sumatriptan, naratriptan, rizatriptan
<b>QL Criteria</b>	6 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Elidel

## Products Affected

- ELIDEL

PA Criteria	Criteria Details
Covered Uses	atopic dermatitis
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year (3 months if less than 2 years old)
Other Criteria	
ST Criteria	FOR ADULTS: A documented contraindication, intolerance, allergy, or failure of a 2 week trial (14 days) of one preferred alternative topical corticosteroid indicated for the patients condition (Step therapy not required if in an area at high risk area such as face, eyelids, or genital areas)
Notes/References	Annual Review: 06/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Eliquis

---

## Products Affected

- ELIQUIS

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Xarelto and Pradaxa
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Embeda

## Products Affected

- EMBEDA

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Embrace Blood Glucose Test

## Products Affected

- EMBRACE BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Emsam

## Products Affected

- EMSAM

PA Criteria	Criteria Details
Covered Uses	Major Depressive Disorder (MDD)
Exclusion Criteria	
Required Medical Information	A diagnosis of Major Depressive Disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of three different antidepressants from at least two different therapeutic subclasses (includes SSRIs, SNRIs, NDRIs, TCAs, tetracyclic antidepressants, and MAOIs) (step therapy not required if patient is a new member and has been receiving medication therapy for more than 4 weeks.)
QL Criteria	1 patch Per 1 Day
Notes/References	Annual Review: 09/2017
Revision Date	Prior Authorization: April 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Emtriva

---

## Products Affected

- EMTRIVA ORAL CAPSULE

<b>QL Criteria</b>	1 cap Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Enbrel

## Products Affected

- ENBREL SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE 25 MG/0.5ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html</a>
QL Criteria	8 syringes Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Enbrel

## Products Affected

- ENBREL SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE 50 MG/ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html</a>
QL Criteria	4 syringes Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017



# Enbrel SureClick

## Products Affected

- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Enbrel.html</a>
QL Criteria	4 syringes Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Endocet

## Products Affected

- *endocet oral tablet 10-325 mg, 5-325 mg*
- *endocet oral tablet 7.5-325 mg*
- ENDOCET ORAL TABLET 2.5-325 MG

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Endometrin

## Products Affected

- ENDOMETRIN

PA Criteria	Criteria Details
Covered Uses	ART (Assisted Reproductive Technology), prevention of early pregnancy failure
Exclusion Criteria	Not covered for uses not approved by the FDA or if the use is unapproved and not supported by the literature or evidence as an accepted off-label use (see Off-Label Use Policy for determining accepted use).
Required Medical Information	Covered for prevention of early pregnancy failure and for ART (Assisted Reproductive Technology) when there is a documented diagnosis of progesterone deficiency in an infertile woman who has infertility coverage
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	Annual Review: 10/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Enoxaparin Sodium

---

## Products Affected

- *enoxaparin sodium*

<b>QL Criteria</b>	2 syringes Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Entecavir

---

## Products Affected

- *entecavir*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Epclusa

## Products Affected

- EPCLUSA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Epiduo Forte

---

## Products Affected

- EPIDUO FORTE

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of tretinoin
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# EPINEPHrine

---

## Products Affected

- *epinephrine injection solution auto-injector*  
*0.15 mg/0.15ml*

<b>QL Criteria</b>	1 pack Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EPINEPHrine

---

## Products Affected

- *epinephrine injection solution auto-injector*  
*0.15 mg/0.3ml, 0.3 mg/0.3ml*

<b>QL Criteria</b>	8 pens Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EpiPen 2-Pak

---

## Products Affected

- EPIPEN 2-PAK INJECTION SOLUTION  
AUTO-INJECTOR

<b>QL Criteria</b>	2 doses Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EpiPen Jr 2-Pak

---

## Products Affected

- EPIPEN JR 2-PAK INJECTION  
SOLUTION AUTO-INJECTOR

<b>QL Criteria</b>	2 doses Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Epogen

## Products Affected

- EPOGEN INJECTION SOLUTION 10000 UNIT/ML, 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/Erythroipoiesis_Stimulating_Agents.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/Erythroipoiesis_Stimulating_Agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Epoprostenol Sodium

## Products Affected

- *epoprostenol sodium*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Eprosartan Mesylate

---

## Products Affected

- *eprosartan mesylate*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Erivedge

## Products Affected

- ERIVEDGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 cap Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Escitalopram Oxalate

---

## Products Affected

- *escitalopram oxalate oral tablet 10 mg*

<b>QL Criteria</b>	1.5 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Escitalopram Oxalate

---

## Products Affected

- *escitalopram oxalate oral tablet 20 mg, 5 mg*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Esomeprazole Magnesium

## Products Affected

- *esomeprazole magnesium*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Diagnosis of Zollinger-Ellison syndrome, Uncomplicated gastroesophageal reflux disease (Gerd) with breakthrough symptoms, Complicated GERD and other higher risk conditions such as feflux-associated laryngitis, recent gastrointestinal bleed, grade 3 or 4 erosive esophagitis, or GERD exacerbated asthma.
<b>Exclusion Criteria</b>	Non-Covered uses include uses not approved by the FDA, or if use is unapproved and not supported by the literature or evidence as an accepted off-label use (see Off-Label Use Policy for determining accepted use). Quantity levels exceeding the quantity limitations on PPIs, Dexilant dosing exceeding 60mg/day
<b>Required Medical Information</b>	A diagnosis of Zollinger-Ellison syndrome, uncomplicated gastroesophageal reflux disease (GERD) with breakthrough symptoms, Complicated GERD and other higher risk conditions such as feflux-associated laryngitis, recent gastrointestinal bleed, grade 3 or 4 erosive esophagitis, or GERD exacerbated asthma.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year, short term court of high dose= 3 months
<b>Other Criteria</b>	
<b>ST Criteria</b>	ONCE DAILY DOSING OF RABEPRAZOLE (20mg), DEXILANT (60mg), AND NEXIUM (40mg): A documented contraindication, intolerance, allergy, or failure of Prilosec OTC/omeprazole, Prevacid 24H OTC, and pantoprazole. HIGH DOSE NEXIUM (80mg) OR HIGH DOSE RABEPRAZOLE (40mg): A documented contraindication, intolerance, allergy, or failure of 80mg/day of Prilosec OTC/omeprazole or pantoprazole or though 60mg/day of Prevacid 24H OTC.
<b>QL Criteria</b>	1 capsule Per 1 Day

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Estradiol

---

## Products Affected

- *estradiol transdermal patch twice weekly*

<b>QL Criteria</b>	8 patches Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Estradiol

---

## Products Affected

- *estradiol transdermal patch weekly*

<b>QL Criteria</b>	4 patches Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Estradiol-Norethindrone Acet

---

## Products Affected

- *estradiol-norethindrone acet*

<b>QL Criteria</b>	1 EA Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Estradiol-Norethindrone Acet

---

## Products Affected

- *estradiol-norethindrone acet*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Estrogel

---

## Products Affected

- ESTROGEL

<b>QL Criteria</b>	50 grams Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Eszopiclone

---

## Products Affected

- *eszopiclone*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Evamist

---

## Products Affected

- EVAMIST

<b>QL Criteria</b>	2 bottles Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## EvenCare + Blood Glucose Test

### Products Affected

- EVENCARE + BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 1 month
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EvenCare Blood Glucose Test

## Products Affected

- EVENCARE BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## EvenCare G2 Test

### Products Affected

- EVENCARE G2 TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## EvenCare G3 Test

### Products Affected

- EVENCARE G3 TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Evolution Autocode

## Products Affected

- EVOLUTION AUTOCODE IN VITRO

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Exjade

## Products Affected

- EXJADE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Anitdotes.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Anitdotes.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Extavia

## Products Affected

- EXTAVIA SUBCUTANEOUS KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	15 vials Per 1 fill
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Ez Smart Blood Glucose Test

### Products Affected

- EZ SMART BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Ez Smart Plus Glucose Test

### Products Affected

- EZ SMART PLUS GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ezetimibe

---

## Products Affected

- *ezetimibe*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ezetimibe-Simvastatin

---

## Products Affected

- *ezetimibe-simvastatin*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: atorvastatin, lovastatin, pravastatin, simvastain
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fabrazyme

## Products Affected

- FABRAZYME

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Famciclovir

---

## Products Affected

- *famciclovir oral*

<b>QL Criteria</b>	21 tabs Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Fanapt

---

## Products Affected

- FANAPT

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: aripiprazole, risperidone, quetiapine, ziprasidone, olanzapine, or clozapine
<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fanapt Titration Pack

---

## Products Affected

- FANAPT TITRATION PACK

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: aripiprazole, risperidone, quetiapine, ziprasidone, olanzapine, or clozapine
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Farxiga

---

## Products Affected

- FARXIGA

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Felodipine ER

---

## Products Affected

- *felodipine er*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Femring

---

## Products Affected

- FEMRING

<b>QL Criteria</b>	1 ring Per 90 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fenofibrate

---

## Products Affected

- *fenofibrate oral capsule*

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fenofibrate

---

## Products Affected

- *fenofibrate oral tablet 145 mg, 160 mg, 48 mg, 54 mg*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fenofibrate Micronized

---

## Products Affected

- *fenofibrate micronized*

<b>QL Criteria</b>	1 cap Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Fenofibric Acid

---

## Products Affected

- *fenofibric acid oral tablet*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FentaNYL

## Products Affected

- *fentanyl*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	20 patches Per 30 Days
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FentaNYL Citrate

## Products Affected

- *fentanyl citrate buccal*

PA Criteria	Criteria Details
Covered Uses	Pain due to malignant diagnosis only
Exclusion Criteria	Non-malignant pain, management of acute or postoperative or in patients not taking chronic opiates or not tolerant to opioid therapy.
Required Medical Information	Covered for members with pain due to malignant diagnosis only
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of two immediate-release opioids including morphine, hydrocodone, oxycodone, or hydromorphone.
QL Criteria	120 lozenges Per 30 Days
Notes/References	Annual Review: 06/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ferriprox

## Products Affected

- FERRIPROX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Anitdotes.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Anitdotes.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fetzima

## Products Affected

- FETZIMA

PA Criteria	Criteria Details
Covered Uses	Major Depressive Disorder (MDD)
Exclusion Criteria	
Required Medical Information	A diagnosis of Major Depressive Disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of three different antidepressants from at least two different therapeutic subclasses (includes SSRIs, SNRIs, NDRIs, TCAs, tetracyclic antidepressants, and MAOIs) (step therapy not required if patient is a new member and has been receiving medication therapy for more than 4 weeks.)
QL Criteria	1 cap Per 1 Day
Notes/References	Annual Review: 05/2017
Revision Date	Prior Authorization: April 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fetzima Titration

## Products Affected

- FETZIMA TITRATION

PA Criteria	Criteria Details
Covered Uses	Major Depressive Disorder (MDD)
Exclusion Criteria	
Required Medical Information	A diagnosis of Major Depressive Disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of three different antidepressants from at least two different therapeutic subclasses (includes SSRIs, SNRIs, NDRIs, TCAs, tetracyclic antidepressants, and MAOIs) (step therapy not required if patient is a new member and has been receiving medication therapy for more than 4 weeks.)
QL Criteria	1 capsule Per 1 Day
Notes/References	Annual Review: 05/2017
Revision Date	Prior Authorization: April 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Fifty50 Glucose Test 2.0

### Products Affected

- FIFTY50 GLUCOSE TEST 2.0

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Firmagon

## Products Affected

- FIRMAGON SUBCUTANEOUS SOLUTION RECONSTITUTED 80 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# First-Progesterone VGS 100

## Products Affected

- FIRST-PROGESTERONE VGS 100

PA Criteria	Criteria Details
Covered Uses	ART (Assisted Reproductive Technology), prevention of early pregnancy failure
Exclusion Criteria	Not covered for uses not approved by the FDA or if the use is unapproved and not supported by the literature or evidence as an accepted off-label use (see Off-Label Use Policy for determining accepted use).
Required Medical Information	Covered for prevention of early pregnancy failure and for ART (Assisted Reproductive Technology) when there is a documented diagnosis of progesterone deficiency in an infertile woman who has infertility coverage
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# First-Progesterone VGS 200

## Products Affected

- FIRST-PROGESTERONE VGS 200

PA Criteria	Criteria Details
Covered Uses	ART (Assisted Reproductive Technology), prevention of early pregnancy failure
Exclusion Criteria	Not covered for uses not approved by the FDA or if the use is unapproved and not supported by the literature or evidence as an accepted off-label use (see Off-Label Use Policy for determining accepted use).
Required Medical Information	Covered for prevention of early pregnancy failure and for ART (Assisted Reproductive Technology) when there is a documented diagnosis of progesterone deficiency in an infertile woman who has infertility coverage
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Flebogamma DIF

## Products Affected

- FLEBOGAMMA DIF

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/ivig.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Flovent Diskus

---

## Products Affected

- FLOVENT DISKUS

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of QVAR
<b>QL Criteria</b>	2 blisters Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: October 30, 2017

# Flovent HFA

---

## Products Affected

- FLOVENT HFA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of QVAR
<b>QL Criteria</b>	1 inhaler Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Flowtuss

---

## Products Affected

- FLOWTUSS

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of a codeine/guaifenesin combination product
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FLUoxetine HCl

---

## Products Affected

- *fluoxetine hcl oral capsule 10 mg*

<b>QL Criteria</b>	1 cap Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# FLUoxetine HCl

---

## Products Affected

- *fluoxetine hcl oral capsule 20 mg*

<b>QL Criteria</b>	4 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FLUoxetine HCl

---

## Products Affected

- *fluoxetine hcl oral capsule 40 mg*

<b>QL Criteria</b>	2 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FLUoxetine HCl

---

## Products Affected

- *fluoxetine hcl oral capsule delayed release*

<b>QL Criteria</b>	4 caps Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FLUoxetine HCl

---

## Products Affected

- *fluoxetine hcl oral tablet 10 mg*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FLUoxetine HCl

---

## Products Affected

- *fluoxetine hcl oral tablet 20 mg*

<b>QL Criteria</b>	4 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fluticasone Propionate

---

## Products Affected

- *fluticasone propionate nasal*

<b>QL Criteria</b>	1 bottle Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fluticasone-Salmeterol

---

## Products Affected

- *fluticasone-salmeterol*

<b>QL Criteria</b>	1 inhaler Per 30 dayss
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fluvastatin Sodium

---

## Products Affected

- *fluvastatin sodium*

<b>QL Criteria</b>	2 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Fluvastatin Sodium ER

---

## Products Affected

- *fluvastatin sodium er*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fluvoxamine Maleate

---

## Products Affected

- *fluvoxamine maleate oral tablet 100 mg*

<b>QL Criteria</b>	3 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fluvoxamine Maleate

---

## Products Affected

- *fluvoxamine maleate oral tablet 25 mg*
- *fluvoxamine maleate oral tablet 50 mg*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Follistim AQ

## Products Affected

- FOLLISTIM AQ INJECTION SOLUTION 75 UNT/0.5ML
- FOLLISTIM AQ SUBCUTANEOUS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infertility.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fondaparinux Sodium

---

## Products Affected

- *fondaparinux sodium*

<b>QL Criteria</b>	2 syringes Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FORA D10 2-in-1 Monitor

## Products Affected

- FORA D10 2-IN-1 MONITOR

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	1 meter Per 1 year
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## FORA D15g 2-in-1 Monitor

### Products Affected

- FORA D15G 2-IN-1 MONITOR

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	1 meter Per 1 year
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FORA D15g Blood Glucose Test

## Products Affected

- FORA D15G BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



## FORA D20 2-in-1 Monitor

### Products Affected

- FORA D20 2-IN-1 MONITOR

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	1 meter Per 1 year
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## FORA D20 Blood Glucose Test

### Products Affected

- FORA D20 BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## FORA G20 Blood Glucose Test

### Products Affected

- FORA G20 BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## FORA G30a Blood Glucose Test

### Products Affected

- FORA G30A BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fora GD20 Test

## Products Affected

- FORA GD20 TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FORA V10 Blood Glucose Test

## Products Affected

- FORA V10 BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## FORA V12 Blood Glucose Test

### Products Affected

- FORA V12 BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## FORA V20 Blood Glucose Test

### Products Affected

- FORA V20 BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



## FORA V30a Blood Glucose Test

### Products Affected

- FORA V30A BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## ForaCare GD40 Test

### Products Affected

- FORACARE GD40 TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## ForaCare premium V10 Test

### Products Affected

- FORACARE PREMIUM V10 TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Forteo

## Products Affected

- FORTEO SUBCUTANEOUS SOLUTION  
600 MCG/2.4ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Fosamax Plus D

---

## Products Affected

- FOSAMAX PLUS D

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of alendronate weekly 70mg
<b>QL Criteria</b>	4 tabs Per 1 month
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fragmin

---

## Products Affected

- FRAGMIN SUBCUTANEOUS SOLUTION  
10000 UNIT/ML, 12500 UNIT/0.5ML,  
15000 UNIT/0.6ML, 18000 UNT/0.72ML,  
2500 UNIT/0.2ML, 5000 UNIT/0.2ML,  
7500 UNIT/0.3ML, 95000 UNIT/3.8ML

<b>QL Criteria</b>	2 syringes Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FreeStyle InsuLinx Test

---

## Products Affected

- FREESTYLE INSULINX TEST

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FreeStyle Lite Test

---

## Products Affected

- FREESTYLE LITE TEST

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# FreeStyle Test

---

## Products Affected

- FREESTYLE TEST

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Frovatriptan Succinate

---

## Products Affected

- *frovatriptan succinate*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: sumatriptan, naratriptan, rizatriptan
<b>QL Criteria</b>	9 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fycompa

---

## Products Affected

- FYCOMPA ORAL TABLET

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	Annual Review: 03/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gabapentin

---

## Products Affected

- *gabapentin oral capsule*

<b>QL Criteria</b>	6 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gabapentin

---

## Products Affected

- *gabapentin oral solution 250 mg/5ml*

<b>QL Criteria</b>	40 ml Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gabapentin

---

## Products Affected

- *gabapentin oral tablet*

<b>QL Criteria</b>	6 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gammaplex

## Products Affected

- GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/200ML, 20 GM/400ML, 5 GM/100ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/ivig.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gamunex-C

## Products Affected

- GAMUNEX-C

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/ivig.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Ganirelix Acetate

## Products Affected

- *ganirelix acetate*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gattex

## Products Affected

- GATTEX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gattex.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gattex.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 box Per 30 fillss
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# GE100 Blood Glucose Test

## Products Affected

- GE100 BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gelnique

---

## Products Affected

- GELNIQUE TRANSDERMAL GEL 10 %

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of oxybutynin or trospium IR and through either Vesicare or Myrbetriq
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Genvoya

## Products Affected

- GENVOYA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviral_hiv.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviral_hiv.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Giazo

---

## Products Affected

- GIAZO

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of balsalazide
<b>QL Criteria</b>	6 tabs Per 1 Day
<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gilenya

## Products Affected

- GILENYA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 cap Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gilotrif

## Products Affected

- GILOTRIF

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tab Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Glatopa

## Products Affected

- GLATOPA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# GlucaGen Diagnostic

---

## Products Affected

- GLUCAGEN DIAGNOSTIC

<b>QL Criteria</b>	1 kit Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# GlucaGen HypoKit

---

## Products Affected

- GLUCAGEN HYPOKIT

<b>QL Criteria</b>	1 kit Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Glucocard 01 Sensor Plus

## Products Affected

- GLUCOCARD 01 SENSOR PLUS

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Glucocard Expression Test

## Products Affected

- GLUCOCARD EXPRESSION TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Glucocard Vital Test

## Products Affected

- GLUCOCARD VITAL TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Glucocard X-Sensor

## Products Affected

- GLUCOCARD X-SENSOR

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# GlucoCom Test

## Products Affected

- GLUCOCOM TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Glyxambi

---

## Products Affected

- GLYXAMBI

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Tradjenta or Jentadueto and either Januvia or Janumet
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gonal-f

## Products Affected

- GONAL-F

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gonal-f RFF

## Products Affected

- GONAL-F RFF

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infer-tility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infer-tility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Gonal-f RFF Rediject

---

### Products Affected

- GONAL-F RFF REDIJECT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gralise

---

## Products Affected

- GRALISE ORAL TABLET 300 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of gabapentin
<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gralise

---

## Products Affected

- GRALISE ORAL TABLET 600 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of gabapentin
<b>QL Criteria</b>	3 tabs Per 1 Day
<b>Notes/ References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gralise Starter

---

## Products Affected

- GRALISE STARTER

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of gabapentin
<b>QL Criteria</b>	1 pack Per 1 fill
<b>Notes/ References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Grastek

## Products Affected

- GRASTEK

PA Criteria	Criteria Details
Covered Uses	Allergic rhinitis with or without conjunctivitis
Exclusion Criteria	
Required Medical Information	A documented diagnosis of allergic rhinitis with or without conjunctivitis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of Claritin OTC, Zyrtec OTC, or Allegra OTC
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# GuanFACINE HCl ER

---

## Products Affected

- *guanfacine hcl er*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of an immediate release stimulant
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Guardian REAL-Time System Ped

## Products Affected

- GUARDIAN REAL-TIME SYSTEM PED

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Halaven

## Products Affected

- HALAVEN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Halaven.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Halaven.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Harvoni

---

## Products Affected

- HARVONI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Helixate FS

## Products Affected

- HELIXATE FS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Hemangeol

## Products Affected

- HEMANGEOL

PA Criteria	Criteria Details
<b>Covered Uses</b>	Proliferating infantile hemangioma
<b>Exclusion Criteria</b>	History of asthma or bronchospasms
<b>Required Medical Information</b>	A documented diagnosis of proliferating infantile hemangioma requiring systemic therapy and documented all of the following: (1) Member was not born prematurely with a corrected age of less than 5 weeks, (2) Member does not weigh less than 2kg, have sustained heart rate less than 80 beats per minute, have greater than first degree heart block, or have decompensated heart failure, and (3) Member does not have sustained blood pressure less than 50/ 30mmHg.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: July 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Hetlioz

## Products Affected

- HETLIOZ

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/sedative-hypnotics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/sedative-hypnotics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Horizant

---

## Products Affected

- HORIZANT ORAL TABLET EXTENDED  
RELEASE 300 MG

<b>ST Criteria</b>	FOR POST-HERPTIC NEURALGIA: A documented contraindication, intolerance, allergy, or failure of gabapentin. FOR RESTLESS LESG SYNDROME: A documented contraindication, intolerance, allergy, or failure of gabapentin or ropinirole.
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Horizant

---

## Products Affected

- HORIZANT ORAL TABLET EXTENDED  
RELEASE 600 MG

<b>ST Criteria</b>	FOR POST-HERPTIC NEURALGIA: A documented contraindication, intolerance, allergy, or failure of gabapentin. FOR RESTLESS LESG SYNDROME: A documented contraindication, intolerance, allergy, or failure of gabapentin or ropinirole.
<b>QL Criteria</b>	1 tablet Per 2 Days
<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Humira

## Products Affected

- HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.2ML, 20 MG/0.4ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
QL Criteria	2 injections Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Humira

## Products Affected

- HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT 40 MG/0.8ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
QL Criteria	6 injections Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Humira Pediatric Crohns Start

## Products Affected

- HUMIRA PEDIATRIC CROHNS START  
SUBCUTANEOUS PREFILLED SYRINGE  
KIT 40 MG/0.8ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
QL Criteria	6 injections Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Humira Pen

## Products Affected

- HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
QL Criteria	6 injections Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Humira Pen-Crohns Starter

---

## Products Affected

- HUMIRA PEN-CROHNS STARTER  
SUBCUTANEOUS PEN-INJECTOR KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
QL Criteria	6 injections Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Humira Pen-Psoriasis Starter

## Products Affected

- HUMIRA PEN-PSORIASIS STARTER  
SUBCUTANEOUS PEN-INJECTOR KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Humira.html</a>
QL Criteria	6 injections Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Hycamtin

## Products Affected

- HYCAMTIN ORAL

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Hydrocodone-Acetaminophen

## Products Affected

- *hydrocodone-acetaminophen oral solution*  
2.5-108 mg/5ml, 5-217 mg/10ml, 7.5-325 mg/15ml

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Hydrocodone-Acetaminophen

## Products Affected

- *hydrocodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 2.5-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Hydrocodone-Ibuprofen

## Products Affected

- *hydrocodone-ibuprofen oral tablet 10-200 mg*
- *hydrocodone-ibuprofen oral tablet 5-200 mg, 7.5-200 mg*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# HYDRomorphone HCl

## Products Affected

- *hydromorphone hcl oral tablet*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# HYDRomorphone HCl

## Products Affected

- *hydromorphone hcl rectal*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# HYDRomorphone HCl ER

## Products Affected

- *hydromorphone hcl er oral tablet er 24 hour abuse-deterrent 12 mg, 32 mg, 8 mg*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# HYDRomorphone HCl ER

## Products Affected

- *hydromorphone hcl er oral tablet er 24 hour abuse-deterrent 16 mg*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Hyqvia

## Products Affected

- HYQVIA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/ivig.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ibandronate Sodium

## Products Affected

- *ibandronate sodium oral*

PA Criteria	Criteria Details
Covered Uses	Osteoporosis
Exclusion Criteria	No failure of formulary bisphosphonates, use in combination with one or more bisphosphonates.
Required Medical Information	A documented diagnosis of osteoporosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of alendronate weekly 70mg
QL Criteria	1 tab Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Ibrance

## Products Affected

- IBRANCE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	21 capsules Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ibudone

## Products Affected

- *ibudone oral tablet 5-200 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Iclusig

## Products Affected

- ICLUSIG ORAL TABLET 15 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Iclusig

## Products Affected

- ICLUSIG ORAL TABLET 45 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tab Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ilaris

## Products Affected

- ILARIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Ilaris.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Ilaris.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Ilaris (150mg Delivered)

### Products Affected

- ILARIS (150MG DELIVERED)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/immunomodulators_CAP.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/immunomodulators_CAP.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Imatinib Mesylate

## Products Affected

- *imatinib mesylate*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Imiquimod

---

## Products Affected

- *imiquimod external*

<b>QL Criteria</b>	48 packets Per 365 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Increlex

---

## Products Affected

- INCRELEX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Increlex.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Increlex.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Incruse Ellipta

---

## Products Affected

- INCRUSE ELLIPTA

<b>QL Criteria</b>	1 blister Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Indomethacin

---

## Products Affected

- *indomethacin oral*

<b>QL Criteria</b>	3 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Infinity Blood Glucose Test

## Products Affected

- INFINITY BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Inlyta

## Products Affected

- INLYTA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Intelligence

---

## Products Affected

- INTELENCE ORAL TABLET 100 MG, 25 MG

<b>QL Criteria</b>	4 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Intelligence

---

## Products Affected

- INTELENCE ORAL TABLET 200 MG

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Intron A

## Products Affected

- INTRON A

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Invokamet

---

## Products Affected

- INVOKAMET

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Invokamet XR

---

## Products Affected

- INVOKAMET XR

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Invokana

---

## Products Affected

- INVOKANA

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ipratropium Bromide

---

## Products Affected

- *ipratropium bromide nasal*

<b>QL Criteria</b>	1 bottle Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Irbesartan

---

## Products Affected

- *irbesartan*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Irbesartan-Hydrochlorothiazide

---

## Products Affected

- *irbesartan-hydrochlorothiazide*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Isentress

---

## Products Affected

- ISENTRESS ORAL TABLET

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Isentress

---

## Products Affected

- ISENTRESS ORAL TABLET CHEWABLE

<b>QL Criteria</b>	6 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Isentress HD

---

## Products Affected

- ISENTRESS HD

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Itraconazole

## Products Affected

- *itraconazole oral*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Onychomycosis, invasive fungal infection, other fungal infection, superficial mycoses
<b>Exclusion Criteria</b>	Cosmetic use, patients with evidence of ventricular dysfunction such as CHF or a history of CHF. Coadministration with certain drugs metabolized by the cytochrome P-450 3A4 isoenzyme system (CYP3A4), cisapride, oral midazolam, pimozide, quinidine, dofetilide, triazolam, HMG-CoA reductase inhibitors metabolized by CYP3A4, such as lovastatin and simvastatin, and ergot alkaloids metabolized by CYP3A4, such as dihydroergotamine, ergotamine, ergonovine, and methylergonovine.
<b>Required Medical Information</b>	Itraconazole is covered for members who meet the following criteria: Invasive fungal infections in patients who are immunocompromised (such as histoplasmosis, aspergillosis, and blastomycosis), treatment of tinea barbae, tinea capitis, tinea favosa, tinea corporis, tinea cruris, tinea faciei, tinea manuum, or tinea pedis, a diagnosis of majocchi granuloma, or a diagnosis of onychomycosis in diabetic patients or patients with peripheral vascular disease and either a positive onychomycosis susceptible pathogen culture or a positive PAS stain performed by a laboratory, or a diagnosis of onychomycosis with documented disabling pain or impairment and a positive onychomycosis susceptible pathogen culture
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Nail: 12 wk(toe),5 wk (finger) per year,Invasive: 1-3 mo based on severity, Other Dx: 1-6 wk
<b>Other Criteria</b>	

<b>ST Criteria</b>	FOR A DIAGNOSIS OF ONYCHOMYCOSIS, TINEA BARBAE, TIBNEA CAPITIS, TINEA FAVOSA: A documented contraindication, intolerance, allergy, or failure of terbinafine. FOR A DIAGNOSIS OF TINEA CORPORIS, TINEA CRURIS, TINEA FACIEI, TINEA MANUUM, TINEA PEDIS: A documented contraindication, intolerance, allergy, or failure of a topical antifungal and terbinafine. FOR A DIAGNOSIS OF TINEA VERSICOLOR: A documented contraindication, intolerance, allergy, or failure of selenium sulfide and a topical antifungal.
<b>QL Criteria</b>	4 capsules Per 1 Day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jakafi

## Products Affected

- JAKAFI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jakafi

## Products Affected

- JAKAFI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Janumet

---

## Products Affected

- JANUMET

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Janumet XR

---

## Products Affected

- JANUMET XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 100-  
1000 MG, 50-500 MG

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Janumet XR

---

## Products Affected

- JANUMET XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 50-1000  
MG

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Januvia

---

## Products Affected

- JANUVIA

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jardiance

---

## Products Affected

- JARDIANCE

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jentaduetto

---

## Products Affected

- JENTADUETO

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jentaducto XR

---

## Products Affected

- JENTADUETO XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 2.5-1000  
MG

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jentaduetto XR

---

## Products Affected

- JENTADUETO XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 5-1000  
MG

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jevtana

## Products Affected

- JEVTANA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/jevtana.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/jevtana.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jublia

## Products Affected

- JUBLIA

PA Criteria	Criteria Details
Covered Uses	Onychomycosis due to dermatophyte
Exclusion Criteria	
Required Medical Information	A documented diagnosis of onychomycosis confirmed by either a positive KOH stain (potassium hydroxide), positive PAS stain (para-aminosalicylic acid), a positive DTM (dermatophyte test medium) or positive fungal culture (NOTE: This positive test should be within the last 3 - 6 months and associated with the current infection)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one systemic (oral) alternative such as terbinafine, itraconazole, griseofulvin
Notes/References	Annual Review: 07/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Juxtapid

## Products Affected

- JUXTAPID ORAL CAPSULE 10 MG, 5 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/Antilipidemic_Agents_HOFH.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/Antilipidemic_Agents_HOFH.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/Antilipidemic_Agents_HOFH.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/Antilipidemic_Agents_HOFH.html</a>
QL Criteria	1 tab Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Juxtapid

## Products Affected

- JUXTAPID ORAL CAPSULE 20 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/Antilipidemic_Agents_HOFH.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/Antilipidemic_Agents_HOFH.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/Antilipidemic_Agents_HOFH.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/Antilipidemic_Agents_HOFH.html</a>
QL Criteria	3 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Juxtapid

## Products Affected

- JUXTAPID ORAL CAPSULE 30 MG, 40 MG, 60 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/Antilipidemic_Agents_HOFH.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/Antilipidemic_Agents_HOFH.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/Antilipidemic_Agents_HOFH.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/Antilipidemic_Agents_HOFH.html</a>
QL Criteria	1 capsule Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kadian

## Products Affected

- KADIAN ORAL CAPSULE EXTENDED  
RELEASE 24 HOUR 200 MG, 40 MG

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of extended release morphine sulfate tablets (generic MS Contin)
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kalydeco

## Products Affected

- KALYDECO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/cystic_fibrosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/cystic_fibrosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 packets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kalydeco

## Products Affected

- KALYDECO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/cystic_fibrosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/cystic_fibrosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kepivance

## Products Affected

- KEPIVANCE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Kerydin

## Products Affected

- KERYDIN

PA Criteria	Criteria Details
Covered Uses	Onychomycosis due to dermatophyte
Exclusion Criteria	
Required Medical Information	A documented diagnosis of onychomycosis confirmed by either a positive KOH stain (potassium hydroxide), positive PAS stain (para-aminosalicylic acid), a positive DTM (dermatophyte test medium) or positive fungal culture (NOTE: This positive test should be within the last 3 - 6 months and associated with the current infection)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of one systemic (oral) alternative such as terbinafine, itraconazole, griseofulvin
Notes/References	Annual Review: 07/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ketoconazole

---

## Products Affected

- *ketoconazole oral*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ketorolac Tromethamine

---

## Products Affected

- *ketorolac tromethamine oral*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kineret

## Products Affected

- KINERET SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Kineret.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Kineret.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Kineret.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Kineret.html</a>
QL Criteria	1 syringe Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kogenate FS

## Products Affected

- KOGENATE FS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kogenate FS Bio-Set

---

## Products Affected

- KOGENATE FS BIO-SET

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kombiglyze XR

---

## Products Affected

- KOMBIGLYZE XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 2.5-1000  
MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Tradjenta or Jentadueto and either Januvia or Janumet
<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kombiglyze XR

---

## Products Affected

- KOMBIGLYZE XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 5-1000  
MG, 5-500 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Tradjenta or Jentadueto and either Januvia or Janumet
<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Korlym

## Products Affected

- KORLYM

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/anti-diabetic-agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/anti-diabetic-agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kroger Blood Glucose Test

## Products Affected

- KROGER BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kroger Premium Glucose Test

## Products Affected

- KROGER PREMIUM GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 1 month
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kroger Test

## Products Affected

- KROGER TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kuvan

## Products Affected

- KUVAN ORAL PACKET 500 MG
- KUVAN ORAL TABLET SOLUBLE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LamoTRIGine

---

## Products Affected

- *lamotrigine oral tablet dispersible 100 mg, 200 mg*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LamoTRIGine

---

## Products Affected

- *lamotrigine oral tablet dispersible 25 mg*

<b>QL Criteria</b>	6 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LamoTRIGine

---

## Products Affected

- *lamotrigine oral tablet dispersible 50 mg*

<b>QL Criteria</b>	3 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# LamoTRIGine ER

---

## Products Affected

- *lamotrigine er oral tablet extended release*  
*24 hour 100 mg, 25 mg, 50 mg*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LamoTRIGine ER

---

## Products Affected

- *lamotrigine er oral tablet extended release*  
*24 hour 200 mg*

<b>QL Criteria</b>	3 tabs Per 1 Day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LamoTRIGine ER

---

## Products Affected

- *lamotrigine er oral tablet extended release*  
*24 hour 250 mg, 300 mg*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lansoprazole

---

## Products Affected

- *lansoprazole oral capsule delayed release 15 mg*

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lansoprazole

---

## Products Affected

- *lansoprazole oral capsule delayed release 30 mg*

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lantus

---

## Products Affected

- LANTUS

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Levemir Vial
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lantus SoloStar

---

## Products Affected

- LANTUS SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Levemir Vial
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Latuda

---

## Products Affected

- LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: aripiprazole, risperidone, quetiapine, ziprasidone, olanzapine, or clozapine
<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Latuda

---

## Products Affected

- LATUDA ORAL TABLET 60 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: aripiprazole, risperidone, quetiapine, ziprasidone, olanzapine, or clozapine
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Latuda

---

## Products Affected

- LATUDA ORAL TABLET 80 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: aripiprazole, risperidone, quetiapine, ziprasidone, olanzapine, or clozapine
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Leflunomide

---

## Products Affected

- *leflunomide oral*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lemtrada

## Products Affected

- LEMTRADA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	999 ML Per 999 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Letairis

## Products Affected

- LETAIRIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Leukine

## Products Affected

- LEUKINE INTRAVENOUS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/G-CSF.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/G-CSF.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Leuprolide Acetate

## Products Affected

- *leuprolide acetate injection*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LevETIRAcetam ER

---

## Products Affected

- *levetiracetam er oral tablet extended release*  
*24 hour 500 mg*

<b>QL Criteria</b>	6 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# LevETIRAcetam ER

---

## Products Affected

- *levetiracetam er oral tablet extended release*  
*24 hour 750 mg*

<b>QL Criteria</b>	4 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Levorphanol Tartrate

## Products Affected

- *levorphanol tartrate oral*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Liberty Next Generation Test

## Products Affected

- LIBERTY NEXT GENERATION TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Liberty Test

## Products Affected

- LIBERTY TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lidocaine

---

## Products Affected

- *lidocaine external ointment*

<b>QL Criteria</b>	50 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lidocaine

## Products Affected

- *lidocaine external patch 5 %*

PA Criteria	Criteria Details
Covered Uses	pain associated with post-herpetic neuralgia
Exclusion Criteria	
Required Medical Information	Documented diagnosis of pain associated with post-herpetic neuralgia
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	3 patches Per 1 Day
Notes/References	Annual Review: 09/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lidocaine-Prilocaine

---

## Products Affected

- *lidocaine-prilocaine external cream*

<b>QL Criteria</b>	30 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Linezolid

---

## Products Affected

- *linezolid oral suspension reconstituted*

<b>QL Criteria</b>	150 ml Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Linezolid

---

## Products Affected

- *linezolid oral tablet*

<b>QL Criteria</b>	28 tablets Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Linzess

---

## Products Affected

- LINZESS

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of lactulose or polyethylene glycol
<b>QL Criteria</b>	1 cap Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Linzess

---

## Products Affected

- LINZESS

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of lactulose or polyethylene glycol
<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Livalo

---

## Products Affected

- LIVALO

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: atorvastatin, lovastatin, pravastatin, simvastain
<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lorcet

## Products Affected

- *lorcet*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lorcet HD

## Products Affected

- *lorcet hd*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017



<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Losartan Potassium

---

## Products Affected

- *losartan potassium oral tablet 25 mg, 50 mg*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lovastatin

---

## Products Affected

- *lovastatin*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lumigan

---

## Products Affected

- LUMIGAN OPHTHALMIC SOLUTION  
0.01 %

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of latanoprost
<b>Notes/ References</b>	Annual Review: 03/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lumizyme

## Products Affected

- LUMIZYME

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lupaneta Pack

---

## Products Affected

- LUPANETA PACK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lupron Depot (1-Month)

## Products Affected

- LUPRON DEPOT (1-MONTH)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lupron Depot (3-Month)

## Products Affected

- LUPRON DEPOT (3-MONTH)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



## Lupron Depot (4-Month)

### Products Affected

- LUPRON DEPOT (4-MONTH)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lupron Depot (6-Month)

## Products Affected

- LUPRON DEPOT (6-MONTH)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Lupron Depot-Ped (1-Month)

### Products Affected

- LUPRON DEPOT-PED (1-MONTH)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Lupron Depot-Ped (3-Month)

### Products Affected

- LUPRON DEPOT-PED (3-MONTH)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lyrica

## Products Affected

- LYRICA

PA Criteria	Criteria Details
Covered Uses	Epilepsy, Diabetic peripheral neuropathy, Post-herpetic neuropathy, Fibromyalgia, Neuropathic pain associated with spinal cord injury
Exclusion Criteria	
Required Medical Information	A diagnosis of epilepsy as adjunct therapy, diabetic peripheral neuropathy, post-herpetic neuropathy, Fibromyalgia with failure of non-pharmacologic therapies (cognitive behavioral therapies, exercise etc.), or for neuropathic pain associated with spinal cord injury
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	FOR A DIAGNOSIS OF DIABETIC PERIPHERAL NEUROPATHY OR POST-HERPETIC NEUROPATHY: A documented contraindication, intolerance, allergy, or failure of gabapentin. FOR A DIAGNOSIS OF FIBROMYALGIA: A documented contraindication, intolerance, allergy, or failure of three drugs from three of the following drug/drug classes: tricyclic antidepressant, muscle relaxant, SSRI, SNRI, gabapentin, or tramadol. FOR A DIAGNOSIS OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY: A documented contraindication, intolerance, allergy, or failure of three drugs from three of the following drug/drug classes: tricyclic antidepressant, muscle relaxant, SNRI, gabapentin, or tramadol.
Notes/References	Annual Review: 05/2017

<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Maprotiline HCl

---

## Products Affected

- *maprotiline hcl oral tablet 25 mg*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Maprotiline HCl

---

## Products Affected

- *maprotiline hcl oral tablet 50 mg*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Maprotiline HCl

---

## Products Affected

- *maprotiline hcl oral tablet 75 mg*

<b>QL Criteria</b>	3 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Matzim LA

---

## Products Affected

- *matzim la oral tablet extended release 24 hour 180 mg, 300 mg, 360 mg*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Matzim LA

---

## Products Affected

- *matzim la oral tablet extended release 24 hour 240 mg*

<b>QL Criteria</b>	2 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mavyret

## Products Affected

- MAVYRET

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
QL Criteria	3 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Meijer Blood Glucose Test

## Products Affected

- MEIJER BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Meijer Premium Glucose Test

## Products Affected

- MEIJER PREMIUM GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 1 month
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mekinist

## Products Affected

- MEKINIST ORAL TABLET 0.5 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mekinist

## Products Affected

- MEKINIST ORAL TABLET 2 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tab Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Memantine HCl

## Products Affected

- *memantine hcl oral tablet*

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Menopur

## Products Affected

- MENOPUR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infer-tility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infer-tility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Menostar

---

## Products Affected

- MENOSTAR

<b>QL Criteria</b>	4 patches Per 28 fills
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Meperidine HCl

## Products Affected

- *meperidine hcl oral tablet*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mesalamine

---

## Products Affected

- *mesalamine oral tablet delayed release 1.2 gm*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mesalamine

---

## Products Affected

- *mesalamine oral tablet delayed release 800 mg*

<b>QL Criteria</b>	6 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Metadate ER

## Products Affected

- *metadate er oral tablet extended release 20 mg*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of an immediate release stimulant
QL Criteria	3 tabs Per 1 Day
Notes/References	Annual Review: 09/2017
Revision Date	Prior Authorization: September 26, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# MetFORMIN HCl ER (OSM)

---

## Products Affected

- *metformin hcl er (osm) oral tablet extended release 24 hour 1000 mg*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of both generic Glucophage and generic Glucophage XR
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# MetFORMIN HCl ER (OSM)

---

## Products Affected

- *metformin hcl er (osm) oral tablet extended release 24 hour 500 mg*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of both generic Glucophage and generic Glucophage XR
<b>QL Criteria</b>	3 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methadone HCl

## Products Affected

- *methadone hcl oral concentrate*
- *methadone hcl oral tablet soluble*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months. (4) FOR A DOCUMENTED DIAGNOSIS OF OPIOID ADDICTION (heroin or other morphine-like drugs): medication must be dispensed by a treatment program certified by SAMHSA (Substance Abuse and Mental Health Services Administration) and the patient will be monitored during therapy for signs and symptoms of abuse/misuse as well as compliance and the potential diversion to others. (Initiation/detoxification treatment = 1 month approval, continuation of therapy/maintenance treatment = 6 month approval).</p>

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	See required medical information
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: November 27, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methadone HCl

## Products Affected

- *methadone hcl oral solution 10 mg/5ml*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months. (4) FOR A DOCUMENTED DIAGNOSIS OF OPIOID ADDICTION (heroin or other morphine-like drugs): medication must be dispensed by a treatment program certified by SAMHSA (Substance Abuse and Mental Health Services Administration) and the patient will be monitored during therapy for signs and symptoms of abuse/misuse as well as compliance and the potential diversion to others. (Initiation/detoxification treatment = 1 month approval, continuation of therapy/maintenance treatment = 6 month approval).</p>

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	See required medical information
<b>Other Criteria</b>	
<b>QL Criteria</b>	60 ML Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: November 27, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methadone HCl

## Products Affected

- *methadone hcl oral solution 5 mg/5ml*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months. (4) FOR A DOCUMENTED DIAGNOSIS OF OPIOID ADDICTION (heroin or other morphine-like drugs): medication must be dispensed by a treatment program certified by SAMHSA (Substance Abuse and Mental Health Services Administration) and the patient will be monitored during therapy for signs and symptoms of abuse/misuse as well as compliance and the potential diversion to others. (Initiation/detoxification treatment = 1 month approval, continuation of therapy/maintenance treatment = 6 month approval).</p>

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	See required medical information
<b>Other Criteria</b>	
<b>QL Criteria</b>	30 ML Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: November 27, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Methadone HCl

## Products Affected

- *methadone hcl oral tablet*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months. (4) FOR A DOCUMENTED DIAGNOSIS OF OPIOID ADDICTION (heroin or other morphine-like drugs): medication must be dispensed by a treatment program certified by SAMHSA (Substance Abuse and Mental Health Services Administration) and the patient will be monitored during therapy for signs and symptoms of abuse/misuse as well as compliance and the potential diversion to others. (Initiation/detoxification treatment = 1 month approval, continuation of therapy/maintenance treatment = 6 month approval).</p>

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	See required medical information
<b>Other Criteria</b>	
<b>QL Criteria</b>	6 tablets Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: November 27, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methadone HCl Intensol

## Products Affected

- *methadone hcl intensol*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months. (4) FOR A DOCUMENTED DIAGNOSIS OF OPIOID ADDICTION (heroin or other morphine-like drugs): medication must be dispensed by a treatment program certified by SAMHSA (Substance Abuse and Mental Health Services Administration) and the patient will be monitored during therapy for signs and symptoms of abuse/misuse as well as compliance and the potential diversion to others. (Initiation/detoxification treatment = 1 month approval, continuation of therapy/maintenance treatment = 6 month approval).</p>

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	See required medical information
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: November 27, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methamphetamine HCl

---

## Products Affected

- *methamphetamine hcl*

<b>QL Criteria</b>	4 tabs Per 1 Day
<b>Notes/ References</b>	Annual Review: 10/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl

---

## Products Affected

- *methylphenidate hcl oral solution 10 mg/5ml*

<b>QL Criteria</b>	30 ML Per 1 Day
<b>Notes/ References</b>	Annual Review: 10/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl

---

## Products Affected

- *methylphenidate hcl oral solution 5 mg/5ml*

<b>QL Criteria</b>	60 ML Per 1 Day
<b>Notes/ References</b>	Annual Review: 10/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl

---

## Products Affected

- *methylphenidate hcl oral tablet*

<b>QL Criteria</b>	6 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Methylphenidate HCl

---

## Products Affected

- *methylphenidate hcl oral tablet chewable*

<b>QL Criteria</b>	6 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 10/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl ER

## Products Affected

- *methylphenidate hcl er oral tablet extended release 10 mg*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of an immediate release stimulant
Notes/References	
Revision Date	Prior Authorization: September 26, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl ER

## Products Affected

- *methylphenidate hcl er oral tablet extended release 18 mg, 27 mg, 54 mg*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of an immediate release stimulant
QL Criteria	2 tablets Per 1 Day
Notes/References	Annual Review: 09/2017
Revision Date	Prior Authorization: September 26, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl ER

## Products Affected

- *methylphenidate hcl er oral tablet extended release 20 mg*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of an immediate release stimulant
QL Criteria	3 tabs Per 1 Day
Notes/References	Annual Review: 09/2017
Revision Date	Prior Authorization: September 26, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl ER

## Products Affected

- *methylphenidate hcl er oral tablet extended release 36 mg*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of an immediate release stimulant
QL Criteria	4 tablets Per 1 Day
Notes/References	Annual Review: 09/2017
Revision Date	Prior Authorization: September 26, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl ER

---

## Products Affected

- *methylphenidate hcl er oral tablet extended release 24 hour 18 mg, 27 mg, 54 mg*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl ER

---

## Products Affected

- *methylphenidate hcl er oral tablet extended release 24 hour 36 mg*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl ER (CD)

## Products Affected

- *methylphenidate hcl er (cd)*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of an immediate release stimulant
QL Criteria	1 cap Per 1 Day
Notes/References	Annual Review: 09/2017
Revision Date	Prior Authorization: September 26, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



## Methylphenidate HCl ER (LA)

### Products Affected

- *methylphenidate hcl er (la)*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of an immediate release stimulant
QL Criteria	1 cap Per 1 Day
Notes/References	Annual Review: 09/2016
Revision Date	Prior Authorization: September 26, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl ER (LA)

## Products Affected

- *methylphenidate hcl er (la)*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of an immediate release stimulant
QL Criteria	1 capsule Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 26, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Metoprolol Succinate ER

---

## Products Affected

- *metoprolol succinate er oral tablet extended release 24 hour 100 mg, 50 mg*

<b>QL Criteria</b>	1.5 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Metoprolol Succinate ER

---

## Products Affected

- *metoprolol succinate er oral tablet extended release 24 hour 200 mg*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Metoprolol Succinate ER

---

## Products Affected

- *metoprolol succinate er oral tablet extended release 24 hour 25 mg*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Miacalcin

---

## Products Affected

- MIACALCIN INJECTION

<b>ST Criteria</b>	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Microdot Test

## Products Affected

- MICRODOT TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mimvey

---

## Products Affected

- *mimvey*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Mimvey Lo

---

## Products Affected

- MIMVEY LO

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mircera

## Products Affected

- MIRCERA INJECTION SOLUTION  
PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/Erythropoiesis_Stimulating_Agents.html">http://www.aetna.com/products/rxnnonmedicare/data/2017/MISC/Erythropoiesis_Stimulating_Agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mirtazapine

---

## Products Affected

- *mirtazapine oral*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mirtazapine

---

## Products Affected

- *mirtazapine oral*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mirvaso

## Products Affected

- MIRVASO

PA Criteria	Criteria Details
Covered Uses	persistent (nontransient) facial erythema of acne rosacea
Exclusion Criteria	
Required Medical Information	A documented diagnosis of persistent (nontransient) facial erythema of acne rosacea
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through topical metronidazole
Notes/References	
Revision Date	Prior Authorization: October 13, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Modafinil

## Products Affected

- *modafinil*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with modafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patient's ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>ST Criteria</b>	FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY: A documented contraindication, intolerance, allergy, or failure of an adequate trial of at least two immediate release stimulants.
<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: June 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Montelukast Sodium

---

## Products Affected

- *montelukast sodium oral*

<b>QL Criteria</b>	1 pack Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Montelukast Sodium

---

## Products Affected

- *montelukast sodium oral*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Morphine Sulfate

## Products Affected

- *morphine sulfate oral solution*
- *morphine sulfate rectal*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Morphine Sulfate

## Products Affected

- *morphine sulfate oral tablet*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Morphine Sulfate (Concentrate)

## Products Affected

- *morphine sulfate (concentrate) oral solution*  
100 mg/5ml, 20 mg/ml

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Morphine Sulfate ER

## Products Affected

- *morphine sulfate er oral capsule extended release 24 hour*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of extended release morphine sulfate tablets (generic MS Contin)
<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Morphine Sulfate ER

## Products Affected

- *morphine sulfate er oral tablet extended release*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Morphine Sulfate ER

## Products Affected

- *morphine sulfate er oral tablet extended release*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Morphine Sulfate ER Beads

## Products Affected

- *morphine sulfate er beads*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of extended release morphine sulfate tablets (generic MS Contin)
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mozobil

## Products Affected

- MOZOBIL

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Mozobil.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Mozobil.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: October 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Multaq

---

## Products Affected

- MULTAQ

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# MyGlucoHealth Test

## Products Affected

- MYGLUCOHEALTH TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Myobloc

## Products Affected

- MYOBLOC

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/botulinum_toxin.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/botulinum_toxin.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Myorisan

---

## Products Affected

- *myorisan oral capsule 10 mg, 20 mg, 40 mg*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of minocycline or doxycycline
<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Myrbetriq

---

## Products Affected

- MYRBETRIQ

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of oxybutynin or trospium IR
<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mytesi

## Products Affected

- MYTESI

PA Criteria	Criteria Details
Covered Uses	Diarrhea
Exclusion Criteria	
Required Medical Information	Covered for adult members who meet the following criteria: (1) Diagnosis of noninfectious diarrhea associated with HIV/AIDS infection that has lasted at least for one month, and (2) Currently stable on anti-retroviral therapy, and (3) Documentation of unsatisfactory effects with, intolerance to, or inability to take at least one anti-motility agent (loperamide, diphenoxylate/atropine, bismuth subsalicylate) or one or more watery bowel movements per day without regular ADM use.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of at least one antimotility agent such as loperamide or atropine/diphenoxylate
QL Criteria	2 tablets Per 1 Day
Notes/References	Annual Review: 03/2017
Revision Date	Prior Authorization: May 25, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Naftifine HCl

---

## Products Affected

- *naftifine hcl*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of clotrimazole and econazole 1%
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Naftin

---

## Products Affected

- NAFTIN EXTERNAL GEL 1 %

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of clotrimazole and econazole 1%
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Naglazyme

## Products Affected

- NAGLAZYME

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Namenda XR

## Products Affected

- NAMENDA XR

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Namenda XR Titration Pack

## Products Affected

- NAMENDA XR TITRATION PACK

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Namzarin

## Products Affected

- NAMZARIC

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Naratriptan HCl

---

## Products Affected

- *naratriptan hcl*

<b>QL Criteria</b>	9 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Neulasta

## Products Affected

- NEULASTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/G-CSF.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/G-CSF.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Neupogen

## Products Affected

- NEUPOGEN INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6ML
- NEUPOGEN INJECTION SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/G-CSF.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/G-CSF.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Neupro

---

## Products Affected

- NEUPRO

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: gabapentin, Ropinirole, pramipexole (covered without trials of Parkinson's)
<b>QL Criteria</b>	1 patch Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



## Neutek 2Tek Glucose/Pressure

### Products Affected

- NEUTEK 2TEK GLUCOSE/PRESSURE

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	1 meter Per 1 year
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Neutek 2Tek Test

## Products Affected

- NEUTEK 2TEK TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nevirapine ER

---

## Products Affected

- *nevirapine er oral tablet extended release 24 hour 100 mg*

<b>QL Criteria</b>	3 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nevirapine ER

---

## Products Affected

- *nevirapine er oral tablet extended release 24 hour 400 mg*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NexAVAR

## Products Affected

- NEXAVAR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NexIUM

## Products Affected

- NEXIUM ORAL PACKET

PA Criteria	Criteria Details
<b>Covered Uses</b>	Diagnosis of Zollinger-Ellison syndrome, Uncomplicated gastroesophageal reflux disease (Gerd) with breakthrough symptoms, Complicated GERD and other higher risk conditions such as feflux-associated laryngitis, recent gastrointestinal bleed, grade 3 or 4 erosive esophagitis, or GERD exacerbated asthma.
<b>Exclusion Criteria</b>	Non-Covered uses include uses not approved by the FDA, or if use is unapproved and not supported by the literature or evidence as an accepted off-label use (see Off-Label Use Policy for determining accepted use). Quantity levels exceeding the quantity limitations on PPIs, Dexilant dosing exceeding 60mg/day
<b>Required Medical Information</b>	A diagnosis of Zollinger-Ellison syndrome, uncomplicated gastroesophageal reflux disease (GERD) with breakthrough symptoms, Complicated GERD and other higher risk conditions such as feflux-associated laryngitis, recent gastrointestinal bleed, grade 3 or 4 erosive esophagitis, or GERD exacerbated asthma.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year, short term court of high dose= 3 months
<b>Other Criteria</b>	
<b>ST Criteria</b>	ONCE DAILY DOSING OF RABEPRAZOLE (20mg), DEXILANT (60mg), AND NEXIUM (40mg): A documented contraindication, intolerance, allergy, or failure of Prilosec OTC/omeprazole, Prevacid 24H OTC, and pantoprazole. HIGH DOSE NEXIUM (80mg) OR HIGH DOSE RABEPRAZOLE (40mg): A documented contraindication, intolerance, allergy, or failure of 80mg/day of Prilosec OTC/omeprazole or pantoprazole or though 60mg/day of Prevacid 24H OTC.
<b>QL Criteria</b>	1 packet Per 1 Day

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NexIUM 24HR

---

## Products Affected

- NEXIUM 24HR ORAL CAPSULE  
DELAYED RELEASE

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Nicotine Polacrilex

---

## Products Affected

- *nicotine polacrilex mouth/throat gum*

<b>QL Criteria</b>	24 pieces Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nicotine Polacrilex

---

## Products Affected

- *nicotine polacrilex mouth/throat lozenge*

<b>QL Criteria</b>	20 pieces Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nicotrol

---

## Products Affected

- NICOTROL

<b>QL Criteria</b>	16 cartridges Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nicotrol NS

---

## Products Affected

- NICOTROL NS

<b>QL Criteria</b>	12 bottles Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nifediac CC

---

## Products Affected

- *nifediac cc oral tablet extended release 24 hour 30 mg*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nifedical XL

---

## Products Affected

- *nifedical xl oral tablet extended release 24 hour 60 mg*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NIFEdipine ER

---

## Products Affected

- *nifedipine er oral tablet extended release 24 hour 30 mg, 90 mg*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NIFEdipine ER

---

## Products Affected

- *nifedipine er oral tablet extended release 24 hour 60 mg*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# NIFEdipine ER Osmotic Release

---

## Products Affected

- *nifedipine er osmotic release oral tablet*  
*extended release 24 hour 30 mg, 90 mg*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NIFEdipine ER Osmotic Release

---

## Products Affected

- *nifedipine er osmotic release oral tablet*  
*extended release 24 hour 60 mg*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nisoldipine ER

---

## Products Affected

- *nisoldipine er oral tablet extended release 24 hour 17 mg, 20 mg, 34 mg, 40 mg, 8.5 mg*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nisoldipine ER

---

## Products Affected

- *nisoldipine er oral tablet extended release 24 hour 30 mg*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Noritate

---

## Products Affected

- NORITATE

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of metronidazole gel and metronidazole cream 0.75%
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nova Max Glucose Test

## Products Affected

- NOVA MAX GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Novarel

## Products Affected

- *novarel intramuscular solution reconstituted  
10000 unit*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infer-tility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/infer-tility.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NovoLOG

---

## Products Affected

- NOVOLOG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of a Humulin or Humalog product
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# NovoLOG FlexPen

---

## Products Affected

- NOVOLOG FLEXPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of a Humulin or Humalog product
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NovoLOG Mix 70/30

---

## Products Affected

- NOVOLOG MIX 70/30

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of a Humulin or Humalog product
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NovoLOG Mix 70/30 FlexPen

---

## Products Affected

- NOVOLOG MIX 70/30 FLEXPEN  
SUBCUTANEOUS SUSPENSION PEN-  
INJECTOR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of a Humulin or Humalog product
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NovoLOG PenFill

---

## Products Affected

- NOVOLOG PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of a Humulin or Humalog product
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Noxafil

## Products Affected

- NOXAFIL ORAL SUSPENSION

PA Criteria	Criteria Details
<b>Covered Uses</b>	Prophylaxis of Invasive Aspergillosis, prophylaxis of invasive candidiasis, treatment of oropharyngeal candidiasis in patients with disease refractory
<b>Exclusion Criteria</b>	Noxafil is NOT covered for members who are pursuing for prophylaxis of invasive aspergillosis or candidiasis who are not severely immunocompromised, for patients less than 13 years of age, patients without refractory disease to first-line antifungal agents, concomitant use with ergot alkaloids, simvastatin, or sirolimus, or concomitant use with CYP3A4 substrates such as, pimozone and quinidine.
<b>Required Medical Information</b>	Noxafil is covered for members who meet any ONE of the following criteria: (1) Prophylaxis of Invasive Aspergillosis in severely immunocompromised patients with active disease, (2) Prophylaxis of Invasive Candidiasis in severely immunocompromised patients, or (3) Treatment of Oropharyngeal Candidiasis
<b>Age Restrictions</b>	13 years of age or greater
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Invasive Aspergillosis/Candidiasis prophylaxis- 3 months, Oropharyngeal Candidiasis-13 days
<b>Other Criteria</b>	Refractory fungal infection is defined as a previous occurrence of disease which failed to improve or respond to a standard course of antifungal therapy. Patients started on Noxafil as an inpatient will be allowed to continue therapy on an outpatient basis without interruption. Initial therapy of one 105ml bottle (7-day supply) will be covered to assure that therapy is not delayed while the prior authorization request is being reviewed.

<b>ST Criteria</b>	FOR A DIAGNOSIS OF INVASIVE CANDIDIASIS: A documented contraindication, intolerance, allergy, or failure of fluconazole. FOR A DIAGNOSIS OF OROPHARYNGEAL CANDIDIASIS: A documented contraindication, intolerance, allergy, or failure of fluconazole or itraconazole
<b>Notes/ References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nplate

## Products Affected

- NPLATE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Neu mega.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Neu mega.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nucynta

## Products Affected

- NUCYNTA

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017



<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two immediate-release opioids such as morphine, oxycodone, or hydromorphone.
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nucynta ER

## Products Affected

- NUCYNTA ER

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>ST Criteria</b>	FOR A DIGANOSIS OF CHRONIC PAIN: A documented contraindication, intolerance, allergy, or failure of extended release morphine sulfate tablets (generic MS Contin). FOR A DIGNOSIS OF DIABETIC PERIPHERAL NEUROPATHY (DPN): A documented contraindication, intolerance, allergy, or failure of extended release morphine sulfate tablets (MS Contin) and two of the following drug/drug classes (each agent must be from a different class): gabapentin, a tricyclic antidepressant, tramadol, Lyrica, or a SNRI
<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nuedexta

## Products Affected

- NUEDEXTA

PA Criteria	Criteria Details
Covered Uses	Treatment of pseudobulbar affect in patients with amyotrophic lateral sclerosis (ALS) OR multiple sclerosis (MS).
Exclusion Criteria	Treatment in other types of emotional lability (i.e. Alzheimers disease and other dementias).
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 caps Per 1 Day
Notes/References	Annual Review: 06/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nulojix

## Products Affected

- NULOJIX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/2017/ID/Nulojix.html">http://www.aetna.com/products/rxnonmedicare/2017/ID/Nulojix.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: November 17, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Octagam

## Products Affected

- OCTAGAM

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/ivig.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Octreotide Acetate

## Products Affected

- *octreotide acetate injection solution 100 mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Sandostatin.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Sandostatin.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Odefsey

---

## Products Affected

- ODEFSEY

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Odomzo

## Products Affected

- ODOMZO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Odomzo.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Odomzo.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 capsule Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OLANZapine

---

## Products Affected

- *olanzapine oral tablet 10 mg, 15 mg, 20 mg, 5 mg, 7.5 mg*
- *olanzapine oral tablet dispersible*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OLANZapine

---

## Products Affected

- *olanzapine oral tablet 2.5 mg*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OLANZapine

---

## Products Affected

- *olanzapine oral tablet dispersible*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OLANZapine-FLUoxetine HCl

---

## Products Affected

- *olanzapine-fluoxetine hcl oral capsule 12-25 mg, 12-50 mg, 6-25 mg, 6-50 mg*

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Olmesartan Medoxomil

---

## Products Affected

- *olmesartan medoxomil oral*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Olmesartan Medoxomil-HCTZ

---

## Products Affected

- *olmesartan medoxomil-hctz*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Olmesartan-Amlodipine-HCTZ

---

## Products Affected

- *olmesartan-amlodipine-hctz*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Omega-3-acid Ethyl Esters

---

## Products Affected

- *omega-3-acid ethyl esters*

<b>QL Criteria</b>	4 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Omeprazole-Sodium Bicarbonate

---

## Products Affected

- *omeprazole-sodium bicarbonate oral capsule*  
*20-1100 mg*

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Omnaris

---

## Products Affected

- OMNARIS

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of fluticasone propionate and flunisolide
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Omnitrope

## Products Affected

- OMNITROPE SUBCUTANEOUS SOLUTION

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Omnitrope

## Products Affected

- OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# On Call Plus Blood Glucose

## Products Affected

- ON CALL PLUS BLOOD GLUCOSE

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# On Call Vivid Blood Glucose

## Products Affected

- ON CALL VIVID BLOOD GLUCOSE

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OneTouch Ultra Blue

---

## Products Affected

- ONETOUCH ULTRA BLUE

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# OneTouch Verio

---

## Products Affected

- ONETOUCH VERIO IN VITRO STRIP

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Onfi

---

## Products Affected

- ONFI ORAL TABLET 10 MG, 20 MG

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Onglyza

---

## Products Affected

- ONGLYZA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Tradjenta or Jentadueto and either Januvia or Janumet
<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	Annual Review: 05/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Opana ER

## Products Affected

- OPANA ER ORAL TABLET ER 12 HOUR ABUSE-DETERRENT

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of extended release morphine sulfate tablets (generic MS Contin)
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Opsumit

## Products Affected

- OPSUMIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oravig

---

## Products Affected

- ORAVIG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of fluconazole, and either nystatin or clotrimazole troche
<b>QL Criteria</b>	14 tabs Per 1 fill
<b>Notes/ References</b>	Annual Review: 10/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Orencia

## Products Affected

- ORENCIA INTRAVENOUS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html</a>
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Orencia

## Products Affected

- ORENCIA SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE 125 MG/ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html</a>
QL Criteria	4 syringes Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Orencia

## Products Affected

- ORENCIA SUBCUTANEOUS SOLUTION  
 PREFILLED SYRINGE 50 MG/0.4ML, 87.5  
 MG/0.7ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html</a>
QL Criteria	4 syringes Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Orencia ClickJect

## Products Affected

- ORENCIA CLICKJECT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Orencia.html</a>
QL Criteria	4 syringes Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Orenitram

## Products Affected

- ORENITRAM

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Orfadin

## Products Affected

- ORFADIN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Orkambi

## Products Affected

- ORKAMBI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/cystic_fibrosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/cystic_fibrosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oseltamivir Phosphate

---

## Products Affected

- *oseltamivir phosphate oral capsule*

<b>QL Criteria</b>	20 capsules Per 365 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Osphena

## Products Affected

- OSPHENA

PA Criteria	Criteria Details
Covered Uses	moderate to severe dyspareunia
Exclusion Criteria	
Required Medical Information	A documented diagnosis of moderate to severe dyspareunia in a female patient
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of an estrogen product such as estradiol, estropipate, or Premarin
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 30, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Otezla

## Products Affected

- OTEZLA ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Otezla.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Otezla.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Otezla.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Otezla.html</a>
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Otezla

## Products Affected

- OTEZLA ORAL TABLET THERAPY PACK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Otezla.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Otezla.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Otezla.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Otezla.html</a>
QL Criteria	1 pack Per 1 year
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Ovidrel

## Products Affected

- OVIDREL

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oxaydo

## Products Affected

- OXAYDO

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oxtellar XR

---

## Products Affected

- OXTELLAR XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 150 MG,  
300 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of immediate release oxcarbazepine
<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oxtellar XR

---

## Products Affected

- OXTELLAR XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 600 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of immediate release oxcarbazepine
<b>QL Criteria</b>	4 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oxybutynin Chloride

---

## Products Affected

- *oxybutynin chloride oral tablet*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Oxybutynin Chloride ER

---

## Products Affected

- *oxybutynin chloride er oral tablet extended release 24 hour 10 mg, 15 mg*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of oxybutynin or trospium IR
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oxybutynin Chloride ER

---

## Products Affected

- *oxybutynin chloride er oral tablet extended release 24 hour 5 mg*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of oxybutynin or trospium IR
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OxyCODONE HCl

## Products Affected

- *oxycodone hcl oral capsule*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 capsules Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OxyCODONE HCl

## Products Affected

- *oxycodone hcl oral concentrate 100 mg/5ml*
- *oxycodone hcl oral solution*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
 Last Update 12/2017

<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# OxyCODONE HCl

## Products Affected

- *oxycodone hcl oral tablet*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017



# OxyCODONE HCl ER

## Products Affected

- *oxycodone hcl er oral tablet er 12 hour abuse-deterrent*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oxycodone-Acetaminophen

## Products Affected

- *oxycodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oxycodone-Aspirin

## Products Affected

- *oxycodone-aspirin oral tablet 4.8355-325 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oxycodone-Ibuprofen

## Products Affected

- *oxycodone-ibuprofen*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# OxyCONTIN

## Products Affected

- OXYCONTIN ORAL TABLET ER 12 HOUR ABUSE-DETERRENT

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Xtampza ER
<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oxymorphone HCl

## Products Affected

- *oxymorphone hcl*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two immediate-release opioids such as morphine, oxycodone, or hydromorphone.
<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OxyMORphone HCl ER

## Products Affected

- *oxymorphone hcl er*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of extended release morphine sulfate tablets (generic MS Contin)
<b>QL Criteria</b>	4 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Paliperidone ER

---

## Products Affected

- *paliperidone er oral tablet extended release*  
*24 hour 1.5 mg, 3 mg, 6 mg*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: aripiprazole, risperidone, quetiapine, ziprasidone, olanzapine, or clozapine
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Paliperidone ER

---

## Products Affected

- *paliperidone er oral tablet extended release*  
24 hour 9 mg

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: aripiprazole, risperidone, quetiapine, ziprasidone, olanzapine, or clozapine
<b>QL Criteria</b>	1 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Pamidronate Disodium

## Products Affected

- *pamidronate disodium*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pancreaze

## Products Affected

- PANCREAZE

PA Criteria	Criteria Details
<b>Covered Uses</b>	Exocrine pancreatic Insufficiency
<b>Exclusion Criteria</b>	Uses not approved by the FDA, uses unapproved and not supported by the literature or evidence as an accepted off-label use. (see Off-Label Use Policy for determining accepted use).
<b>Required Medical Information</b>	Diagnosis of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 2 weeks of Zenpep
<b>Notes/References</b>	Annual Review: 07/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Paricalcitol

---

## Products Affected

- *paricalcitol oral*

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# PARoxetine HCl

---

## Products Affected

- *paroxetine hcl oral tablet 10 mg, 20 mg*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# PARoxetine HCl

---

## Products Affected

- *paroxetine hcl oral tablet 30 mg, 40 mg*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# PARoxetine HCl ER

---

## Products Affected

- *paroxetine hcl er*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of paroxetine
<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pegasys

## Products Affected

- PEGASYS SUBCUTANEOUS SOLUTION

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pegasys ProClick

## Products Affected

- PEGASYS PROCLICK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Pentasa

---

## Products Affected

- PENTASA ORAL CAPSULE EXTENDED  
RELEASE 250 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Apriso
<b>QL Criteria</b>	16 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pentasa

---

## Products Affected

- PENTASA ORAL CAPSULE EXTENDED  
RELEASE 500 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Apriso
<b>QL Criteria</b>	8 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pentazocine-Naloxone HCl

## Products Affected

- *pentazocine-naloxone hcl*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Perforomist

## Products Affected

- PERFOROMIST

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disease (COPD)
Exclusion Criteria	
Required Medical Information	Documented physical limitation that prevents the use of a non-nebulized long-acting bronchodilator with or without use of a spacer
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	60 vials Per 1 fill
Notes/References	Annual Review: 07/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pertzye

## Products Affected

- PERTZYE

PA Criteria	Criteria Details
<b>Covered Uses</b>	Exocrine pancreatic Insufficiency
<b>Exclusion Criteria</b>	Uses not approved by the FDA, uses unapproved and not supported by the literature or evidence as an accepted off-label use. (see Off-Label Use Policy for determining accepted use).
<b>Required Medical Information</b>	Diagnosis of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 2 weeks of Zenpep
<b>Notes/References</b>	Annual Review: 07/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pharmacist Choice Autocode

## Products Affected

- PHARMACIST CHOICE AUTOCODE

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 1 month
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Phenoxybenzamine HCl

## Products Affected

- *phenoxybenzamine hcl oral*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/antihypertensive_misc.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/antihypertensive_misc.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Picato

---

## Products Affected

- PICATO

<b>QL Criteria</b>	1 box Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pioglitazone HCl

---

## Products Affected

- *pioglitazone hcl*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pioglitazone HCl-Glimepiride

---

## Products Affected

- *pioglitazone hcl-glimepiride*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pioglitazone HCl-Metformin HCl

---

## Products Affected

- *pioglitazone hcl-metformin hcl*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Plegridy

## Products Affected

- PLEGRIDY

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	2 syringes Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Plegridy

## Products Affected

- PLEGRIDY

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	2 syringes Per 28 months
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Plegridy Starter Pack

## Products Affected

- PLEGRIDY STARTER PACK  
SUBCUTANEOUS SOLUTION PEN-  
INJECTOR

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>ST Criteria</b>	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
<b>QL Criteria</b>	1 kit Per 365 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Plegridy Starter Pack

## Products Affected

- PLEGRIDY STARTER PACK  
SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	2 syringes Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# PocketChem EZ Test

## Products Affected

- POCKETCHEM EZ TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pomalyst

## Products Affected

- POMALYST

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 cap Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Praluent

## Products Affected

- PRALUENT SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/PCS K9.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/PCS K9.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/PCS K9.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/PCS K9.html</a>
QL Criteria	2 syringes Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pramipexole Dihydrochloride ER

---

## Products Affected

- *pramipexole dihydrochloride er*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prasugrel HCl

## Products Affected

- *prasugrel hcl*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acute coronary syndrome (ACS) managed with percutaneous coronary intervention which includes unstable angina or non-ST elevation myocardial infarction or ST elevation myocardial infarction (MI)
<b>Exclusion Criteria</b>	History of Stroke or transient ischemic attack (TIA)
<b>Required Medical Information</b>	Member has a documented diagnosis of acute coronary syndrome (ACS) and is managed by percutaneous coronary intervention (PCI), which includes unstable angina, non-ST-elevation myocardial infarction (NSTEMI), or ST -elevation myocardial infarction (STEMI) managed with primary or delayed PCI and member has no prior history of stroke or transient ischemic attack (TIA)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 08, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pravastatin Sodium

---

## Products Affected

- *pravastatin sodium*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Precision PCx

---

## Products Affected

- PRECISION PCX

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Precision PCX Plus Test

---

## Products Affected

- PRECISION PCX PLUS TEST

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Precision Point of Care Test

---

## Products Affected

- PRECISION POINT OF CARE TEST

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Precision QID Test

---

## Products Affected

- PRECISION QID TEST

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Precision Sof-Tact Test

---

## Products Affected

- PRECISION SOF-TACT TEST

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Precision Xtra Blood Glucose

---

## Products Affected

- PRECISION XTRA BLOOD GLUCOSE

<b>QL Criteria</b>	300 strips Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prefest

---

## Products Affected

- PREFEST

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pregnyl

---

## Products Affected

- PREGNYL

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/inferility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prezista

---

## Products Affected

- PREZISTA ORAL SUSPENSION

<b>QL Criteria</b>	2 bottles Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prezista

---

## Products Affected

- PREZISTA ORAL TABLET 150 MG, 600 MG, 75 MG

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Prezista

---

## Products Affected

- PREZISTA ORAL TABLET 800 MG

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Procrit

---

## Products Affected

- PROCIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Erythropoiesis_Stimulating_Agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Erythropoiesis_Stimulating_Agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prodigy No Coding Blood Gluc

## Products Affected

- PRODIGY NO CODING BLOOD GLUC

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Progesterone Micronized

---

## Products Affected

- *progesterone micronized oral*

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prolastin-C

## Products Affected

- PROLASTIN-C INTRAVENOUS  
SOLUTION RECONSTITUTED 1000 MG

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Alpha-1%20Antitrypsin%20Inhibitor%20Therapy.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Alpha-1 Antitrypsin Inhibitor Therapy.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Proleukin

## Products Affected

- PROLEUKIN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOP/L/Interleukin_2.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOP/L/Interleukin_2.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prolia

## Products Affected

- PROLIA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Promacta

## Products Affected

- PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Promacta.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Promacta.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tab Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Propafenone HCl ER

---

## Products Affected

- *propafenone hcl er*

<b>QL Criteria</b>	2 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prudoxin

---

## Products Affected

- PRUDOXIN

<b>QL Criteria</b>	45 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pulmicort Flexhaler

---

## Products Affected

- PULMICORT FLEXHALER

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of QVAR
<b>QL Criteria</b>	1 inhaler Per 1 month
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pulmozyme

## Products Affected

- PULMOZYME

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/cystic_fibrosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/cystic_fibrosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	60 units Per 1 fill
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Qnasl

---

## Products Affected

- QNASL

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of fluticasone propionate and flunisolide
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Qnasl Childrens

---

## Products Affected

- QNASL CHILDRENS

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of fluticasone propionate and flunisolide
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Qsymia

## Products Affected

- QSYMIA ORAL CAPSULE EXTENDED  
RELEASE 24 HOUR 11.25-69 MG

PA Criteria	Criteria Details
<b>Covered Uses</b>	Body Mass Index (BMI) greater than 30kg/m <sup>2</sup> or BMI greater than 27kg/m <sup>2</sup> with one or more of the items in the required medical information section
<b>Exclusion Criteria</b>	Concomitant use of two or more anti-obesity agents, pregnancy
<b>Required Medical Information</b>	Hypertension (systolic blood pressure greater than 140mm Hg or diastolic blood pressure greater than 90mm Hg on more than one occasion), Dyslipidemia (LDL cholesterol greater than/= 160mg/dL: HDL cholesterol less than 35mg/dL: triglycerides greater than/= 400mg/dL), Type 2 Diabetes Mellitus, Coronary Heart Disease, or Obstructive Sleep Apnea
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of phentermine cap or phendimetrazine tab
<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/References</b>	Annual Review: 04/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# QUetiapine Fumarate

---

## Products Affected

- *quetiapine fumarate oral tablet 100 mg, 50 mg*

<b>QL Criteria</b>	3 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# QUetiapine Fumarate

---

## Products Affected

- *quetiapine fumarate oral tablet 200 mg*

<b>QL Criteria</b>	4 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# QUetiapine Fumarate

---

## Products Affected

- *quetiapine fumarate oral tablet 25 mg*

<b>QL Criteria</b>	6 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# QUetiapine Fumarate

---

## Products Affected

- *quetiapine fumarate oral tablet 300 mg, 400 mg*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# QUetiapine Fumarate ER

---

## Products Affected

- *quetiapine fumarate er oral tablet extended release 24 hour 150 mg, 200 mg*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# QUetiapine Fumarate ER

---

## Products Affected

- *quetiapine fumarate er oral tablet extended release 24 hour 300 mg, 400 mg, 50 mg*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Quillivant XR

## Products Affected

- QUILLIVANT XR

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD)
Age Restrictions	For Quillivant Only- 17 years of age and older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of an immediate release stimulant
QL Criteria	1 bottle Per 1 fill
Notes/References	Annual Review: 09/2017
Revision Date	Prior Authorization: September 26, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RA TRUEtest Test

## Products Affected

- RA TRUETEST TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RABEprazole Sodium

## Products Affected

- *rabeprazole sodium*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Diagnosis of Zollinger-Ellison syndrome, Uncomplicated gastroesophageal reflux disease (Gerd) with breakthrough symptoms, Complicated GERD and other higher risk conditions such as feflux-associated laryngitis, recent gastrointestinal bleed, grade 3 or 4 erosive esophagitis, or GERD exacerbated asthma.
<b>Exclusion Criteria</b>	Non-Covered uses include uses not approved by the FDA, or if use is unapproved and not supported by the literature or evidence as an accepted off-label use (see Off-Label Use Policy for determining accepted use). Quantity levels exceeding the quantity limitations on PPIs, Dexilant dosing exceeding 60mg/day
<b>Required Medical Information</b>	A diagnosis of Zollinger-Ellison syndrome, uncomplicated gastroesophageal reflux disease (GERD) with breakthrough symptoms, Complicated GERD and other higher risk conditions such as feflux-associated laryngitis, recent gastrointestinal bleed, grade 3 or 4 erosive esophagitis, or GERD exacerbated asthma.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year, short term court of high dose= 3 months
<b>Other Criteria</b>	
<b>ST Criteria</b>	ONCE DAILY DOSING OF RABEPRAZOLE (20mg), DEXILANT (60mg), AND NEXIUM (40mg): A documented contraindication, intolerance, allergy, or failure of Prilosec OTC/omeprazole, Prevacid 24H OTC, and pantoprazole. HIGH DOSE NEXIUM (80mg) OR HIGH DOSE RABEPRAZOLE (40mg): A documented contraindication, intolerance, allergy, or failure of 80mg/day of Prilosec OTC/omeprazole or pantoprazole or though 60mg/day of Prevacid 24H OTC.
<b>QL Criteria</b>	1 tab Per 1 Day

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017



<b>Notes/ References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ranexa

---

## Products Affected

- RANEXA

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rasagiline Mesylate

---

## Products Affected

- *rasagiline mesylate oral*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ravicti

## Products Affected

- RAVICTI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	20 bottles Per 30 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rebetol

---

## Products Affected

- REBETOL ORAL SOLUTION

<b>QL Criteria</b>	500 milliliters Per 1 prescription
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rebif

## Products Affected

- REBIF SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	12 syringes Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rebif Rebidose

## Products Affected

- REBIF REBIDOSE SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	12 syringes Per 28 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rebif Rebidoose Titration Pack

## Products Affected

- REBIF REBIDOSE TITRATION PACK  
SUBCUTANEOUS SOLUTION AUTO-  
INJECTOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 titration pack Per 1 month
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Rebif Titration Pack

## Products Affected

- REBIF TITRATION PACK  
SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 titration pack Per 1 month
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rectiv

---

## Products Affected

- RECTIV

<b>QL Criteria</b>	30 grams Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: November 06, 2017

## RefuAH Plus Blood Glucose Test

### Products Affected

- REFUAH PLUS BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 1 month
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Relenza Diskhaler

---

## Products Affected

- RELENZA DISKHALER

<b>QL Criteria</b>	20 inhalations Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Relistor

## Products Affected

- RELISTOR SUBCUTANEOUS SOLUTION 12 MG/0.6ML

PA Criteria	Criteria Details
Covered Uses	Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, OIC in adults with advanced illness
Exclusion Criteria	
Required Medical Information	A documented diagnosis of opioid induced constipation due to non-cancer pain, OR a documented diagnosis of an advanced illness (i.e., incurable cancer, end-stage COPD/emphysema, cardiovascular disease/heart failure, Alzheimer's disease/dementia, HIV/AIDS), receiving palliative care, and response to laxative therapy has not been sufficient and documented concomitant use of opioid therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	0.6 ml Per 1 Day
Notes/References	Annual Review: 10/2017
Revision Date	Prior Authorization: April 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Relistor

## Products Affected

- RELISTOR SUBCUTANEOUS SOLUTION 8 MG/0.4ML

PA Criteria	Criteria Details
Covered Uses	Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, OIC in adults with advanced illness
Exclusion Criteria	
Required Medical Information	A documented diagnosis of opioid induced constipation due to non-cancer pain, OR a documented diagnosis of an advanced illness (i.e., incurable cancer, end-stage COPD/emphysema, cardiovascular disease/heart failure, Alzheimer's disease/dementia, HIV/AIDS), receiving palliative care, and response to laxative therapy has not been sufficient and documented concomitant use of opioid therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	0.4 ml Per 1 Day
Notes/References	Annual Review: 10/2017
Revision Date	Prior Authorization: April 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Remicade

## Products Affected

- REMICADE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Remicade.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Remicade.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Remodulin

## Products Affected

- REMODULIN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Repaglinide-Metformin HCl

---

## Products Affected

- *repaglinide-metformin hcl*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Repatha

## Products Affected

- REPATHA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCS K9.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCS K9.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/PCS K9.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/PCS K9.html</a>
QL Criteria	2 injections Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Repatha Pushtronex System

## Products Affected

- REPATHA PUSHTRONEX SYSTEM

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/PCS_K9.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/PCS_K9.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/PCS_K9.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/PCS_K9.html</a>
QL Criteria	1 syringe Per 1 month
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Repatha SureClick

## Products Affected

- REPATHA SURECLICK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCS K9.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCS K9.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/PCS K9.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/PCS K9.html</a>
QL Criteria	2 injections Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Rescula

---

## Products Affected

- RESCULA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of latanoprost
<b>Notes/ References</b>	Annual Review: 03/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Reveal Blood Glucose Test

## Products Affected

- REVEAL BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 1 month
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Revlimid

## Products Affected

- REVLIMID

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 cap Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rexall Blood Glucose Test

## Products Affected

- REXALL BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 1 month
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Rexulti

## Products Affected

- REXULTI

PA Criteria	Criteria Details
Covered Uses	Major Depressive Disorder (MDD), Schizophrenia
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Major Depressive Disorder (MDD) or Schizophrenia
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of two of the following: aripiprazole, risperidone, quetiapine, ziprasidone, olanzapine, or clozapine
QL Criteria	1 tablet Per 1 Day
Notes/References	Annual Review: 08/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Reyataz

---

## Products Affected

- REYATAZ ORAL CAPSULE 150 MG
- REYATAZ ORAL CAPSULE 300 MG

<b>QL Criteria</b>	1 cap Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Reyataz

---

## Products Affected

- REYATAZ ORAL CAPSULE 200 MG

<b>QL Criteria</b>	2 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rightest GS100 Blood Glucose

## Products Affected

- RIGHTEST GS100 BLOOD GLUCOSE

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 1 month
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rightest GS300 Blood Glucose

## Products Affected

- RIGHTEST GS300 BLOOD GLUCOSE

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 1 month
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rightest GS550 Blood Glucose

## Products Affected

- RIGHTEST GS550 BLOOD GLUCOSE

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 1 month
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Risedronate Sodium

---

## Products Affected

- *risedronate sodium oral tablet 150 mg*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of alendronate weekly 70mg
<b>QL Criteria</b>	1 tablet Per 28 Days
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Risedronate Sodium

---

## Products Affected

- *risedronate sodium oral tablet 30 mg, 5 mg*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of alendronate weekly 70mg
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Risedronate Sodium

---

## Products Affected

- *risedronate sodium oral tablet 35 mg* *release*
- *risedronate sodium oral tablet delayed*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of alendronate weekly 70mg
<b>QL Criteria</b>	4 tablets Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RisperiDONE

---

## Products Affected

- *risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg*
- *risperidone oral tablet dispersible 0.5 mg*
- *risperidone oral tablet dispersible 1 mg, 2 mg*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RisperiDONE

---

## Products Affected

- *risperidone oral tablet 3 mg*
- *risperidone oral tablet dispersible 3 mg*

<b>QL Criteria</b>	3 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RisperiDONE

---

## Products Affected

- *risperidone oral tablet 4 mg*
- *risperidone oral tablet dispersible 4 mg*

<b>QL Criteria</b>	4 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RisperiD ONE M-TAB

---

## Products Affected

- *risperidone m-tab oral tablet dispersible 0.5 mg, 1 mg, 2 mg*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RisperiD ONE M-TAB

---

## Products Affected

- *risperidone m-tab oral tablet dispersible 3 mg*

<b>QL Criteria</b>	3 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RisperiD ONE M-TAB

---

## Products Affected

- *risperidone m-tab oral tablet dispersible 4 mg*

<b>QL Criteria</b>	4 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rituxan

## Products Affected

- RITUXAN INTRAVENOUS SOLUTION

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Rituxan.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Rituxan.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Rituxan.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Rituxan.html</a>
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Rizatriptan Benzoate

---

## Products Affected

- *rizatriptan benzoate*

<b>QL Criteria</b>	9 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ROPINIRole HCl ER

---

## Products Affected

- *ropinirole hcl er oral tablet extended release*  
*24 hour 12 mg*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ROPINIRole HCl ER

---

## Products Affected

- *ropinirole hcl er oral tablet extended release*  
*24 hour 2 mg, 4 mg, 6 mg, 8 mg*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rosuvastatin Calcium

---

## Products Affected

- *rosuvastatin calcium*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: atorvastatin, lovastatin, pravastatin, simvastain
<b>QL Criteria</b>	1 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rozerem

## Products Affected

- ROZEREM

PA Criteria	Criteria Details
Covered Uses	Insomnia
Exclusion Criteria	
Required Medical Information	A documented diagnosis of insomnia
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of either zolpidem tartrate or zaleplon, and through zolpidem tartrate extended-release
QL Criteria	1 tab Per 1 Day
Notes/References	Annual Review: 08/2017
Revision Date	Prior Authorization: July 18, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rubraca

## Products Affected

- RUBRACA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Rubraca.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Rubraca.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: January 09, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sabril

## Products Affected

- SABRIL

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/anticonvulsants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/anticonvulsants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	6 packs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Samsca

## Products Affected

- SAMSCA ORAL TABLET 15 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/samsca.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/samsca.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tab Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Samsca

## Products Affected

- SAMSCA ORAL TABLET 30 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/samsca.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/samsca.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sancuso

## Products Affected

- SANCUSO

PA Criteria	Criteria Details
<b>Covered Uses</b>	Chemotherapy induced nausea and vomiting
<b>Exclusion Criteria</b>	Cancer patients with non-chemotherapy related nausea and vomiting, patients with radiation-induced nausea and vomiting, patients with pregnancy-related nausea and vomiting, patients with post-operative nausea and vomiting
<b>Required Medical Information</b>	Patient is currently receiving chemotherapy and remains symptomatic despite treatment with oral antiemetics
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of oral ondansetron or oral granisetron
<b>QL Criteria</b>	1 patch Per 1 fill
<b>Notes/References</b>	Annual Review: 10/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Saphris

---

## Products Affected

- SAPHRIS

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: aripiprazole, risperidone, quetiapine, ziprasidone, olanzapine, or clozapine
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Savella

## Products Affected

- SAVELLA

PA Criteria	Criteria Details
Covered Uses	Fibromyalgia
Exclusion Criteria	
Required Medical Information	A diagnosis of fibromyalgia and documentation of trials of non-pharmacologic therapies (cognitive behavioral therapies, exercise etc.)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of three drugs from three of the following drug/drug classes: tricyclic antidepressant, muscle relaxant, SSRI, SNRI, gabapentin, or tramadol
QL Criteria	2 tabs Per 1 Day
Notes/References	Annual Review: 03/2017
Revision Date	Prior Authorization: May 10, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Savella Titration Pack

## Products Affected

- SAVELLA TITRATION PACK

PA Criteria	Criteria Details
Covered Uses	Fibromyalgia
Exclusion Criteria	
Required Medical Information	A diagnosis of fibromyalgia and documentation of trials of non-pharmacologic therapies (cognitive behavioral therapies, exercise etc.)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of three drugs from three of the following drug/drug classes: tricyclic antidepressant, muscle relaxant, SSRI, SNRI, gabapentin, or tramadol
QL Criteria	2 tablets Per 1 Day
Notes/References	Annual Review: 03/2017
Revision Date	Prior Authorization: May 10, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Selzentry

---

## Products Affected

- SELZENTRY ORAL SOLUTION

<b>QL Criteria</b>	8 bottles Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Selzentry

---

## Products Affected

- SELZENTRY ORAL TABLET 150 MG

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Selzentry

---

## Products Affected

- SELZENTRY ORAL TABLET 25 MG

<b>QL Criteria</b>	8 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Selzentry

---

## Products Affected

- SELZENTRY ORAL TABLET 75 MG

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sensipar

## Products Affected

- SENSIPAR

PA Criteria	Criteria Details
<b>Covered Uses</b>	Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis, Hypercalcemia in adult patients with Parathyroid Carcinoma, or Hypercalcemia in adult patients with primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of one of Secondary Hyperparathyroidism (HPT) in an adult patient with chronic kidney disease (CKD) on dialysis, Hypercalcemia in an adult patient with parathyroid carcinoma (PC), or Hypercalcemia in an adult patient with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: July 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Serevent Diskus

---

## Products Affected

- SEREVENT DISKUS

<b>QL Criteria</b>	1 box Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sertraline HCl

---

## Products Affected

- *sertraline hcl oral tablet 100 mg*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sertraline HCl

---

## Products Affected

- *sertraline hcl oral tablet 25 mg*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sertraline HCl

---

## Products Affected

- *sertraline hcl oral tablet 50 mg*

<b>QL Criteria</b>	1.5 tag Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Signifor

## Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Signifor.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Signifor.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 amps Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sildenafil Citrate

## Products Affected

- *sildenafil citrate oral*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Simponi

## Products Affected

- SIMPONI SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- SIMPONI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Simponi.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Simponi.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Simponi.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Simponi.html</a>
QL Criteria	1 pen Per 1 fill
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Simponi Aria

## Products Affected

- SIMPONI ARIA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Simponi_Aria.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Simponi_Aria.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	1 syringe Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Simulect

## Products Affected

- SIMULECT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ID/Simulect.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ID/Simulect.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Simvastatin

---

## Products Affected

- *simvastatin oral*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sirturo

## Products Affected

- SIRTURO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antimycobacterial_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antimycobacterial_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	188 tabs Per 365 Days
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sivextro

---

## Products Affected

- SIVEXTRO ORAL

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of linezolid
<b>QL Criteria</b>	6 tabs Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Smartest Blood Glucose Test

## Products Affected

- SMARTEST BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sodium Phenylbutyrate

## Products Affected

- *sodium phenylbutyrate*
- *sodium phenylbutyrate oral powder 3 gm/tsp*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Solus V2 Test

## Products Affected

- SOLUS V2 TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Somatuline Depot

## Products Affected

- SOMATULINE DEPOT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/San_dostatin.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/San_dostatin.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Somavert

## Products Affected

- SOMAVERT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sovaldi

## Products Affected

- SOVALDI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tab Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Spiriva HandiHaler

---

## Products Affected

- SPIRIVA HANDIHALER

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Incruse
<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Spiriva Respimat

---

## Products Affected

- SPIRIVA RESPIMAT INHALATION  
AEROSOL SOLUTION 1.25 MCG/ACT

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Incruse
<b>QL Criteria</b>	1 inhaler Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sporanox

## Products Affected

- SPORANOX ORAL SOLUTION

PA Criteria	Criteria Details
<b>Covered Uses</b>	Onychomycosis, invasive fungal infection, other fungal infection, superficial mycoses
<b>Exclusion Criteria</b>	Cosmetic use, patients with evidence of ventricular dysfunction such as CHF or a history of CHF. Coadministration with certain drugs metabolized by the cytochrome P-450 3A4 isoenzyme system (CYP3A4), cisapride, oral midazolam, pimozide, quinidine, dofetilide, triazolam, HMG-CoA reductase inhibitors metabolized by CYP3A4, such as lovastatin and simvastatin, and ergot alkaloids metabolized by CYP3A4, such as dihydroergotamine, ergotamine, ergonovine, and methylergonovine.
<b>Required Medical Information</b>	Itraconazole is covered for members who meet the following criteria: Invasive fungal infections in patients who are immunocompromised (such as histoplasmosis, aspergillosis, and blastomycosis), treatment of tinea barbae, tinea capitis, tinea favosa, tinea corporis, tinea cruris, tinea faciei, tinea manuum, or tinea pedis, a diagnosis of majocchi granuloma, or a diagnosis of onychomycosis in diabetic patients or patients with peripheral vascular disease and either a positive onychomycosis susceptible pathogen culture or a positive PAS stain performed by a laboratory, or a diagnosis of onychomycosis with documented disabling pain or impairment and a positive onychomycosis susceptible pathogen culture
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Nail: 12 wk(toe),5 wk (finger) per year,Invasive: 1-3 mo based on severity, Other Dx: 1-6 wk
<b>Other Criteria</b>	

<b>ST Criteria</b>	FOR A DIAGNOSIS OF ONYCHOMYCOSIS, TINEA BARBAE, TIBNEA CAPITIS, TINEA FAVOSA: A documented contraindication, intolerance, allergy, or failure of terbinafine. FOR A DIAGNOSIS OF TINEA CORPORIS, TINEA CRURIS, TINEA FACIEI, TINEA MANUUM, TINEA PEDIS: A documented contraindication, intolerance, allergy, or failure of a topical antifungal and terbinafine. FOR A DIAGNOSIS OF TINEA VERSICOLOR: A documented contraindication, intolerance, allergy, or failure of selenium sulfide and a topical antifungal.
<b>Notes/References</b>	Annual Review: 09/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Sprycel

## Products Affected

- SPRYCEL ORAL TABLET 100 MG, 140 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
QL Criteria	1 tab Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sprycel

## Products Affected

- SPRYCEL ORAL TABLET 20 MG, 50 MG, 70 MG, 80 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
QL Criteria	2 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Stelara

## Products Affected

- STELARA INTRAVENOUS PREFILLED SYRINGE
- STELARA SUBCUTANEOUS SOLUTION

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Stelara.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Stelara.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>ST Criteria</b>	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Stelara.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Stelara.html</a>
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Stimate

---

## Products Affected

- STIMATE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/misendocrine.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/misendocrine.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Stiolto Respimat

---

## Products Affected

- STIOLTO RESPIMAT

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Anoro Ellipta
<b>QL Criteria</b>	1 inhaler Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Stivarga

## Products Affected

- STIVARGA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Striant

## Products Affected

- STRIANT

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	Patients with carcinoma of the breast or suspected carcinoma of the prostate, or in a patient who will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available), Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only, or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 buccals Per 1 Day
Notes/References	Annual Review: 02/2017

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>Revision Date</b>	Prior Authorization: February 08, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---



# Stribild

## Products Affected

- STRIBILD

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviral_hiv.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviral_hiv.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tab Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Striverdi Respimat

## Products Affected

- STRIVERDI RESPIMAT

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Chronic obstructive pulmonary disease (COPD)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of Serevent
QL Criteria	1 inhaler Per 30 Days
Notes/References	Annual Review: 07/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Suboxone

---

## Products Affected

- SUBOXONE SUBLINGUAL FILM

<b>QL Criteria</b>	2 films Per 1 Day
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SulfaSALazine

---

## Products Affected

- *sulfasalazine oral*

<b>QL Criteria</b>	8 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sulfazine

---

## Products Affected

- *sulfazine*

<b>QL Criteria</b>	8 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SUMAtriptan

---

## Products Affected

- *sumatriptan nasal*

<b>QL Criteria</b>	6 sprays Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SUMatriptan Succinate

---

## Products Affected

- *sumatriptan succinate oral*

<b>QL Criteria</b>	9 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SUMatriptan Succinate

---

## Products Affected

- *sumatriptan succinate subcutaneous solution*  
*6 mg/0.5ml*

<b>QL Criteria</b>	10 vials Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# SUMatriptan Succinate

---

## Products Affected

- *sumatriptan succinate subcutaneous solution auto-injector 4 mg/0.5ml, 6 mg/0.5ml*

<b>QL Criteria</b>	2 boxes Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SUMatriptan Succinate Refill

---

## Products Affected

- *sumatriptan succinate refill subcutaneous solution cartridge*

<b>QL Criteria</b>	2 boxes Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Supprelin LA

## Products Affected

- SUPPRELIN LA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sure Edge Test

## Products Affected

- SURE EDGE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SureChek Blood Glucose Test

## Products Affected

- SURECHEK BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SureStep Pro Linearity

## Products Affected

- SURESTEP PRO LINEARITY

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Sure-Test EasyPlus Mini Test

### Products Affected

- SURE-TEST EASYPLUS MINI TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sutent

## Products Affected

- SUTENT ORAL CAPSULE 12.5 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Sutent

## Products Affected

- SUTENT ORAL CAPSULE 25 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sutent

## Products Affected

- SUTENT ORAL CAPSULE 37.5 MG, 50 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 cap Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sylatron

## Products Affected

- SYLATRON SUBCUTANEOUS KIT 200 MCG, 300 MCG, 600 MCG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Symbicort

---

## Products Affected

- SYMBICORT

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Dulera
<b>QL Criteria</b>	1 inhaler Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SymlinPen 120

## Products Affected

- SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
Covered Uses	All FDA Approved uses
Exclusion Criteria	Poor compliance with current insulin regimen, Poor compliance with prescribed self-blood glucose monitorings, An A1C greater than 9%, Recurrent severe hypoglycemia requiring assistance during the previous 6 months, Presence of hypoglycemia unawareness, Confirmed diagnosis of gastroparesis, Need for medications that stimulate GI motility , Patient is less than 18 years old, Concurrent use with other oral antidiabetic medications (except metformin and sulfonylureas) or drugs that alter gastrointestinal motility
Required Medical Information	A documented diagnosis of type 1 or type 2 diabetes mellitus and the patient concurrently using rapid or short-acting insulin (e.g., Humalog or regular insulin). For extended renewals: a documented diagnosis of type 1 or type 2 diabetes mellitus and the patient concurrently using rapid or short-acting insulin (e.g., Humalog or regular insulin), and the patient demonstrated an expected reduction in HbA1c since starting this therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	initial: 6 months - extended: 12 months
Other Criteria	
QL Criteria	4 pens Per 1 month
Notes/References	Annual Review: 05/2017
Revision Date	Prior Authorization: June 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# SymlinPen 60

## Products Affected

- SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
Covered Uses	All FDA Approved uses
Exclusion Criteria	Poor compliance with current insulin regimen, Poor compliance with prescribed self-blood glucose monitorings, An A1C greater than 9%, Recurrent severe hypoglycemia requiring assistance during the previous 6 months, Presence of hypoglycemia unawareness, Confirmed diagnosis of gastroparesis, Need for medications that stimulate GI motility , Patient is less than 18 years old, Concurrent use with other oral antidiabetic medications (except metformin and sulfonylureas) or drugs that alter gastrointestinal motility
Required Medical Information	A documented diagnosis of type 1 or type 2 diabetes mellitus and the patient concurrently using rapid or short-acting insulin (e.g., Humalog or regular insulin). For extended renewals: a documented diagnosis of type 1 or type 2 diabetes mellitus and the patient concurrently using rapid or short-acting insulin (e.g., Humalog or regular insulin), and the patient demonstrated an expected reduction in HbA1c since starting this therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	initial: 6 months - extended: 12 months
Other Criteria	
Notes/References	Annual Review: 05/2017
Revision Date	Prior Authorization: June 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Synagis

## Products Affected

- SYNAGIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Synagis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Synagis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Synarel

---

## Products Affected

- SYNAREL

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Synjardy

---

## Products Affected

- SYNJARDY

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Synjardy XR

---

## Products Affected

- SYNJARDY XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 10-1000  
MG, 12.5-1000 MG, 5-1000 MG

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Synjardy XR

---

## Products Affected

- SYNJARDY XR ORAL TABLET  
EXTENDED RELEASE 24 HOUR 25-1000  
MG

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Synribo

## Products Affected

- SYNRIBO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Syprine

## Products Affected

- SYPRINE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Taclonex

---

## Products Affected

- TACLONEX EXTERNAL SUSPENSION

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of calcipotriene and a medium to high potency topical steroid
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tacrolimus

---

## Products Affected

- *tacrolimus external*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 2 weeks (14 days) of one preferred alternative topical corticosteroid (triamcinolone acetonide, fluocinonide cream, augmented betamethasone gel, betamethasone dipropionate, or fluticasone propionate ointment)
<b>Notes/ References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tafinlar

## Products Affected

- TAFINLAR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 caps Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Tamiflu

---

## Products Affected

- TAMIFLU ORAL SUSPENSION  
RECONSTITUTED 6 MG/ML

<b>QL Criteria</b>	3 bottles Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tanzeum

## Products Affected

- TANZEUM

PA Criteria	Criteria Details
<b>Covered Uses</b>	Type 2 Diabetes Mellitus (NIDDM)
<b>Exclusion Criteria</b>	Diagnosis of metabolic syndrome or any other pre-diabetic diagnosis, diagnosis of Type 1 Diabetes, treatment of diabetic ketoacidosis, pediatric patients, patients with multiple endocrine neoplasia syndrome type 2 (MEN2), family history of medullary thyroid carcinoma (MTC), patients with a history of pancreatitis
<b>Required Medical Information</b>	Patient must have an A1C level is greater than 6.5%,
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: Invokana/Invokamet, Jentaduetto/Tradjenta, or Januvia/Janumet/Janumet XR
<b>QL Criteria</b>	4 pens Per 1 month
<b>Notes/References</b>	Annual Review: 02/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Tarceva

## Products Affected

- TARCEVA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tab Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Targretin

## Products Affected

- TARGRETIN EXTERNAL

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Targretin.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Targretin.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tasigna

## Products Affected

- TASIGNA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	4 caps Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tazarotene

---

## Products Affected

- *tazarotene external*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of tretinoin
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tazorac

---

## Products Affected

- TAZORAC EXTERNAL CREAM 0.05 %
- TAZORAC EXTERNAL GEL

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of tretinoin
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Taztia XT

---

## Products Affected

- *taztia xt oral capsule extended release 24 hour 120 mg, 180 mg, 300 mg, 360 mg*

<b>QL Criteria</b>	1 cap Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Taztia XT

---

## Products Affected

- *taztia xt oral capsule extended release 24 hour 240 mg*

<b>QL Criteria</b>	2 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tecfidera

## Products Affected

- TECFIDERA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html</a>
QL Criteria	2 caps Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Technivie

## Products Affected

- TECHNIVIE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tekturna

---

## Products Affected

- TEKTURNA

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tekturna HCT

---

## Products Affected

- TEKTURNA HCT

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Telcare Blood Glucose Test

## Products Affected

- TELCARE BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Telmisartan

---

## Products Affected

- *telmisartan*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Telmisartan-Amlodipine

---

## Products Affected

- *telmisartan-amlodipine*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Telmisartan-HCTZ

---

## Products Affected

- *telmisartan-hctz*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Temazepam

---

## Products Affected

- *temazepam oral capsule 22.5 mg, 7.5 mg*

<b>QL Criteria</b>	1 cap Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Temozolomide

## Products Affected

- *temozolomide*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Testopel

## Products Affected

- TESTOPEL

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	Patients with carcinoma of the breast or suspected carcinoma of the prostate, or in a patient who will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available), Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only, or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>Revision Date</b>	Prior Authorization: February 08, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

# Testosterone

## Products Affected

- *testosterone transdermal gel 10 mg/act (2%)*

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	Patients with carcinoma of the breast or suspected carcinoma of the prostate, or in a patient who will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available), Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only, or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	60 grams Per 1 fill
Notes/References	Annual Review: 02/2017

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>Revision Date</b>	Prior Authorization: February 08, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

# Testosterone

## Products Affected

- *testosterone transdermal gel 12.5 mg/act (1%)*
- *testosterone transdermal gel 50 mg/5gm (1%)*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
<b>Exclusion Criteria</b>	Patients with carcinoma of the breast or suspected carcinoma of the prostate, or in a patient who will be using therapy for muscle building purposes
<b>Required Medical Information</b>	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available), Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only, or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	10 grams Per 1 Day
<b>Notes/References</b>	Annual Review: 02/2017

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017



<b>Revision Date</b>	Prior Authorization: February 08, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

# Testosterone

## Products Affected

- *testosterone transdermal gel 25 mg/2.5gm (1%)*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
<b>Exclusion Criteria</b>	Patients with carcinoma of the breast or suspected carcinoma of the prostate, or in a patient who will be using therapy for muscle building purposes
<b>Required Medical Information</b>	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available), Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only, or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	2.5 grams Per 1 Day
<b>Notes/References</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>Revision Date</b>	Prior Authorization: February 08, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

# Testosterone

## Products Affected

- *testosterone transdermal solution*

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	Patients with carcinoma of the breast or suspected carcinoma of the prostate, or in a patient who will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available), Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only, or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	6 milliliters Per 1 Day
Notes/References	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>Revision Date</b>	Prior Authorization: February 08, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

# Tetrabenazine

## Products Affected

- *tetrabenazine oral tablet 12.5 mg*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/xenazine.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/xenazine.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	8 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 31, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tetrabenazine

## Products Affected

- *tetrabenazine oral tablet 25 mg*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/xenazine.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/xenazine.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 31, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TGT Blood Glucose Test

## Products Affected

- *tgt blood glucose test*

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 1 month
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Thalomid

## Products Affected

- THALOMID

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Thiola

## Products Affected

- THIOLA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TiaGABine HCl

---

## Products Affected

- *tiagabine hcl oral tablet 2 mg*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TiaGABine HCl

---

## Products Affected

- *tiagabine hcl oral tablet 4 mg*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tivicay

---

## Products Affected

- TIVICAY

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tivicay

---

## Products Affected

- TIVICAY

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tobramycin

---

## Products Affected

- *tobramycin inhalation*

<b>QL Criteria</b>	56 vials Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tolterodine Tartrate

---

## Products Affected

- *tolterodine tartrate*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of oxybutynin or trospium IR
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Tolterodine Tartrate ER

---

## Products Affected

- *tolterodine tartrate er*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of oxybutynin or trospium IR
<b>QL Criteria</b>	1 cap Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Topiramate

---

## Products Affected

- *topiramate oral capsule sprinkle*

<b>QL Criteria</b>	4 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Toviaz

---

## Products Affected

- TOVIAZ

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of oxybutynin or trospium IR and through either Vesicare or Myrbetriq
<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tracleer

## Products Affected

- TRACLEER

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tradjenta

---

## Products Affected

- TRADJENTA

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TraMADol HCl

## Products Affected

- *tramadol hcl oral*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
 Last Update 12/2017

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TraMADol HCl ER

## Products Affected

- *tramadol hcl er oral tablet extended release 24 hour*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of tramadol
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TraMADol HCl ER (Biphasic)

## Products Affected

- *tramadol hcl er (biphasic)*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of tramadol
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tramadol-Acetaminophen

## Products Affected

- *tramadol-acetaminophen*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tranexamic Acid

---

## Products Affected

- *tranexamic acid oral*

<b>QL Criteria</b>	30 tablet Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Trelstar Mixject

## Products Affected

- TRELSTAR MIXJECT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tresiba FlexTouch

---

## Products Affected

- TRESIBA FLEXTOUCH

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Levemir
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Triamcinolone Acetonide

---

## Products Affected

- *triamcinolone acetonide nasal aerosol*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of fluticasone propionate and flunisolide
<b>QL Criteria</b>	1 bottle Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Trintellix

## Products Affected

- TRINTELLIX

PA Criteria	Criteria Details
Covered Uses	Major Depressive Disorder (MDD)
Exclusion Criteria	
Required Medical Information	A diagnosis of Major Depressive Disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of three different antidepressants from at least two different therapeutic subclasses (includes SSRIs, SNRIs, NDRIs, TCAs, tetracyclic antidepressants, and MAOIs) (step therapy not required if patient is a new member and has been receiving medication therapy for more than 4 weeks.)
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: April 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Triptodur

---

## Products Affected

- TRIPTODUR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/Gonadotropins.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: February 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Triumeq

---

## Products Affected

- TRIUMEQ

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Trospium Chloride

---

## Products Affected

- *trospium chloride*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Trospium Chloride ER

---

## Products Affected

- *trospium chloride er*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of oxybutynin or trospium IR
<b>QL Criteria</b>	1 cap Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TRUEtest Test

## Products Affected

- TRUETEST TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TrueTrack Test

## Products Affected

- TRUETRACK TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Trulicity

## Products Affected

- TRULICITY

PA Criteria	Criteria Details
<b>Covered Uses</b>	Type 2 Diabetes Mellitus (NIDDM)
<b>Exclusion Criteria</b>	Diagnosis of metabolic syndrome or any other pre-diabetic diagnosis, diagnosis of Type 1 Diabetes, treatment of diabetic ketoacidosis, pediatric patients, patients with multiple endocrine neoplasia syndrome type 2 (MEN2), family history of medullary thyroid carcinoma (MTC), patients with a history of pancreatitis
<b>Required Medical Information</b>	Patient must have an A1C level is greater than 6.5%,
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: Invokana/Invokamet, Jentaduetto/Tradjenta, or Januvia/Janumet/Janumet XR
<b>QL Criteria</b>	4 injections Per 30 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Truvada

---

## Products Affected

- TRUVADA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviral_hiv.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviral_hiv.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tudorza Pressair

---

## Products Affected

- TUDORZA PRESSAIR INHALATION  
AEROSOL POWDER BREATH  
ACTIVATED

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of Incruse
<b>QL Criteria</b>	1 inhaler Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TussiCaps

---

## Products Affected

- TUSSICAPS

<b>QL Criteria</b>	20 caps Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tybost

---

## Products Affected

- TYBOST

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tykerb

---

## Products Affected

- TYKERB

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Uceris

---

## Products Affected

- UCERIS ORAL

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ulesfia

---

## Products Affected

- ULESFIA

<b>QL Criteria</b>	3 bottles Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Uloric

---

## Products Affected

- ULORIC

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of allopurinol
<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ultima Test

## Products Affected

- ULTIMA TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# UltraTRAK PRO Test

## Products Affected

- ULTRATRAK PRO TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# UltraTRAK Ultimate Test

## Products Affected

- ULTRATRAK ULTIMATE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Valcyte

## Products Affected

- VALCYTE ORAL SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviraltopical.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviraltopical.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ValGANciclovir HCl

## Products Affected

- *valganciclovir hcl oral solution reconstituted*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviraltopical.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviraltopical.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ValGANciclovir HCl

## Products Affected

- *valganciclovir hcl oral tablet*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviraltopical.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviraltopical.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	102 tablets Per 30 30s
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Valsartan

---

## Products Affected

- *valsartan*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Valsartan-Hydrochlorothiazide

---

## Products Affected

- *valsartan-hydrochlorothiazide*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vectibix

## Products Affected

- VECTIBIX INTRAVENOUS SOLUTION  
100 MG/5ML, 400 MG/20ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOP/L/Vectibix.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOP/L/Vectibix.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Velcade

## Products Affected

- VELCADE INJECTION

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Velcade.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Velcade.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venlafaxine HCl

---

## Products Affected

- *venlafaxine hcl oral tablet 100 mg, 25 mg*

<b>QL Criteria</b>	3 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venlafaxine HCl

---

## Products Affected

- *venlafaxine hcl oral tablet 37.5 mg*

<b>QL Criteria</b>	4 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venlafaxine HCl

---

## Products Affected

- *venlafaxine hcl oral tablet 50 mg*

<b>QL Criteria</b>	6 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venlafaxine HCl

---

## Products Affected

- *venlafaxine hcl oral tablet 75 mg*

<b>QL Criteria</b>	5 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venlafaxine HCl ER

---

## Products Affected

- *venlafaxine hcl er oral capsule extended release 24 hour 150 mg*

<b>QL Criteria</b>	2 cap Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Venlafaxine HCl ER

---

## Products Affected

- *venlafaxine hcl er oral capsule extended release 24 hour 37.5 mg, 75 mg*

<b>QL Criteria</b>	1 cap Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ventavis

---

## Products Affected

- VENTAVIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: December 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Verapamil HCl ER

---

## Products Affected

- *verapamil hcl er oral capsule extended release 24 hour 100 mg, 300 mg*

<b>QL Criteria</b>	1 cap Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Verapamil HCl ER

---

## Products Affected

- *verapamil hcl er oral capsule extended release 24 hour 200 mg*

<b>QL Criteria</b>	2 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# VESicare

---

## Products Affected

- VESICARE

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of oxybutynin or trospium IR
<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vicodin

## Products Affected

- *vicodin oral tablet 5-300 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vicodin ES

## Products Affected

- *vicodin es oral tablet 7.5-300 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017



<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vicodin HP

## Products Affected

- *vicodin hp oral tablet 10-300 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Victory AGM-4000 Test

## Products Affected

- VICTORY AGM-4000 TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Victoza

## Products Affected

- VICTOZA SUBCUTANEOUS SOLUTION  
PEN-INJECTOR

PA Criteria	Criteria Details
Covered Uses	Type 2 Diabetes Mellitus (NIDDM)
Exclusion Criteria	Diagnosis of metabolic syndrome or any other pre-diabetic diagnosis, diagnosis of Type 1 Diabetes, treatment of diabetic ketoacidosis, pediatric patients, patients with multiple endocrine neoplasia syndrome type 2 (MEN2), family history of medullary thyroid carcinoma (MTC), patients with a history of pancreatitis
Required Medical Information	Patient must have an A1C level is greater than 6.5%,
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of two of the following: Invokana/Invokamet, Jentaduetto/Tradjenta, or Januvia/Janumet/Janumet XR
QL Criteria	9 ML Per 1 month
Notes/References	Annual Review: 02/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Viekira Pak

## Products Affected

- VIEKIRA PAK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Viekira XR

## Products Affected

- VIEKIRA XR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
QL Criteria	3 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vigabatrin

## Products Affected

- *vigabatrin*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/anticonvulsants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/anticonvulsants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	6 packets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Viibryd

## Products Affected

- VIIBRYD ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	Major Depressive Disorder (MDD)
Exclusion Criteria	
Required Medical Information	A diagnosis of Major Depressive Disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of three different antidepressants from at least two different therapeutic subclasses (includes SSRIs, SNRIs, NDRIs, TCAs, tetracyclic antidepressants, and MAOIs) (step therapy not required if patient is a new member and has been receiving medication therapy for more than 4 weeks.)
QL Criteria	1 tab Per 1 Day
Notes/References	Annual Review: 05/2017
Revision Date	Prior Authorization: April 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Viibryd Starter Pack

## Products Affected

- VIIBRYD STARTER PACK

PA Criteria	Criteria Details
Covered Uses	Major Depressive Disorder (MDD)
Exclusion Criteria	
Required Medical Information	A diagnosis of Major Depressive Disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of three different antidepressants from at least two different therapeutic subclasses (includes SSRIs, SNRIs, NDRIs, TCAs, tetracyclic antidepressants, and MAOIs) (step therapy not required if patient is a new member and has been receiving medication therapy for more than 4 weeks.)
Notes/References	Annual Review: 05/2017
Revision Date	Prior Authorization: April 20, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vimpat

---

## Products Affected

- VIMPAT ORAL TABLET

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Viokace

## Products Affected

- VIOKACE

PA Criteria	Criteria Details
<b>Covered Uses</b>	Exocrine pancreatic Insufficiency
<b>Exclusion Criteria</b>	Uses not approved by the FDA, uses unapproved and not supported by the literature or evidence as an accepted off-label use. (see Off-Label Use Policy for determining accepted use).
<b>Required Medical Information</b>	Diagnosis of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of 2 weeks of Zenpep
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Viread

---

## Products Affected

- VIREAD ORAL TABLET

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vocal Point Blood Glucose Test

## Products Affected

- VOCAL POINT BLOOD GLUCOSE TEST

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 30 Days
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Voriconazole

## Products Affected

- *voriconazole oral tablet*

PA Criteria	Criteria Details
Covered Uses	Fungal infections
Exclusion Criteria	
Required Medical Information	Diagnosis of invasive aspergillosis or with a serious systemic fungal infection caused by <i>Scedosporium apiospermum</i> and <i>Fusarium</i> spp., for the treatment of esophageal candidiasis that is resistant to treatment with fluconazole and itraconazole, or for the treatment of candidemia in non-neutropenic patients and the following <i>Candida</i> infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds that are unresponsive to treatment with fluconazole (Continue therapy for 14 days after the patient is afebrile and blood cultures are negative).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Invasive aspergillosis: 12 weeks, Oral Candidiasis: 3 weeks MAX, Candidemia: 12 weeks
Other Criteria	
Notes/References	Annual Review: 09/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vosevi

## Products Affected

- VOSEVI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Votrient

## Products Affected

- VOTRIENT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vpriv

---

## Products Affected

- VPRIV

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gaucher_disease.html">?http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gaucher_disease.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vraylar

## Products Affected

- VRAYLAR ORAL CAPSULE 1.5 MG

PA Criteria	Criteria Details
Covered Uses	Bipolar disorder or schizophrenia
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of two of the following: aripiprazole, risperidone, quetiapine, ziprasidone, olanzapine, or clozapine
QL Criteria	4 capsule Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vraylar

## Products Affected

- VRAYLAR ORAL CAPSULE 3 MG

PA Criteria	Criteria Details
Covered Uses	Bipolar disorder or schizophrenia
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of two of the following: aripiprazole, risperidone, quetiapine, ziprasidone, olanzapine, or clozapine
QL Criteria	2 capsule Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vraylar

## Products Affected

- VRAYLAR ORAL CAPSULE 4.5 MG, 6 MG

PA Criteria	Criteria Details
Covered Uses	Bipolar disorder or schizophrenia
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of two of the following: aripiprazole, risperidone, quetiapine, ziprasidone, olanzapine, or clozapine
QL Criteria	1 capsule Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vraylar

## Products Affected

- VRAYLAR ORAL CAPSULE THERAPY PACK

PA Criteria	Criteria Details
Covered Uses	Bipolar disorder or schizophrenia
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of two of the following: aripiprazole, risperidone, quetiapine, ziprasidone, olanzapine, or clozapine
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vyvanse

## Products Affected

- VYVANSE

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD), Binge Eating Disorder
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD) or Binge Eating Disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of regular/immediate acting amphetamine salts and dextroamphetamine/amphetamine ER
QL Criteria	2 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: November 14, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vyvanse

## Products Affected

- VYVANSE

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD), Binge Eating Disorder
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Attention deficit hyperactivity disorder (ADHD) or Binge Eating Disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented contraindication, intolerance, allergy, or failure of regular/immediate acting amphetamine salts and dextroamphetamine/amphetamine ER
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: November 14, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# WaveSense Presto

## Products Affected

- WAVESENSE PRESTO

PA Criteria	Criteria Details
Covered Uses	Type II Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	There is documentation the member has a physical limitation that makes utilization of an Abbott or Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Abbott or Lifescan product lines, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, limit one meter per year
Other Criteria	
QL Criteria	300 strips Per 1 month
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Wide-Seal Diaphragm 60

---

## Products Affected

- WIDE-SEAL DIAPHRAGM 60

<b>QL Criteria</b>	1 diaphragm Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Wide-Seal Diaphragm 65

---

## Products Affected

- WIDE-SEAL DIAPHRAGM 65

<b>QL Criteria</b>	1 diaphragm Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Wide-Seal Diaphragm 70

---

## Products Affected

- WIDE-SEAL DIAPHRAGM 70

<b>QL Criteria</b>	1 diaphragm Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Wide-Seal Diaphragm 75

---

## Products Affected

- WIDE-SEAL DIAPHRAGM 75

<b>QL Criteria</b>	1 diaphragm Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Wide-Seal Diaphragm 80

---

## Products Affected

- WIDE-SEAL DIAPHRAGM 80

<b>QL Criteria</b>	1 diaphragm Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Wide-Seal Diaphragm 85

---

## Products Affected

- WIDE-SEAL DIAPHRAGM 85

<b>QL Criteria</b>	1 diaphragm Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Wide-Seal Diaphragm 90

---

## Products Affected

- WIDE-SEAL DIAPHRAGM 90

<b>QL Criteria</b>	1 diaphragm Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Wide-Seal Diaphragm 95

---

## Products Affected

- WIDE-SEAL DIAPHRAGM 95

<b>QL Criteria</b>	1 diaphragm Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xalkori

## Products Affected

- XALKORI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 caps Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xatmep

## Products Affected

- XATMEP

PA Criteria	Criteria Details
Covered Uses	Treatment of acute lymphoblastic leukemia (ALL) or polyarticular juvenile idiopathic arthritis (pJIA) in pediatric patients
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Acute Lymphoblastic Leukemia (ALL) in a pediatric patient (18 years and younger) as part of a multi-phase, combination chemotherapy maintenance regimen or a diagnosis of Polyarticular Juvenile Idiopathic Arthritis (PJIA) in pediatric patients (18 years and younger) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs). Regardless of diagnosis, the patient must have a documented inability to swallow tablets/capsules.
Age Restrictions	Approved for those 18 years of age or younger
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: July 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xeljanz

## Products Affected

- XELJANZ

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Xeljanz_XeljanzXR.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Xeljanz_XeljanzXR.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Xeljanz_XeljanzXR.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Xeljanz_XeljanzXR.html</a>
QL Criteria	2 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xeljanz XR

## Products Affected

- XELJANZ XR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Xeljanz_XeljanzXR.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Xeljanz_XeljanzXR.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Xeljanz_XeljanzXR.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/Xeljanz_XeljanzXR.html</a>
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xeomin

## Products Affected

- XEOMIN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/botulinum_toxin.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/botulinum_toxin.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xgeva

## Products Affected

- XGEVA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xiaflex

---

## Products Affected

- XIAFLEX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/duputrens_contracture_treatments.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/duputrens_contracture_treatments.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Xifaxan

---

## Products Affected

- XIFAXAN ORAL TABLET 200 MG

<b>QL Criteria</b>	9 tabs Per 1 fill
<b>Notes/ References</b>	Annual Review: 04/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xifaxan

## Products Affected

- XIFAXAN ORAL TABLET 550 MG

PA Criteria	Criteria Details
Covered Uses	Hepatic Encephalopathy, Irritable Bowel Syndrome (IBS) with Diarrhea.
Exclusion Criteria	Pregnancy, Severe hepatic impairment (child-Pugh C)
Required Medical Information	FOR HEPATIC ENCEPHALOPATHY: Member must have a documented diagnosis and be 18 years and older. FOR IBS WITH DIARRHEA: Member must have a documented diagnosis and must have been prescribed a 14-day course of therapy with three times a day dosing. For reauthorization of 2nd or 3rd course of therapy, there must be at least a 10-week treatment free period from the previous course of therapy.
Age Restrictions	18 years or older
Prescriber Restrictions	
Coverage Duration	HEPATIC ENCEPHALOPATHY: 1 year. IBS: 14 days.
Other Criteria	
ST Criteria	FOR HEPATIC ENCEPHALOPATHY: A documented contraindication, intolerance, allergy, or failure of lactulose solution
QL Criteria	3 tablets Per 1 Day
Notes/References	Annual Review: 04/2017
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Xigduo XR

---

## Products Affected

- XIGDUO XR ORAL TABLET EXTENDED  
RELEASE 24 HOUR 10-1000 MG, 10-500  
MG, 5-500 MG

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xigduo XR

---

## Products Affected

- XIGDUO XR ORAL TABLET EXTENDED  
RELEASE 24 HOUR 5-1000 MG

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xtampza ER

## Products Affected

- XTAMPZA ER

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xtandi

## Products Affected

- XTANDI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
QL Criteria	4 caps Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xuriden

## Products Affected

- XURIDEN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 packets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Xylon

## Products Affected

- XYLON

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Length of Therapy; see required medical information
<b>Other Criteria</b>	

<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

# Xyrem

## Products Affected

- XYREM

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/cataplaxy-xyrem.html">http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/cataplaxy-xyrem.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Yervoy

---

## Products Affected

- YERVOY

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/yervoy.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/yervoy.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zaleplon

---

## Products Affected

- *zaleplon*

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zamicet

## Products Affected

- ZAMICET

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	(1) A MEMBER WILL RECEIVE LIFETIME APPROVAL OF THE REQUESTED MEDICATION WHEN: Member is in hospice care, if terminally ill or has end-of-life care (other than hospice), or has an active oncology diagnosis (pain medication being used for pain for cancer patients) or palliative care. (2) FOR A DOCUMENTED DIAGNOSIS OF MODERATE TO SEVERE ACUTE PAIN (INCLUDING POST-SURGICAL PAIN), TRAUMATIC INJURY, OR FOR A CHILD ON AN OPIOID WEAN AT TIME OF HOSPITAL DISCHARGE: additional medication after initial coverage will be approved for up to 1 month. (3) FOR A DOCUMENTED DIAGNOSIS OF CHRONIC PAIN: which includes conditions of chronic pain not mentioned above, the prescriber must certify there is an active treatment plan that includes but is not limited to a specific treatment objective, the use of other pharmacological and non-pharmacological agents for pain relief as appropriate, that there has been an informed consent document signed and an addiction risk assessment performed, and that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists. When these criteria are met, the medication will be approved for an initial 3 months. Continuation requests may be approved for up to an additional 6 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Length of Therapy; see required medical information
Other Criteria	

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: September 06, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zarxio

---

## Products Affected

- ZARXIO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/G-CSF.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/G-CSF.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Zavesca

## Products Affected

- ZAVESCA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gaucher_disease.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gaucher_disease.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gaucher_disease.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/gaucher_disease.html</a>
QL Criteria	3 caps Per 1 Day
Notes/References	
Revision Date	Prior Authorization: January 11, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zegerid OTC

---

## Products Affected

- ZEGERID OTC

<b>QL Criteria</b>	1 cap Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zelapar

---

## Products Affected

- ZELAPAR

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of selegiline
<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zelboraf

## Products Affected

- ZELBORAF

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	8 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zemaira

## Products Affected

- ZEMAIRA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Alpha-1 Antitrypsin Inhibitor Therapy.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/Alpha-1 Antitrypsin Inhibitor Therapy.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zenatane

---

## Products Affected

- ZENATANE

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of minocycline or doxycycline
<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zepatier

## Products Affected

- ZEPATIER

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zetonna

---

## Products Affected

- ZETONNA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of fluticasone propionate and flunisolide
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Ziana

---

## Products Affected

- ZIANA

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of tretinoin
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zioptan

---

## Products Affected

- ZIOPTAN

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of latanoprost
<b>Notes/ References</b>	Annual Review: 03/2017
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ziprasidone HCl

---

## Products Affected

- *ziprasidone hcl*

<b>QL Criteria</b>	2 caps Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zoledronic Acid

## Products Affected

- *zoledronic acid intravenous concentrate*
- *zoledronic acid intravenous solution*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MUSC/bone_disease_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zolinza

## Products Affected

- ZOLINZA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 caps Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ZOLMitriptan

---

## Products Affected

- *zolmitriptan oral tablet*
- *zolmitriptan oral tablet dispersible 2.5 mg*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: sumatriptan, naratriptan, rizatriptan
<b>QL Criteria</b>	6 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ZOLMitriptan

---

## Products Affected

- *zolmitriptan oral tablet dispersible 5 mg*

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: sumatriptan, naratriptan, rizatriptan
<b>QL Criteria</b>	30 tablet Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zolpidem Tartrate

---

## Products Affected

- *zolpidem tartrate oral*

<b>QL Criteria</b>	2 tabs Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Zolpidem Tartrate ER

---

## Products Affected

- *zolpidem tartrate er*

<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zomig

---

## Products Affected

- ZOMIG NASAL SOLUTION 5 MG

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of two of the following: sumatriptan, naratriptan, rizatriptan
<b>QL Criteria</b>	6 sprays Per 30 fills
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zonalon

---

## Products Affected

- ZONALON

<b>QL Criteria</b>	45 grams Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zontivity

## Products Affected

- ZONTIVITY

PA Criteria	Criteria Details
<b>Covered Uses</b>	Reduction of the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD)
<b>Exclusion Criteria</b>	Do not use in patients with history of stroke, history of transient ischemic attack (TIA), or history of intracranial hemorrhage (ICH), or active pathological bleeding
<b>Required Medical Information</b>	Documented diagnosis or history of myocardial infarction (MI) or peripheral arterial disease (PAD) and concurrent use of aspirin or clopidogrel
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tab Per 1 Day
<b>Notes/References</b>	Annual Review: 06/2017
<b>Revision Date</b>	Prior Authorization: July 19, 2017 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zovirax

---

## Products Affected

- ZOVIRAX EXTERNAL CREAM

<b>ST Criteria</b>	A documented contraindication, intolerance, allergy, or failure of oral acyclovir
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zydelig

## Products Affected

- ZYDELIG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zykadia

---

## Products Affected

- ZYKADIA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zytiga

## Products Affected

- ZYTIGA ORAL TABLET 250 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Zytiga

## Products Affected

- ZYTIGA ORAL TABLET 500 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Index

<i>acamprosate calcium</i> .....	1	ADVOCATE TEST.....	38
ACCU-CHEK AVIVA PLUS IN VITRO.....	2	<i>afeditab cr oral tablet extended release 24 hour 30 mg</i> .....	39
ACCU-CHEK COMPACT PLUS.....	3	<i>afeditab cr oral tablet extended release 24 hour 60 mg</i> .....	40
ACCU-CHEK SMARTVIEW.....	4	AFINITOR.....	41
ACCU-CHEK SOFTCLIX LANCET DEV KIT.....	5	AGAMATRIX AMP TEST.....	42
ACCUTREND GLUCOSE.....	6	AGAMATRIX JAZZ TEST.....	43
<i>acetaminophen-codeine #2</i> .....	11	AGAMATRIX KEYNOTE TEST.....	44
<i>acetaminophen-codeine #3</i> .....	13	AGAMATRIX PRESTO TEST.....	45
<i>acetaminophen-codeine #4</i> .....	15	AKYNZEO.....	46
<i>acetaminophen-codeine oral solution</i> .....	7	ALDURAZYME.....	47
<i>acetaminophen-codeine oral tablet</i> .....	9	<i>alendronate sodium oral tablet 10 mg</i> .....	48
<i>acitretin</i> .....	17	<i>alendronate sodium oral tablet 35 mg, 70 mg</i> .....	49
<i>acitretin</i> .....	18	<i>alendronate sodium oral tablet 40 mg, 50 mg</i> .....	50
ACTEMRA INTRAVENOUS.....	19	<i>alfuzosin hcl er</i> .....	51
ACTEMRA SUBCUTANEOUS.....	20	ALIMTA.....	52
ACTIMMUNE.....	21	<i>almotriptan malate</i> .....	53
ACTOPLUS MET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 15-1000 MG.....	22	<i>alogliptin benzoate</i> .....	54
ACTOPLUS MET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 30-1000 MG.....	23	<i>alogliptin-metformin hcl</i> .....	55
<i>adapalene external lotion</i> .....	24	<i>alogliptin-pioglitazone</i> .....	56
ADCIRCA.....	25	<i>alose tron hcl</i> .....	57
ADDYI.....	26	ALOXI INTRAVENOUS SOLUTION 0.25 MG/5ML.....	58
<i>adefovir dipivoxil</i> .....	28	<i>alprazolam er</i> .....	59
ADEMPAS.....	29	<i>alprazolam xr</i> .....	60
ADVAIR DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 100-50 MCG/DOSE, 250-50 MCG/DOSE.....	30	ALTOPREV.....	61
ADVAIR DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 500-50 MCG/DOSE.....	31	ALVESCO.....	62
ADVAIR HFA.....	32	AMITIZA.....	63
ADVANCE INTUITION TEST.....	33	<i>amlodipine besylate-valsartan</i> .....	64
ADVATE.....	34	<i>amlodipine-olmesartan</i> .....	65
ADVOCATE DUO DEVICE.....	35	<i>amlodipine-valsartan-hctz</i> .....	66
ADVOCATE REDI-CODE IN VITRO.....	36	<i>amnesteam</i> .....	67
ADVOCATE REDI-CODE+ TEST.....	37	<i>amphetamine-dextroamphet er</i> .....	68
2017 Aetna Pharmacy Drug List - Individual Last Update 12/2017		<i>amphetamine-dextroamphetamine</i> .....	69
		AMPYRA.....	70
		ANORO ELLIPTA.....	71
		ANZEMET ORAL.....	72
		<i>apap-caff-dihydrocodeine oral capsule</i> .....	73
		APIDRA.....	75

APIDRA SOLOSTAR		<i>atomoxetine hcl oral capsule 100 mg, 80</i>	
SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	76	<i>mg</i> .....	104
<i>aprepitant oral capsule 40 mg, 80 mg</i> .....	77	<i>atorvastatin calcium oral</i> .....	105
<i>aprepitant oral capsule 80 &amp; 125 mg</i> .....	78	ATRIPLA.....	106
APRISO.....	79	AUBAGIO.....	107
APTIOM ORAL TABLET 200 MG.....	80	AVANDIA ORAL TABLET 2 MG, 4	
ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG, 500 MG.....	81	MG.....	108
ARANESP (ALBUMIN FREE) INJECTION SOLUTION 100 MCG/ML, 200 MCG/ML, 25 MCG/ML, 300 MCG/ML, 40 MCG/ML, 60 MCG/ML.....	82	AVONEX.....	109
ARANESP (ALBUMIN FREE) INJECTION SOLUTION PREFILLED SYRINGE 100 MCG/0.5ML, 150 MCG/0.3ML, 200 MCG/0.4ML, 25 MCG/0.42ML, 300 MCG/0.6ML, 40 MCG/0.4ML, 500 MCG/ML, 60 MCG/0.3ML.....	82	AVONEX PEN INTRAMUSCULAR	
ARCALYST.....	83	AUTO-INJECTOR KIT.....	110
ARCAPTA NEOHALER.....	84	AVONEX PREFILLED	
<i>aripiprazole oral solution</i> .....	85	INTRAMUSCULAR PREFILLED	
<i>aripiprazole oral tablet</i> .....	86	SYRINGE KIT.....	111
<i>aripiprazole oral tablet dispersible</i> .....	86	<i>balsalazide disodium</i> .....	112
<i>armodafinil oral tablet 150 mg</i> .....	87	BANZEL ORAL TABLET.....	113
<i>armodafinil oral tablet 200 mg, 250 mg</i> .....	87	BAYER BREEZE 2 TEST.....	114
<i>armodafinil oral tablet 50 mg</i> .....	89	BAYER CONTOUR NEXT TEST.....	115
ARZERRA.....	91	BAYER CONTOUR TEST.....	116
<i>ascomp-codeine</i> .....	92	BECONASE AQ.....	117
ASMANEX 120 METERED DOSES.....	94	BELSOMRA.....	118
ASMANEX 14 METERED DOSES.....	95	BELVIQ.....	119
ASMANEX 30 METERED DOSES.....	96	BENLYSTA INTRAVENOUS.....	120
ASMANEX 60 METERED DOSES.....	97	BENLYSTA SUBCUTANEOUS.....	121
ASMANEX HFA.....	98	BERINERT.....	122
ASSURE 3 TEST.....	99	BETASERON SUBCUTANEOUS KIT	
ASSURE 4 TEST.....	100	.....	123
ASSURE PLATINUM.....	101	<i>bexarotene</i> .....	124
ASSURE PRO TEST.....	102	<i>bicalutamide</i> .....	125
<i>atomoxetine hcl oral capsule 10 mg, 18 mg, 25 mg, 40 mg, 60 mg</i> .....	103	<i>bimatoprost ophthalmic</i> .....	126
2017 Aetna Pharmacy Drug List - Individual Last Update 12/2017		BOSULIF ORAL TABLET 100 MG....	127
		BOSULIF ORAL TABLET 500 MG....	128
		BOTOX.....	129
		BRAVELLE.....	130
		BREO ELLIPTA.....	131
		BRILINTA.....	132
		BRILINTA.....	133
		BROVANA.....	134
		<i>budesonide inhalation</i> .....	135
		BUNAVAIL BUCCAL FILM 2.1-0.3	
		MG.....	136
		BUNAVAIL BUCCAL FILM 4.2-0.7	
		MG.....	137

BUNAVAIL BUCCAL FILM 6.3-1 MG.....	138	<i>cartia xt oral capsule extended release 24 hour 180 mg.....</i>	172
BUPHENYL ORAL TABLET.....	139	<i>cartia xt oral capsule extended release 24 hour 240 mg.....</i>	173
<i>buprenorphine.....</i>	140	CAYSTON.....	174
<i>buprenorphine hcl sublingual.....</i>	142	<i>celecoxib oral.....</i>	175
<i>buprenorphine hcl-naloxone hcl.....</i>	143	CERDELGA.....	176
<i>bupropion hcl er (smoking det).....</i>	145	CEREZYME INTRAVENOUS SOLUTION RECONSTITUTED 400 UNIT.....	177
<i>bupropion hcl er (sr).....</i>	146	CESAMET.....	178
<i>bupropion hcl er (xl).....</i>	147	CETROTIDE SUBCUTANEOUS KIT 0.25 MG.....	179
<i>bupropion hcl oral.....</i>	144	<i>cevimeline hcl.....</i>	180
<i>butalbital-apap-caff-cod oral capsule 50- 325-40-30 mg.....</i>	148	CHANTIX.....	181
<i>butalbital-asa-caff-codeine.....</i>	150	CHANTIX CONTINUING MONTH PAK.....	182
<i>butorphanol tartrate nasal.....</i>	152	CHENODAL.....	183
BYDUREON SUBCUTANEOUS PEN-INJECTOR.....	154	<i>chorionic gonadotropin intramuscular.....</i>	184
BYETTA 10 MCG PEN SUBCUTANEOUS SOLUTION PEN- INJECTOR.....	155	CIALIS ORAL TABLET 5 MG.....	185
BYETTA 5 MCG PEN SUBCUTANEOUS SOLUTION PEN- INJECTOR.....	156	<i>ciclodan external solution.....</i>	186
BYSTOLIC ORAL TABLET 10 MG, 5 MG.....	157	<i>ciclopirox external solution.....</i>	187
BYSTOLIC ORAL TABLET 2.5 MG..	157	CIMZIA PREFILLED.....	189
BYSTOLIC ORAL TABLET 20 MG...	158	CIMZIA STARTER KIT.....	190
<i>calcipotriene external.....</i>	159	CIMZIA SUBCUTANEOUS KIT 2 X 200 MG.....	188
<i>calcipotriene-betameth diprop.....</i>	160	<i>citalopram hydrobromide oral tablet.....</i>	191
<i>calcitonin (salmon).....</i>	161	<i>citalopram hydrobromide oral tablet.....</i>	192
<i>calcitrene.....</i>	162	<i>claravis.....</i>	193
CANASA.....	163	CLEVER CHEK AUTO-CODE.....	194
<i>candesartan cilexetil oral tablet 16 mg, 4 mg, 8 mg.....</i>	164	CLEVER CHEK AUTO-CODE TEST	195
<i>candesartan cilexetil-hctz.....</i>	165	CLEVER CHEK AUTO-CODE VOICE IN VITRO.....	196
<i>capecitabine.....</i>	166	CLEVER CHEK TEST.....	197
CAPRELSA ORAL TABLET 100 MG	167	CLEVER CHOICE AUTO-CODE TEST.....	198
CAPRELSA ORAL TABLET 300 MG	168	CLEVER CHOICE MICRO TEST.....	199
CARBAGLU.....	169	CLIMARA PRO.....	200
CARDURA XL.....	170	<i>clonidine hcl er.....</i>	201
CARESENS N GLUCOSE TEST.....	171	<i>clopidogrel bisulfate oral.....</i>	202
<i>cartia xt oral capsule extended release 24 hour 120 mg, 300 mg.....</i>	172	<i>clopidogrel bisulfate oral.....</i>	203
		<i>clozapine oral tablet 100 mg.....</i>	204
		<i>clozapine oral tablet 200 mg.....</i>	205

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<i>clozapine oral tablet 25 mg, 50 mg</i> .....	206	<i>dexmethylphenidate hcl</i> .....	245
<i>clozapine oral tablet dispersible 100 mg</i> ...	204	<i>dexmethylphenidate hcl er</i> .....	246
<i>clozapine oral tablet dispersible 12.5 mg</i> ...	207	<i>dextroamphetamine sulfate er</i> .....	249
<i>clozapine oral tablet dispersible 150 mg</i> ...	208	<i>dextroamphetamine sulfate oral solution</i> .	247
<i>clozapine oral tablet dispersible 200 mg</i> ...	209	<i>dextroamphetamine sulfate oral tablet</i> .....	248
<i>clozapine oral tablet dispersible 25 mg</i> .....	206	<i>diazepam rectal</i> .....	250
<i>codeine sulfate oral tablet</i> .....	210	<i>diclofenac sodium transdermal gel 1 %</i> ....	251
<i>colchicine oral tablet</i> .....	212	<b>DIFICID</b> .....	252
<b>COMBIPATCH</b> .....	213	<i>diltiazem cd oral capsule extended release</i>	
<b>COMETRIQ (100 MG DAILY DOSE)</b>	214	<i>24 hour 120 mg, 180 mg</i> .....	253
<b>COMETRIQ (140 MG DAILY DOSE)</b>	215	<i>diltiazem cd oral capsule extended release</i>	
<b>COMETRIQ (60 MG DAILY DOSE)</b> ..	216	<i>24 hour 240 mg</i> .....	254
<b>COMPLERA</b> .....	217	<i>diltiazem hcl er beads oral capsule</i>	
<b>CONTRAVE</b> .....	218	<i>extended release 24 hour 120 mg, 180 mg,</i>	
<b>COPAXONE SUBCUTANEOUS</b>		<i>300 mg, 360 mg</i> .....	256
<b>SOLUTION PREFILLED SYRINGE</b>		<i>diltiazem hcl er beads oral capsule</i>	
<b>40 MG/ML</b> .....	219	<i>extended release 24 hour 240 mg</i> .....	257
<b>CORDRAN EXTERNAL TAPE</b> .....	220	<i>diltiazem hcl er beads oral capsule</i>	
<b>COREG CR</b> .....	221	<i>extended release 24 hour 420 mg</i> .....	258
<b>CORLANOR</b> .....	222	<i>diltiazem hcl er coated beads oral capsule</i>	
<b>COSOPT PF</b> .....	223	<i>extended release 24 hour 120 mg, 180 mg</i>	259
<b>CREON</b> .....	224	<i>diltiazem hcl er coated beads oral capsule</i>	
<b>CRINONE VAGINAL GEL 4 %</b> .....	225	<i>extended release 24 hour 240 mg</i> .....	260
<b>CRINONE VAGINAL GEL 8 %</b> .....	226	<i>diltiazem hcl er coated beads oral capsule</i>	
<b>CUVPOSA</b> .....	227	<i>extended release 24 hour 300 mg</i> .....	261
<b>CYCLOSET</b> .....	228	<i>diltiazem hcl er coated beads oral capsule</i>	
<b>CYSTAGON</b> .....	229	<i>extended release 24 hour 360 mg</i> .....	259
<b>CYSTARAN</b> .....	230	<i>diltiazem hcl er oral capsule extended</i>	
<b>DACOGEN</b> .....	231	<i>release 24 hour 240 mg</i> .....	255
<b>DAKLINZA</b> .....	232	<i>dilt-xr oral capsule extended release 24</i>	
<b>DALIRESP</b> .....	233	<i>hour 240 mg</i> .....	262
<i>darifenacin hydrobromide er</i> .....	234	<b>DIPENTUM</b> .....	263
<b>DAYTRANA</b> .....	235	<b>DIVIGEL</b> .....	264
<i>decitabine</i> .....	236	<i>donepezil hcl oral tablet 23 mg</i> .....	265
<b>DELZICOL</b> .....	237	<i>doxycycline</i> .....	266
<b>DENAVIR</b> .....	238	<i>dronabinol</i> .....	267
<b>DESCOVY</b> .....	239	<b>DUAVEE</b> .....	268
<i>desloratadine oral tablet</i> .....	240	<b>DULERA</b> .....	269
<i>desloratadine oral tablet dispersible 2.5</i>		<i>duloxetine hcl oral capsule delayed release</i>	
<i>mg</i> .....	240	<i>particles 20 mg</i> .....	270
<i>desloratadine oral tablet dispersible 5 mg</i>	241	<i>duloxetine hcl oral capsule delayed release</i>	
<i>desvenlafaxine succinate er</i> .....	242	<i>particles 30 mg</i> .....	271
<b>DEXILANT</b> .....	243		

<i>duloxetine hcl oral capsule delayed release particles 40 mg</i> .....	271
<i>duloxetine hcl oral capsule delayed release particles 60 mg</i> .....	272
<i>dutasteride</i> .....	273
EASY PLUS II GLUCOSE TEST.....	274
EASY STEP TEST.....	275
EASY TALK BLOOD GLUCOSE TEST.....	276
EASY TOUCH TEST.....	277
EASY TRAK BLOOD GLUCOSE TEST.....	278
EASYGLUCO IN VITRO.....	279
EASYMAX 15 TEST.....	280
EASYMAX TEST.....	281
EASYPLUS BLOOD GLUCOSE TEST.....	282
EASYPRO PLUS IN VITRO.....	283
EDARBI.....	284
EDARBYCLOR.....	285
EDURANT.....	286
ELAPRASE.....	287
ELELYSO.....	288
ELEMENT TEST.....	289
ELESTRIN.....	290
<i>eletriptan hydrobromide</i> .....	291
ELIDEL.....	292
ELIQUIS.....	293
EMBEDA.....	294
EMBRACE BLOOD GLUCOSE TEST.....	296
EMSAM.....	297
EMTRIVA ORAL CAPSULE.....	298
ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 25 MG/0.5ML.....	299
ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 50 MG/ML.....	300
ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR.....	301
<i>endocet oral tablet 10-325 mg, 5-325 mg</i> .....	302

ENDOCET ORAL TABLET 2.5-325 MG.....	302
<i>endocet oral tablet 7.5-325 mg</i> .....	302
ENDOMETRIN.....	304
<i>enoxaparin sodium</i> .....	305
<i>entecavir</i> .....	306
EPCLUSA.....	307
EPIDUO FORTE.....	308
<i>epinephrine injection solution auto-injector 0.15 mg/0.15ml</i> .....	309
<i>epinephrine injection solution auto-injector 0.15 mg/0.3ml, 0.3 mg/0.3ml</i> .....	310
EPIPEN 2-PAK INJECTION SOLUTION AUTO-INJECTOR.....	311
EPIPEN JR 2-PAK INJECTION SOLUTION AUTO-INJECTOR.....	312
EPOGEN INJECTION SOLUTION 10000 UNIT/ML, 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML.....	313
<i>epoprostenol sodium</i> .....	314
<i>eprosartan mesylate</i> .....	315
ERIVEDGE.....	316
<i>escitalopram oxalate oral tablet 10 mg</i> ....	317
<i>escitalopram oxalate oral tablet 20 mg, 5 mg</i> .....	318
<i>esomeprazole magnesium</i> .....	319
<i>estradiol transdermal patch twice weekly</i> .....	321
<i>estradiol transdermal patch weekly</i> .....	322
<i>estradiol-norethindrone acet</i> .....	323
<i>estradiol-norethindrone acet</i> .....	324
ESTROGEL.....	325
<i>eszopiclone</i> .....	326
EVAMIST.....	327
EVENCARE + BLOOD GLUCOSE TEST.....	328
EVENCARE BLOOD GLUCOSE TEST.....	329
EVENCARE G2 TEST.....	330
EVENCARE G3 TEST.....	331
EVOLUTION AUTOCODE IN VITRO.....	332
EXJADE.....	333



EXTAVIA SUBCUTANEOUS KIT .....	334	<i>fluvastatin sodium er</i> .....	373
EZ SMART BLOOD GLUCOSE TEST		<i>fluvoxamine maleate oral tablet 100 mg</i> ..	374
.....	335	<i>fluvoxamine maleate oral tablet 25 mg</i> ....	375
EZ SMART PLUS GLUCOSE TEST ...	336	<i>fluvoxamine maleate oral tablet 50 mg</i> ....	375
<i>ezetimibe</i> .....	337	FOLLISTIM AQ INJECTION	
<i>ezetimibe-simvastatin</i> .....	338	SOLUTION 75 UNT/0.5ML .....	376
FABRAZYME .....	339	FOLLISTIM AQ SUBCUTANEOUS ..	376
<i>famciclovir oral</i> .....	340	<i>fondaparinux sodium</i> .....	377
FANAPT .....	341	FORA D10 2-IN-1 MONITOR .....	378
FANAPT TITRATION PACK .....	342	FORA D15G 2-IN-1 MONITOR .....	379
FARXIGA .....	343	FORA D15G BLOOD GLUCOSE	
<i>felodipine er</i> .....	344	TEST .....	380
FEMRING .....	345	FORA D20 2-IN-1 MONITOR .....	381
<i>fenofibrate micronized</i> .....	348	FORA D20 BLOOD GLUCOSE TEST	382
<i>fenofibrate oral capsule</i> .....	346	FORA G20 BLOOD GLUCOSE TEST	383
<i>fenofibrate oral tablet 145 mg, 160 mg, 48</i>		FORA G30A BLOOD GLUCOSE	
<i>mg, 54 mg</i> .....	347	TEST .....	384
<i>fenofibric acid oral tablet</i> .....	349	FORA GD20 TEST .....	385
<i>fentanyl</i> .....	350	FORA V10 BLOOD GLUCOSE TEST	386
<i>fentanyl citrate buccal</i> .....	352	FORA V12 BLOOD GLUCOSE TEST	387
FERRIPROX .....	353	FORA V20 BLOOD GLUCOSE TEST	388
FETZIMA .....	354	FORA V30A BLOOD GLUCOSE	
FETZIMA TITRATION .....	355	TEST .....	389
FIFTY50 GLUCOSE TEST 2.0 .....	356	FORACARE GD40 TEST .....	390
FIRMAGON SUBCUTANEOUS		FORACARE PREMIUM V10 TEST ...	391
SOLUTION RECONSTITUTED 80		FORTEO SUBCUTANEOUS	
MG .....	357	SOLUTION 600 MCG/2.4ML .....	392
FIRST-PROGESTERONE VGS 100 .....	358	FOSAMAX PLUS D .....	393
FIRST-PROGESTERONE VGS 200 .....	359	FRAGMIN SUBCUTANEOUS	
FLEBOGAMMA DIF .....	360	SOLUTION 10000 UNIT/ML, 12500	
FLOVENT DISKUS .....	361	UNIT/0.5ML, 15000 UNIT/0.6ML,	
FLOVENT HFA .....	362	18000 UNT/0.72ML, 2500	
FLOWTUSS .....	363	UNIT/0.2ML, 5000 UNIT/0.2ML, 7500	
<i>fluoxetine hcl oral capsule 10 mg</i> .....	364	UNIT/0.3ML, 95000 UNIT/3.8ML .....	394
<i>fluoxetine hcl oral capsule 20 mg</i> .....	365	FREESTYLE INSULINX TEST .....	395
<i>fluoxetine hcl oral capsule 40 mg</i> .....	366	FREESTYLE LITE TEST .....	396
<i>fluoxetine hcl oral capsule delayed release</i>		FREESTYLE TEST .....	397
.....	367	<i>frovatriptan succinate</i> .....	398
<i>fluoxetine hcl oral tablet 10 mg</i> .....	368	FYCOMPA ORAL TABLET .....	399
<i>fluoxetine hcl oral tablet 20 mg</i> .....	369	<i>gabapentin oral capsule</i> .....	400
<i>fluticasone propionate nasal</i> .....	370	<i>gabapentin oral solution 250 mg/5ml</i> .....	401
<i>fluticasone-salmeterol</i> .....	371	<i>gabapentin oral tablet</i> .....	402
<i>fluvastatin sodium</i> .....	372		

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/200ML, 20 GM/400ML, 5 GM/100ML.....	403	HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 40 MG/0.8ML.....	440
GAMUNEX-C.....	404	HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT.....	441
<i>ganirelix acetate</i> .....	405	HUMIRA PEN-CROHNS STARTER SUBCUTANEOUS PEN-INJECTOR KIT.....	442
GATTEX.....	406	HUMIRA PEN-PSORIASIS STARTER SUBCUTANEOUS PEN-INJECTOR KIT.....	443
GE100 BLOOD GLUCOSE TEST.....	407	HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.2ML, 20 MG/0.4ML.....	438
GELNIQUE TRANSDERMAL GEL 10 %.....	408	HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT 40 MG/0.8ML.....	439
GENVOYA.....	409	HYCAMTIN ORAL.....	444
GIAZO.....	410	<i>hydrocodone-acetaminophen oral solution 2.5-108 mg/5ml, 5-217 mg/10ml, 7.5-325 mg/15ml</i> .....	445
GILENYA.....	411	<i>hydrocodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 2.5-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg</i> ....	447
GILOTRIF.....	412	<i>hydrocodone-ibuprofen oral tablet 10-200 mg</i> .....	449
GLATOPA.....	413	<i>hydrocodone-ibuprofen oral tablet 5-200 mg, 7.5-200 mg</i> .....	449
GLUCAGEN DIAGNOSTIC.....	414	<i>hydromorphone hcl er oral tablet er 24 hour abuse-deterrent 12 mg, 32 mg, 8 mg</i>	455
GLUCAGEN HYPOKIT.....	415	<i>hydromorphone hcl er oral tablet er 24 hour abuse-deterrent 16 mg</i> .....	457
GLUCOCARD 01 SENSOR PLUS.....	416	<i>hydromorphone hcl oral tablet</i> .....	451
GLUCOCARD EXPRESSION TEST..	417	<i>hydromorphone hcl rectal</i> .....	453
GLUCOCARD VITAL TEST.....	418	HYQVIA.....	459
GLUCOCARD X-SENSOR.....	419	<i>ibandronate sodium oral</i> .....	460
GLUCOCOM TEST.....	420	IBRANCE.....	461
GLYXAMBI.....	421	<i>ibudone oral tablet 5-200 mg</i> .....	462
GONAL-F.....	422	ICLUSIG ORAL TABLET 15 MG.....	464
GONAL-F RFF.....	423	ICLUSIG ORAL TABLET 45 MG.....	465
GONAL-F RFF REDIJECT.....	424	ILARIS.....	466
GRALISE ORAL TABLET 300 MG...	425	ILARIS (150MG DELIVERED).....	467
GRALISE ORAL TABLET 600 MG...	426		
GRALISE STARTER.....	427		
GRASTEK.....	428		
<i>guanfacine hcl er</i> .....	429		
GUARDIAN REAL-TIME SYSTEM PED.....	430		
HALAVEN.....	431		
HARVONI.....	432		
HELIXATE FS.....	433		
HEMANGEOL.....	434		
HETLIOZ.....	435		
HORIZANT ORAL TABLET EXTENDED RELEASE 300 MG.....	436		
HORIZANT ORAL TABLET EXTENDED RELEASE 600 MG.....	437		

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017



<i>imatinib mesylate</i> .....	468	JUXTAPID ORAL CAPSULE 10 MG, 5 MG.....	501
<i>imiquimod external</i> .....	469	JUXTAPID ORAL CAPSULE 20 MG	502
INCRELEX.....	470	JUXTAPID ORAL CAPSULE 30 MG, 40 MG, 60 MG.....	503
INCRUSE ELLIPTA.....	471	KADIAN ORAL CAPSULE	
<i>indomethacin oral</i> .....	472	EXTENDED RELEASE 24 HOUR 200 MG, 40 MG.....	504
INFINITY BLOOD GLUCOSE TEST	473	KALYDECO.....	506
INLYTA.....	474	KALYDECO.....	507
INTELENCE ORAL TABLET 100 MG, 25 MG.....	475	KEPIVANCE.....	508
INTELENCE ORAL TABLET 200 MG .....	476	KERYDIN.....	509
INTRON A.....	477	<i>ketoconazole oral</i> .....	510
INVOKAMET.....	478	<i>ketorolac tromethamine oral</i> .....	511
INVOKAMET XR.....	479	KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.	512
INVOKANA.....	480	KOGENATE FS.....	513
<i>ipratropium bromide nasal</i> .....	481	KOGENATE FS BIO-SET.....	514
<i>irbesartan</i> .....	482	KOMBIGLYZE XR ORAL TABLET EXTENDED RELEASE 24 HOUR 2.5- 1000 MG.....	515
<i>irbesartan-hydrochlorothiazide</i> .....	483	KOMBIGLYZE XR ORAL TABLET EXTENDED RELEASE 24 HOUR 5- 1000 MG, 5-500 MG.....	516
ISENTRESS HD.....	486	KORLYM.....	517
ISENTRESS ORAL TABLET.....	484	KROGER BLOOD GLUCOSE TEST.	518
ISENTRESS ORAL TABLET CHEWABLE.....	485	KROGER PREMIUM GLUCOSE TEST.....	519
<i>itraconazole oral</i> .....	487	KROGER TEST.....	520
JAKAFI.....	489	KUVAN ORAL PACKET 500 MG.....	521
JAKAFI.....	490	KUVAN ORAL TABLET SOLUBLE.	521
JANUMET.....	491	<i>lamotrigine er oral tablet extended release</i> <i>24 hour 100 mg, 25 mg, 50 mg</i> .....	525
JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 100-1000 MG, 50-500 MG.....	492	<i>lamotrigine er oral tablet extended release</i> <i>24 hour 200 mg</i> .....	526
JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 50- 1000 MG.....	493	<i>lamotrigine er oral tablet extended release</i> <i>24 hour 250 mg, 300 mg</i> .....	527
JANUVIA.....	494	<i>lamotrigine oral tablet dispersible 100 mg, 200 mg</i> .....	522
JARDIANCE.....	495	<i>lamotrigine oral tablet dispersible 25 mg.</i>	523
JENTADUETO.....	496	<i>lamotrigine oral tablet dispersible 50 mg.</i>	524
JENTADUETO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 2.5- 1000 MG.....	497	<i>lansoprazole oral capsule delayed release</i> <i>15 mg</i> .....	528
JENTADUETO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 5- 1000 MG.....	498		
JEVTANA.....	499		
JUBLIA.....	500		

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<i>lansoprazole oral capsule delayed release</i>		LUPRON DEPOT (6-MONTH).....	566
30 mg.....	529	LUPRON DEPOT-PED (1-MONTH)..	567
LANTUS.....	530	LUPRON DEPOT-PED (3-MONTH)..	568
LANTUS SOLOSTAR		LYRICA.....	569
SUBCUTANEOUS SOLUTION PEN-		<i>maprotiline hcl oral tablet 25 mg</i> .....	571
INJECTOR.....	531	<i>maprotiline hcl oral tablet 50 mg</i> .....	572
LATUDA ORAL TABLET 120 MG, 20		<i>maprotiline hcl oral tablet 75 mg</i> .....	573
MG, 40 MG.....	532	<i>matzim la oral tablet extended release 24</i>	
LATUDA ORAL TABLET 60 MG.....	533	<i>hour 180 mg, 300 mg, 360 mg</i> .....	574
LATUDA ORAL TABLET 80 MG.....	534	<i>matzim la oral tablet extended release 24</i>	
<i>leflunomide oral</i> .....	535	<i>hour 240 mg</i> .....	575
LEMTRADA.....	536	MAVYRET.....	576
LETAIRIS.....	537	MEIJER BLOOD GLUCOSE TEST....	577
LEUKINE INTRAVENOUS.....	538	MEIJER PREMIUM GLUCOSE TEST	
<i>leuprolide acetate injection</i> .....	539	.....	578
<i>levetiracetam er oral tablet extended</i>		MEKINIST ORAL TABLET 0.5 MG..	579
<i>release 24 hour 500 mg</i> .....	540	MEKINIST ORAL TABLET 2 MG....	580
<i>levetiracetam er oral tablet extended</i>		<i>memantine hcl oral tablet</i> .....	581
<i>release 24 hour 750 mg</i> .....	541	MENOPUR.....	582
<i>levorphanol tartrate oral</i> .....	542	MENOSTAR.....	583
LIBERTY NEXT GENERATION		<i>mepredine hcl oral tablet</i> .....	584
TEST.....	544	<i>mesalamine oral tablet delayed release 1.2</i>	
LIBERTY TEST.....	545	<i>gm</i> .....	586
<i>lidocaine external ointment</i> .....	546	<i>mesalamine oral tablet delayed release</i>	
<i>lidocaine external patch 5 %</i> .....	547	<i>800 mg</i> .....	587
<i>lidocaine-prilocaine external cream</i> .....	548	<i>metadate er oral tablet extended release</i>	
<i>linezolid oral suspension reconstituted</i> ....	549	<i>20 mg</i> .....	588
<i>linezolid oral tablet</i> .....	550	<i>metformin hcl er (osm) oral tablet</i>	
LINZESS.....	551	<i>extended release 24 hour 1000 mg</i> .....	589
LINZESS.....	552	<i>metformin hcl er (osm) oral tablet</i>	
LIVALO.....	553	<i>extended release 24 hour 500 mg</i> .....	590
<i>lorcet</i> .....	554	<i>methadone hcl intensol</i> .....	599
<i>lorcet hd</i> .....	556	<i>methadone hcl oral concentrate</i> .....	591
<i>losartan potassium oral tablet 25 mg, 50</i>		<i>methadone hcl oral solution 10 mg/5ml</i> ....	593
<i>mg</i> .....	558	<i>methadone hcl oral solution 5 mg/5ml</i> ....	595
<i>lovastatin</i> .....	559	<i>methadone hcl oral tablet</i> .....	597
LUMIGAN OPHTHALMIC		<i>methadone hcl oral tablet soluble</i> .....	591
SOLUTION 0.01 %.....	560	<i>methamphetamine hcl</i> .....	601
LUMIZYME.....	561	<i>methylphenidate hcl er (cd)</i> .....	612
LUPANETA PACK.....	562	<i>methylphenidate hcl er (la)</i> .....	613
LUPRON DEPOT (1-MONTH).....	563	<i>methylphenidate hcl er (la)</i> .....	614
LUPRON DEPOT (3-MONTH).....	564	<i>methylphenidate hcl er oral tablet</i>	
LUPRON DEPOT (4-MONTH).....	565	<i>extended release 10 mg</i> .....	606

<i>methylphenidate hcl er oral tablet extended release 18 mg, 27 mg, 54 mg</i> .....	607	<i>morphine sulfate er oral tablet extended release</i> .....	640
<i>methylphenidate hcl er oral tablet extended release 20 mg</i> .....	608	<i>morphine sulfate oral solution</i> .....	630
<i>methylphenidate hcl er oral tablet extended release 24 hour 18 mg, 27 mg, 54 mg</i> .....	610	<i>morphine sulfate oral tablet</i> .....	632
<i>methylphenidate hcl er oral tablet extended release 24 hour 36 mg</i> .....	611	<i>morphine sulfate rectal</i> .....	630
<i>methylphenidate hcl er oral tablet extended release 36 mg</i> .....	609	MOZOBIL.....	644
<i>methylphenidate hcl oral solution 10 mg/5ml</i> .....	602	MULTAQ.....	645
<i>methylphenidate hcl oral solution 5 mg/5ml</i> .....	603	MYGLUCOHEALTH TEST.....	646
<i>methylphenidate hcl oral tablet</i> .....	604	MYOBLOC.....	647
<i>methylphenidate hcl oral tablet chewable</i> .....	605	<i>myorisan oral capsule 10 mg, 20 mg, 40 mg</i> .....	648
<i>metoprolol succinate er oral tablet extended release 24 hour 100 mg, 50 mg</i> .....	615	MYRBETRIQ.....	649
<i>metoprolol succinate er oral tablet extended release 24 hour 200 mg</i> .....	616	MYTESI.....	650
<i>metoprolol succinate er oral tablet extended release 24 hour 25 mg</i> .....	617	<i>naftifine hcl</i> .....	651
MIACALCIN INJECTION.....	618	NAFTIN EXTERNAL GEL 1 %.....	652
MICRODOT TEST.....	619	NAGLAZYME.....	653
<i>mimvey</i> .....	620	NAMENDA XR.....	654
MIMVEY LO.....	621	NAMENDA XR TITRATION PACK.....	655
MIRCERA INJECTION SOLUTION PREFILLED SYRINGE.....	622	NAMZARIC.....	656
<i>mirtazapine oral</i> .....	623	<i>naratriptan hcl</i> .....	657
<i>mirtazapine oral</i> .....	624	NEULASTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	658
MIRVASO.....	625	NEUPOGEN INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6ML.....	659
<i>modafinil</i> .....	626	NEUPOGEN INJECTION SOLUTION PREFILLED SYRINGE.....	659
<i>montelukast sodium oral</i> .....	628	NEUPRO.....	660
<i>montelukast sodium oral</i> .....	629	NEUTEK 2TEK GLUCOSE/PRESSURE.....	661
<i>morphine sulfate (concentrate) oral solution 100 mg/5ml, 20 mg/ml</i> .....	634	NEUTEK 2TEK TEST.....	662
<i>morphine sulfate er beads</i> .....	642	<i>nevirapine er oral tablet extended release 24 hour 100 mg</i> .....	663
<i>morphine sulfate er oral capsule extended release 24 hour</i> .....	636	<i>nevirapine er oral tablet extended release 24 hour 400 mg</i> .....	664
<i>morphine sulfate er oral tablet extended release</i> .....	638	NEXAVAR.....	665
		NEXIUM 24HR ORAL CAPSULE DELAYED RELEASE.....	668
		NEXIUM ORAL PACKET.....	666
		<i>nicotine polacrilex mouth/throat gum</i> .....	669
		<i>nicotine polacrilex mouth/throat lozenge</i> .....	670
		NICOTROL.....	671
		NICOTROL NS.....	672

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

*nifediac cc oral tablet extended release 24 hour 30 mg*.....673  
*nifedical xl oral tablet extended release 24 hour 60 mg*.....674  
*nifedipine er oral tablet extended release 24 hour 30 mg, 90 mg*.....675  
*nifedipine er oral tablet extended release 24 hour 60 mg*.....676  
*nifedipine er osmotic release oral tablet extended release 24 hour 30 mg, 90 mg*....677  
*nifedipine er osmotic release oral tablet extended release 24 hour 60 mg*.....678  
*nisoldipine er oral tablet extended release 24 hour 17 mg, 20 mg, 34 mg, 40 mg, 8.5 mg*.....679  
*nisoldipine er oral tablet extended release 24 hour 30 mg*.....680  
 NORITATE.....681  
 NOVA MAX GLUCOSE TEST.....682  
*novarel intramuscular solution reconstituted 10000 unit*.....683  
 NOVOLOG.....684  
 NOVOLOG FLEXPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR.....685  
 NOVOLOG MIX 70/30.....686  
 NOVOLOG MIX 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR.....687  
 NOVOLOG PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE.....688  
 NOXAFIL ORAL SUSPENSION.....689  
 NPLATE.....691  
 NUCYNTA.....692  
 NUCYNTA ER.....694  
 NUEDEXTA.....696  
 NULOJIX.....697  
 OCTAGAM.....698  
*octreotide acetate injection solution 100 mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml*.....699  
 ODEFSEY.....700  
 2017 Aetna Pharmacy Drug List - Individual Last Update 12/2017

ODOMZO.....701  
*olanzapine oral tablet 10 mg, 15 mg, 20 mg, 5 mg, 7.5 mg*.....702  
*olanzapine oral tablet 2.5 mg*.....703  
*olanzapine oral tablet dispersible*.....702  
*olanzapine oral tablet dispersible*.....704  
*olanzapine-fluoxetine hcl oral capsule 12-25 mg, 12-50 mg, 6-25 mg, 6-50 mg*.....705  
*olmesartan medoxomil oral*.....706  
*olmesartan medoxomil-hctz*.....707  
*olmesartan-amlodipine-hctz*.....708  
*omega-3-acid ethyl esters*.....709  
*omeprazole-sodium bicarbonate oral capsule 20-1100 mg*.....710  
 OMNARIS.....711  
 OMNITROPE SUBCUTANEOUS SOLUTION.....712  
 OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED.....713  
 ON CALL PLUS BLOOD GLUCOSE.....714  
 ON CALL VIVID BLOOD GLUCOSE.....715  
 ONETOUCH ULTRA BLUE.....716  
 ONETOUCH VERIO IN VITRO STRIP.....717  
 ONFI ORAL TABLET 10 MG, 20 MG.....718  
 ONGLYZA.....719  
 OPANA ER ORAL TABLET ER 12 HOUR ABUSE-DETERRENT.....720  
 OPSUMIT.....722  
 ORAVIG.....723  
 ORENCIA CLICKJECT.....727  
 ORENCIA INTRAVENOUS.....724  
 ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 125 MG/ML.....725  
 ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 50 MG/0.4ML, 87.5 MG/0.7ML.....726  
 ORENITRAM.....728  
 ORFADIN.....729  
 ORKAMBI.....730  
*oseltamivir phosphate oral capsule*.....731  
 OSPHENA.....732

OTEZLA ORAL TABLET .....	733	PEGASYS PROCLICK.....	772
OTEZLA ORAL TABLET THERAPY PACK.....	734	PEGASYS SUBCUTANEOUS SOLUTION.....	771
OVIDREL.....	735	PENTASA ORAL CAPSULE EXTENDED RELEASE 250 MG.....	773
OXAYDO.....	736	PENTASA ORAL CAPSULE EXTENDED RELEASE 500 MG.....	774
OXTELLAR XR ORAL TABLET EXTENDED RELEASE 24 HOUR 150 MG, 300 MG.....	738	<i>pentazocine-naloxone hcl</i> .....	775
OXTELLAR XR ORAL TABLET EXTENDED RELEASE 24 HOUR 600 MG.....	739	PERFOROMIST.....	777
<i>oxybutynin chloride er oral tablet extended release 24 hour 10 mg, 15 mg....</i>	741	PERTZYE.....	778
<i>oxybutynin chloride er oral tablet extended release 24 hour 5 mg.....</i>	742	PHARMACIST CHOICE AUTOCODE.....	779
<i>oxybutynin chloride oral tablet.....</i>	740	<i>phenoxybenzamine hcl oral.....</i>	780
<i>oxycodone hcl er oral tablet er 12 hour abuse-deterrent.....</i>	749	PICATO.....	781
<i>oxycodone hcl oral capsule.....</i>	743	<i>pioglitazone hcl.....</i>	782
<i>oxycodone hcl oral concentrate 100 mg/5ml.....</i>	745	<i>pioglitazone hcl-glimepiride.....</i>	783
<i>oxycodone hcl oral solution.....</i>	745	<i>pioglitazone hcl-metformin hcl.....</i>	784
<i>oxycodone hcl oral tablet.....</i>	747	PLEGRIDY.....	785
<i>oxycodone-acetaminophen oral tablet 10- 325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg.....</i>	751	PLEGRIDY.....	786
<i>oxycodone-aspirin oral tablet 4.8355-325 mg.....</i>	753	PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION PEN- INJECTOR.....	787
<i>oxycodone-ibuprofen.....</i>	755	PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	788
OXYCONTIN ORAL TABLET ER 12 HOUR ABUSE-DETERRENT.....	757	POCKETCHEM EZ TEST.....	789
<i>oxymorphone hcl.....</i>	759	POMALYST.....	790
<i>oxymorphone hcl er.....</i>	761	PRALUENT SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	791
<i>paliperidone er oral tablet extended release 24 hour 1.5 mg, 3 mg, 6 mg.....</i>	763	<i>pramipexole dihydrochloride er.....</i>	792
<i>paliperidone er oral tablet extended release 24 hour 9 mg.....</i>	764	<i>prasugrel hcl.....</i>	793
<i>pamidronate disodium.....</i>	765	<i>pravastatin sodium.....</i>	794
PANCREAZE.....	766	PRECISION PCX.....	795
<i>paricalcitol oral.....</i>	767	PRECISION PCX PLUS TEST.....	796
<i>paroxetine hcl er.....</i>	770	PRECISION POINT OF CARE TEST.....	797
<i>paroxetine hcl oral tablet 10 mg, 20 mg... 768</i>		PRECISION QID TEST.....	798
<i>paroxetine hcl oral tablet 30 mg, 40 mg... 769</i>		PRECISION SOF-TACT TEST.....	799
2017 Aetna Pharmacy Drug List - Individual Last Update 12/2017		PRECISION XTRA BLOOD GLUCOSE.....	800
		PREFEST.....	801
		PREGNYL.....	802
		PREZISTA ORAL SUSPENSION.....	803



PREZISTA ORAL TABLET 150 MG, 600 MG, 75 MG.....	804	REBIF REBIDOSE SUBCUTANEOUS SOLUTION AUTO-INJECTOR.....	835
PREZISTA ORAL TABLET 800 MG..	805	REBIF REBIDOSE TITRATION PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR.....	836
PROCRIT.....	806	REBIF SUBCUTANEOUS SOLUTION PREFILLED SYRINGE..	834
PRODIGY NO CODING BLOOD GLUC.....	807	REBIF TITRATION PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	837
<i>progesterone micronized oral</i> .....	808	RECTIV.....	838
PROLASTIN-C INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG.....	809	REFUAH PLUS BLOOD GLUCOSE TEST.....	839
PROLEUKIN.....	810	RELENZA DISKHALER.....	840
PROLIA.....	811	RELISTOR SUBCUTANEOUS SOLUTION 12 MG/0.6ML.....	841
PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG.....	812	RELISTOR SUBCUTANEOUS SOLUTION 8 MG/0.4ML.....	842
<i>propafenone hcl er</i> .....	813	REMICADE.....	843
PRUDOXIN.....	814	REMODULIN.....	844
PULMICORT FLEXHALER.....	815	<i>repaglinide-metformin hcl</i> .....	845
PULMOZYME.....	816	REPATHA.....	846
QNASL.....	817	REPATHA PUSHTRONEX SYSTEM	847
QNASL CHILDRENS.....	818	REPATHA SURECLICK.....	848
QSYMIA ORAL CAPSULE EXTENDED RELEASE 24 HOUR 11.25-69 MG.....	819	RESCULA.....	849
<i>quetiapine fumarate er oral tablet extended release 24 hour 150 mg, 200 mg</i>	824	REVEAL BLOOD GLUCOSE TEST..	850
<i>quetiapine fumarate er oral tablet extended release 24 hour 300 mg, 400 mg, 50 mg.....</i>	825	REVLIMID.....	851
<i>quetiapine fumarate oral tablet 100 mg, 50 mg.....</i>	820	REXALL BLOOD GLUCOSE TEST..	852
<i>quetiapine fumarate oral tablet 200 mg...</i>	821	REXULTI.....	853
<i>quetiapine fumarate oral tablet 25 mg....</i>	822	REYATAZ ORAL CAPSULE 150 MG	854
<i>quetiapine fumarate oral tablet 300 mg, 400 mg.....</i>	823	REYATAZ ORAL CAPSULE 200 MG	855
QUILLIVANT XR.....	826	REYATAZ ORAL CAPSULE 300 MG	854
RA TRUETEST TEST.....	827	RIGHTEST GS100 BLOOD GLUCOSE.....	856
<i>rabeprazole sodium</i> .....	828	RIGHTEST GS300 BLOOD GLUCOSE.....	857
RANEXA.....	830	RIGHTEST GS550 BLOOD GLUCOSE.....	858
<i>rasagiline mesylate oral</i> .....	831	<i>risedronate sodium oral tablet 150 mg....</i>	859
RAVICTI.....	832	<i>risedronate sodium oral tablet 30 mg, 5 mg.....</i>	860
REBETOL ORAL SOLUTION.....	833	<i>risedronate sodium oral tablet 35 mg.....</i>	861

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<i>risedronate sodium oral tablet delayed release</i> .....	861	<i>sertraline hcl oral tablet 50 mg</i> .....	890
<i>risperidone m-tab oral tablet dispersible 0.5 mg, 1 mg, 2 mg</i> .....	865	SIGNIFOR.....	891
<i>risperidone m-tab oral tablet dispersible 3 mg</i> .....	866	<i>sildenafil citrate oral</i> .....	892
<i>risperidone m-tab oral tablet dispersible 4 mg</i> .....	867	SIMPONI ARIA.....	894
<i>risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg</i> .....	862	SIMPONI SUBCUTANEOUS SOLUTION AUTO-INJECTOR.....	893
<i>risperidone oral tablet 3 mg</i> .....	863	SIMPONI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	893
<i>risperidone oral tablet 4 mg</i> .....	864	SIMULECT.....	895
<i>risperidone oral tablet dispersible 0.5 mg</i> .....	862	<i>simvastatin oral</i> .....	896
<i>risperidone oral tablet dispersible 1 mg, 2 mg</i> .....	862	SIRTURO.....	897
<i>risperidone oral tablet dispersible 3 mg</i> .....	863	SIVEXTRO ORAL.....	898
<i>risperidone oral tablet dispersible 4 mg</i> .....	864	SMARTEST BLOOD GLUCOSE TEST.....	899
RITUXAN INTRAVENOUS SOLUTION.....	868	<i>sodium phenylbutyrate</i> .....	900
<i>rizatriptan benzoate</i> .....	869	<i>sodium phenylbutyrate oral powder 3 gmltsp</i> .....	900
<i>ropinirole hcl er oral tablet extended release 24 hour 12 mg</i> .....	870	SOLUS V2 TEST.....	901
<i>ropinirole hcl er oral tablet extended release 24 hour 2 mg, 4 mg, 6 mg, 8 mg</i> ...	871	SOMATULINE DEPOT.....	902
<i>rosuvastatin calcium</i> .....	872	SOMAVERT.....	903
ROZEREM.....	873	SOVALDI.....	904
RUBRACA.....	874	SPIRIVA HANDIHALER.....	905
SABRIL.....	875	SPIRIVA RESPIMAT INHALATION AEROSOL SOLUTION 1.25 MCG/ACT.....	906
SAMSCA ORAL TABLET 15 MG.....	876	SPORANOX ORAL SOLUTION.....	907
SAMSCA ORAL TABLET 30 MG.....	877	SPRYCEL ORAL TABLET 100 MG, 140 MG.....	909
SANCUSO.....	878	SPRYCEL ORAL TABLET 20 MG, 50 MG, 70 MG, 80 MG.....	910
SAPHRIS.....	879	STELARA INTRAVENOUS.....	911
SAVELLA.....	880	STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	911
SAVELLA TITRATION PACK.....	881	STIMATE.....	912
SELZENTRY ORAL SOLUTION.....	882	STIOLTO RESPIMAT.....	913
SELZENTRY ORAL TABLET 150 MG.....	883	STIVARGA.....	914
SELZENTRY ORAL TABLET 25 MG.....	884	STRIANT.....	915
SELZENTRY ORAL TABLET 75 MG.....	885	STRIBILD.....	917
SENSIPAR.....	886	STRIVERDI RESPIMAT.....	918
SEREVENT DISKUS.....	887	SUBOXONE SUBLINGUAL FILM.....	919
<i>sertraline hcl oral tablet 100 mg</i> .....	888	<i>sulfasalazine oral</i> .....	920
<i>sertraline hcl oral tablet 25 mg</i> .....	889	<i>sulfazine</i> .....	921
		<i>sumatriptan nasal</i> .....	922

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017

<i>sumatriptan succinate oral</i> .....	923	TARCEVA.....	951
<i>sumatriptan succinate refill subcutaneous solution cartridge</i> .....	926	TARGRETIN EXTERNAL.....	952
<i>sumatriptan succinate subcutaneous solution 6 mg/0.5ml</i> .....	924	TASIGNA.....	953
<i>sumatriptan succinate subcutaneous solution auto-injector 4 mg/0.5ml, 6 mg/0.5ml</i> .....	925	<i>tazarotene external</i> .....	954
SUPPRELIN LA.....	927	TAZORAC EXTERNAL CREAM 0.05 %.....	955
SURE EDGE TEST.....	928	TAZORAC EXTERNAL GEL.....	955
SURECHEK BLOOD GLUCOSE TEST.....	929	<i>taztia xt oral capsule extended release 24 hour 120 mg, 180 mg, 300 mg, 360 mg</i> ....	956
SURESTEP PRO LINEARITY.....	930	<i>taztia xt oral capsule extended release 24 hour 240 mg</i> .....	957
SURE-TEST EASYPLUS MINI TEST.....	931	TECFIDERA.....	958
SUTENT ORAL CAPSULE 12.5 MG.....	932	TECHNIVIE.....	959
SUTENT ORAL CAPSULE 25 MG....	933	TEKTURNA.....	960
SUTENT ORAL CAPSULE 37.5 MG, 50 MG.....	934	TEKTURNA HCT.....	961
SYLATRON SUBCUTANEOUS KIT 200 MCG, 300 MCG, 600 MCG.....	935	TELCARE BLOOD GLUCOSE TEST.....	962
SYMBICORT.....	936	<i>telmisartan</i> .....	963
SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	937	<i>telmisartan-amlodipine</i> .....	964
SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	938	<i>telmisartan-hctz</i> .....	965
SYNAGIS.....	939	<i>temazepam oral capsule 22.5 mg, 7.5 mg</i> .....	966
SYNAREL.....	940	<i>temozolomide</i> .....	967
SYNJARDY.....	941	TESTOPEL.....	968
SYNJARDY XR ORAL TABLET EXTENDED RELEASE 24 HOUR 10-1000 MG, 12.5-1000 MG, 5-1000 MG... ..	942	<i>testosterone transdermal gel 10 mg/lact (2%)</i> .....	970
SYNJARDY XR ORAL TABLET EXTENDED RELEASE 24 HOUR 25-1000 MG.....	943	<i>testosterone transdermal gel 12.5 mg/lact (1%)</i> .....	972
SYNRIBO.....	944	<i>testosterone transdermal gel 25 mg/2.5gm (1%)</i> .....	974
SYPRINE.....	945	<i>testosterone transdermal gel 50 mg/5gm (1%)</i> .....	972
TACLONEX EXTERNAL SUSPENSION.....	946	<i>testosterone transdermal solution</i> .....	976
<i>tacrolimus external</i> .....	947	<i>tetrabenazine oral tablet 12.5 mg</i> .....	978
TAFINLAR.....	948	<i>tetrabenazine oral tablet 25 mg</i> .....	979
TAMIFLU ORAL SUSPENSION RECONSTITUTED 6 MG/ML.....	949	<i>tgt blood glucose test</i> .....	980
TANZEUM.....	950	THALOMID.....	981
2017 Aetna Pharmacy Drug List - Individual Last Update 12/2017		THIOLA.....	982
		<i>tiagabine hcl oral tablet 2 mg</i> .....	983
		<i>tiagabine hcl oral tablet 4 mg</i> .....	984
		TIVICAY.....	985
		TIVICAY.....	986
		<i>tobramycin inhalation</i> .....	987
		<i>tolterodine tartrate</i> .....	988
		<i>tolterodine tartrate er</i> .....	989



<i>topiramate oral capsule sprinkle</i> .....	990	VECTIBIX INTRAVENOUS	
TOVIAZ.....	991	SOLUTION 100 MG/5ML, 400	
TRACLEER.....	992	MG/20ML.....	1030
TRADJENTA.....	993	VELCADE INJECTION.....	1031
<i>tramadol hcl er (biphasic)</i> .....	998	<i>venlafaxine hcl er oral capsule extended</i>	
<i>tramadol hcl er oral tablet extended</i>		<i>release 24 hour 150 mg</i> .....	1036
<i>release 24 hour</i> .....	996	<i>venlafaxine hcl er oral capsule extended</i>	
<i>tramadol hcl oral</i> .....	994	<i>release 24 hour 37.5 mg, 75 mg</i> .....	1037
<i>tramadol-acetaminophen</i> .....	1000	<i>venlafaxine hcl oral tablet 100 mg, 25 mg</i>	
<i>tranexamic acid oral</i> .....	1002	.....	1032
TRELSTAR MIXJECT.....	1003	<i>venlafaxine hcl oral tablet 37.5 mg</i> .....	1033
TRESIBA FLEXTOUCH.....	1004	<i>venlafaxine hcl oral tablet 50 mg</i> .....	1034
<i>triamcinolone acetonide nasal aerosol</i> ....	1005	<i>venlafaxine hcl oral tablet 75 mg</i> .....	1035
TRINTELLIX.....	1006	VENTAVIS.....	1038
TRIPTODUR.....	1007	<i>verapamil hcl er oral capsule extended</i>	
TRIUMEQ.....	1008	<i>release 24 hour 100 mg, 300 mg</i> .....	1039
<i>trospium chloride</i> .....	1009	<i>verapamil hcl er oral capsule extended</i>	
<i>trospium chloride er</i> .....	1010	<i>release 24 hour 200 mg</i> .....	1040
TRUETEST TEST.....	1011	VESICARE.....	1041
TRUETRACK TEST.....	1012	<i>vicodin es oral tablet 7.5-300 mg</i> .....	1044
TRULICITY.....	1013	<i>vicodin hp oral tablet 10-300 mg</i> .....	1046
TRUVADA.....	1014	<i>vicodin oral tablet 5-300 mg</i> .....	1042
TUDORZA PRESSAIR		VICTORY AGM-4000 TEST.....	1048
INHALATION AEROSOL POWDER		VICTOZA SUBCUTANEOUS	
BREATH ACTIVATED.....	1015	SOLUTION PEN-INJECTOR.....	1049
TUSSICAPS.....	1016	VIEKIRA PAK.....	1050
TYBOST.....	1017	VIEKIRA XR.....	1051
TYKERB.....	1018	<i>vigabatrin</i> .....	1052
UCERIS ORAL.....	1019	VIIIBRYD ORAL TABLET.....	1053
ULESFIA.....	1020	VIIIBRYD STARTER PACK.....	1054
ULORIC.....	1021	VIMPAT ORAL TABLET.....	1055
ULTIMA TEST.....	1022	VIOKACE.....	1056
ULTRATRAK PRO TEST.....	1023	VIREAD ORAL TABLET.....	1057
ULTRATRAK ULTIMATE TEST....	1024	VOCAL POINT BLOOD GLUCOSE	
VALCYTE ORAL SOLUTION		TEST.....	1058
RECONSTITUTED.....	1025	<i>voriconazole oral tablet</i> .....	1059
<i>valganciclovir hcl oral solution</i>		VOSEVI.....	1060
<i>reconstituted</i> .....	1026	VOTRIENT.....	1061
<i>valganciclovir hcl oral tablet</i> .....	1027	VPRIV.....	1062
<i>valsartan</i> .....	1028	VRAYLAR ORAL CAPSULE 1.5 MG	
<i>valsartan-hydrochlorothiazide</i> .....	1029	.....	1063
		VRAYLAR ORAL CAPSULE 3 MG.	1064

VRAYLAR ORAL CAPSULE 4.5 MG, 6 MG.....	1065	ZEMAIRA.....	1105
VRAYLAR ORAL CAPSULE THERAPY PACK.....	1066	ZENATANE.....	1106
VYVANSE.....	1067	ZEPATIER.....	1107
VYVANSE.....	1068	ZETONNA.....	1108
WAVESENSE PRESTO.....	1069	ZIANA.....	1109
WIDE-SEAL DIAPHRAGM 60.....	1070	ZIOPTAN.....	1110
WIDE-SEAL DIAPHRAGM 65.....	1071	<i>ziprasidone hcl</i> .....	1111
WIDE-SEAL DIAPHRAGM 70.....	1072	<i>zoledronic acid intravenous concentrate</i> .....	1112
WIDE-SEAL DIAPHRAGM 75.....	1073	<i>zoledronic acid intravenous solution</i> .....	1112
WIDE-SEAL DIAPHRAGM 80.....	1074	ZOLINZA.....	1113
WIDE-SEAL DIAPHRAGM 85.....	1075	<i>zolmitriptan oral tablet</i> .....	1114
WIDE-SEAL DIAPHRAGM 90.....	1076	<i>zolmitriptan oral tablet dispersible 2.5 mg</i> .....	1114
WIDE-SEAL DIAPHRAGM 95.....	1077	<i>zolmitriptan oral tablet dispersible 5 mg</i>	1115
XALKORI.....	1078	<i>zolpidem tartrate er</i> .....	1117
XATMEP.....	1079	<i>zolpidem tartrate oral</i> .....	1116
XELJANZ.....	1080	ZOMIG NASAL SOLUTION 5 MG..	1118
XELJANZ XR.....	1081	ZONALON.....	1119
XEOMIN.....	1082	ZONTIVITY.....	1120
XGEVA.....	1083	ZOVIRAX EXTERNAL CREAM....	1121
XIAFLEX.....	1084	ZYDELIG.....	1122
XIFAXAN ORAL TABLET 200 MG.	1085	ZYKADIA.....	1123
XIFAXAN ORAL TABLET 550 MG.	1086	ZYTIGA ORAL TABLET 250 MG....	1124
XIGDUO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 10- 1000 MG, 10-500 MG, 5-500 MG.....	1087	ZYTIGA ORAL TABLET 500 MG....	1125
XIGDUO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 5- 1000 MG.....	1088		
XTAMPZA ER.....	1089		
XTANDI.....	1091		
XURIDEN.....	1092		
XYLON.....	1093		
XYREM.....	1095		
YERVOY.....	1096		
<i>zaleplon</i> .....	1097		
ZAMICET.....	1098		
ZARXIO.....	1100		
ZAVESCA.....	1101		
ZEGERID OTC.....	1102		
ZELAPAR.....	1103		
ZELBORAF.....	1104		

2017 Aetna Pharmacy Drug List - Individual  
Last Update 12/2017